Urinary protein profiling of drug-induced liver injury: Search for biomarkers and mechanisms by Swelm, R.P.L. van
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/112901
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
Urinary protein profiling of drug-induced liver injury
Search for biomarkers and mechanisms
Rachel van Swelm
Urinary Protein Profiling of Drug-Induced Liver Injury: Search for Biomarkers and 
Mechanisms
Rachel van Swelm
Thesis Radboud University Nijmegen, the Netherlands
ISBN: 978-94-6191-792-8
Printed by: Ipskamp Drukkers
Cover design: Nynke van der Linden
© 2013 Rachel van Swelm
This research project was supported by the Dutch Top Institute Pharma consortium 
[D3-201].
The research presented in this thesis was performed at the Department of Phar-
macology and Toxicology, Nijmegen Centre for Molecular Life Sciences, Radboud 
University Nijmegen Medical Centre, the Netherlands.
Urinary protein profiling of drug-induced liver injury
Search for biomarkers and mechanisms
Proefschrift
ter verkrijging van de graad van doctor
aan de Radboud Universiteit Nijmegen
op gezag van de rector magnificus prof. mr. S.C.J.J. Kortmann,
volgens besluit van het college van decanen
in het openbaar te verdedigen op dinsdag 10 september 2013
om 10.30 uur precies
door
Rachel Petronella Louisa van Swelm
geboren op 7 april 1985
te Arcen 
Promotor:
Prof. dr. F.G.M Russel
Copromotor:
Dr. R. Masereeuw
Manuscriptcommissie:
Prof. dr. J.P.H. Drenth (voorzitter)
Prof. dr. A.J. van Gool 
Prof. dr. ir. I.M.C.M. Rietjens (Wageningen University & Research Centre) 
Urinary protein profiling of drug-induced liver injury
Search for biomarkers and mechanisms
Doctoral thesis
to obtain the degree of doctor
from Radboud University Nijmegen
on the authority of the Rector Magnificus prof. dr. S.C.J.J. Kortmann,
according to the decision of the Council of Deans
to be defended in public on Tuesday, September 10, 2013
at 10.30 hours
by
Rachel Petronella Louisa van Swelm
Born on April 7, 1985
in Arcen, the Netherlands 
Supervisor:
Prof. dr. F.G.M Russel
Co-supervisor:
Dr. R. Masereeuw
Doctoral Thesis committee:
Prof. dr. J.P.H. Drenth (chairman)
Prof. dr. A.J. van Gool 
Prof. dr. ir. I.M.C.M. Rietjens (Wageningen University & Research Centre) 
Woar ge ok loept en wat ge ok bint,
 niemand di zet ow wat good is of slecht.
 Niemand di wet wie verluust of wint
 ge komt op ‘t end bij ow zelf terecht.
Blieve Loepe, Rowwen Hèze

Table of contents
Chapter 1
General Introduction
11
Chapter 2
Identification of novel translational urinary biomarkers for 
acetaminophen-induced acute liver injury using proteomic 
profiling in mice
39
Chapter 3
Acute acetaminophen intoxication leads to hepatic iron 
loading by decreased hepcidin synthesis
61
Chapter 4
Urinary proteomic profiling reveals diclofenac-induced renal 
injury and hepatic regeneration in mice
81
Chapter 5
Proteomic profiling in incubation medium of mouse, rat and 
human precision-cut liver slices for biomarker detection 
regarding acute drug-induced liver injury
105
Chapter 6
Biomarkers for methotrexate-induced liver injury: urinary 
protein profiling of psoriasis patients
125
Chapter 7
General discussion
141
Chapter 8
Summary
Samenvatting
Lis of abbreviations
Curriculum vitae
List of publications
Dankwoord
Appendice
175
181
187
191
192
195
201

1General introduction
12
Chapter 1
1
13
General introduction
1Drug-induced liver injuryGeneralDrug-induced liver injury (DILI) is the leading cause of acute liver injury with an 
estimated overall incidence of 10-15 cases per 100.000 patient years.1 Morbidity 
and mortality of DILI are high, with nearly 10% of patients that die or require liver 
transplantation.2 Moreover, DILI is the most common cause for drug withdrawal 
or denied approval from the FDA.3 DILI can manifest as different clinical patterns, 
including hepatocellular injury, cholestatic injury, fibrosis, steatosis and cirrhosis; 
mixed patterns have also been observed such as combined hepatocellular and 
cholestatic injury.4-5 An overview of the various types of DILI with examples of drugs 
is given in Table 1. DILI can be caused by many drugs, and a single drug may be 
able to induce multiple types of liver injury. Cholestatic injury has been observed 
predominantly with oral contraceptives, steroids and non-steroidal anti-inflammatory 
drugs (NSAIDs), but NSAIDs can also give hepatitis.6-7 Hepatocellular necrosis can be 
caused by acetaminophen (APAP)8, and during isoniazide or ketaconazole treatment 
liver injury is associated with an inflammatory response.9-10 An inflammatory response 
can also occur after methotrexate (MTX) treatment, which can lead to fibrosis and 
ultimately cirrhosis.11 In addition, MTX has been associated with steatosis12, a clinical 
pattern that has also been observed with tamoxifen and valproate.13-14 
Idiosyncratic DILI is observed with specific drugs at therapeutic doses, by definition 
at a low incidence estimated to be 1 per 10.000 to 100.000 treated patients.15 This 
type of DILI is usually not detected in (pre)clinical trials during drug development, 
but only after the drug is released onto the market. Idiosyncratic DILI cannot be 
predicted from the mode of action or structure of the drug and is not related to the 
dose, however, individual susceptibility appears to play a role in these reactions.16 
It may present as any of the clinical patterns described above, but the mechanisms 
underlying idiosyncratic DILI remain largely unknown.17
Proposed mechanisms in DILI
Various processes can play a role in DILI as summarized in Table 1. Acetaminophen 
(APAP) is often studied as model compound for DILI and its toxic effects, which occur 
at supratherapeutic dosages and lead to acute, hepatocellular, injury. A requisite 
for APAP-induced liver injury is metabolism of the parent compound to the reactive 
metabolite N-acetyl-p-benzoquinone imine (NAPQI) by cytochrome P450 enzyme 
2E1.18 NAPQI can form adducts with cellular macromolecules, thus affecting their 
function.19 In case of APAP, this will result in mitochondrial damage, leading to the 
formation of oxidative stress.20 
14
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1
Figure 1. Mechanisms involved in DILI
This figure summarizes the mechanisms that can play a role in DILI, alone or in combination. 
Four different processes that contribute to various types of drug-induced hepatotoxicity can be 
distinguished: oxidative stress (A), alteration of regulatory pathways (B), the innate immune 
response (C) and the adaptive immune response (D). Enzymatic metabolic activation of the 
parent drug can lead to formation of a reactive metabolite, which can be detoxified by binding 
to small endogenous molecules such as glutathione (GSH). If there is no detoxification or if 
the pool of small molecules becomes depleted, the reactive metabolite can lead to oxidative/
19
General introduction
1nitrative stress and mitochondrial injury, either directly or via covalent binding to a cellular macromolecules. Cellular stress and/or covalent binding to cellular proteins can influence regulatory factors, such as Nrf2/Keap-1, NFκB and c-Jun kinase that can affect processes such as lipid metabolism or apoptosis. A drug or metabolite that is covalently bound to a 
cellular protein is also called a hapten. Hapten formation can trigger the immune system, 
either by attracting cells of the innate immune response, or activation of the adaptive immune 
response via antigen presenting cells. Activation of the adaptive immune system can lead to 
a T-cell or B-cell response. In some cases, the parent drug is able to elicit a T-cell immune 
response without metabolic activation. In other cases, an additional stimulus, such as a viral 
or bacterial infection, is necessary to trigger the adaptive immune response, which is called 
a danger signal. 
Oxidative stress, in turn, can disturb intracellular processes such as calcium 
homeostasis, ultimately leading to cell death.21 In general, covalent binding and 
oxidative stress can influence factors, such as Nrf2/Keap-1, NFκB and c-Jun kinase, 
that play a role in regulatory processes, for instance in lipid metabolism, induction of 
phase II enzymes or apoptosis.22-26 Many drugs that are known to cause liver injury 
form reactive intermediates, a process that can be considered to play a significant 
role in the induction of hepatocellular damage.27 
Another important factor that plays a role in DILI is the immune system.28 Clinical 
features of DILI include infiltration of neutrophils and macrophages in the liver, 
suggesting a role for the innate immune system. But also the adaptive immune 
system is believed to be involved, based on the infiltration of specific lymphocytes 
and delayed onset of DILI for certain drugs.29 Especially in idiosyncratic DILI the 
adaptive immune system has been proposed to be a key player. Although the 
formation of reactive metabolites and, subsequent, adduct formation and oxidative 
stress may be sufficient for some drugs to cause liver injury, additional stimuli are 
necessary for drugs that cause idiosyncratic DILI.30 There are various hypotheses on 
the mechanism by which the immune system can be triggered in idiosyncratic DILI, 
including the formation of a hapten and necessity of a danger signal, but apparently in 
many cases both metabolic activation and the immune system might play a role.31 For 
diclofenac (DF), and recently also for carbamazapine, metabolic activation followed 
by an immune response have been demonstrated as mechanisms participating in 
idiosyncratic DILI.32-33 In other cases, the parent drug is able to interact with T-cells 
directly, without metabolic activation.34 Moreover, it has been found that immune 
cells can metabolize drugs themselves thus also contributing to hepatotoxicity.35 A 
schematic overview of the proposed mechanisms involved in DILI is depicted in 
Figure 1.
20
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1SusceptibilityIdiosyncratic DILI is rare and is unpredictable from (pre)clinical trials; therefore, differences in interindividual susceptibility are thought to be important factors that influence the occurrence of this adverse event. Predisposing factors can be attributed 
to any of the mechanisms, for example enhanced metabolic activation or increased 
sensitivity of the immune system. Polymorphisms in metabolizing enzymes or drug 
transporters may result in enhanced concentrations of a reactive metabolite at the 
target organ by increased formation or reduced excretion.36 The immune system can 
also be sensitized by an underlying disease state at the time of drug treatment, such 
as viral infection with hepatitis B or C; or due to polymorphisms of factors involved 
in the immune system, such as the human leukocyte antigens (HLA) or cytokines.37
Prediction and monitoring of idiosyncratic DILI
Because of the low incidence and multifactorial cause, idiosyncratic DILI cannot 
be predicted yet during drug development. Many studies focus on developing new 
methods, both in vitro and in vivo, however, with model systems it remains difficult to 
mimic clinical features like interindividual differences in susceptibility. Methods have 
been developed to introduce susceptibility of the animal, tissue slice or cell culture 
for an adverse drug response by adding factors that boost the immune system, 
such as lipopolysaccharide or cytokines, or by knocking down genes involved in 
the immune response or drug metabolism.38-40 Furthermore, the intrinsic ability of a 
drug to get metabolically activated or to elicit an immune response can be assessed, 
whether or not this would occur in the general population.
Another approach to reduce the incidence of idiosyncratic DILI is to find predictive 
biomarkers that can be used to identify and monitor patients that are at risk. Since only 
as little as 1 in 100,000 patients might experience an adverse effect, many patients 
would be deprived of their medication if a drug were withdrawn from the market. 
Examples of drugs that have been withdrawn include troglitazone and bromfenac.41-42 
Adequate biomarkers would allow the drug to remain on the market and keep the 
risk of DILI low. There are many conventionally used biomarkers of liver injury, of 
which the plasma liver enzymes are mostly used. Plasma alanine aminotransferase 
(ALT) is considered to be the golden standard for liver injury, especially for acute 
hepatocellular injury.43 Other plasma biomarkers include aspartate aminotransferase 
(AST) and sorbitol dehydrogenase (SDG); biomarkers used for hepatobiliary injury 
and cholestasis are total bilirubin, gamma-glutamyl transferase, bile acids and 
alkaline phosphatase.44 These are straightforward liver injury biomarkers, however, 
a drawback is their intracellular localization and leakage from the hepatocytes upon 
damage. Therefore, these markers are not particularly predictive for liver injury but 
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1are associated with membrane disruption processes.
44-45 Moreover, most of these 
biomarkers are not specific for hepatic injury; for instance, plasma ALT and AST are 
also markers for skeletal muscle injury.46 In addition, some drugs lead to elevation of 
these plasma liver enzymes without causing liver injury, thus impeding their use as 
biomarker.47 For example, diclofenac and methotrexate are able to cause transiently 
increased plasma ALT levels, while there is no evidence for liver injury.41, 42 For such 
drugs, currently the most reliable method to evaluate liver injury is taking a biopsy, 
which is a burden for the patient and not without risk.4 Thus, there is a need for new 
predictive biomarkers of DILI that can be used to monitor patients. Many alternatives 
have been proposed and good progress has been made, but so far, none have been 
implemented in routine clinical practice yet. Because inflammatory processes are 
involved in many types of DILI, cytokines and chemokines have been suggested 
as potential biomarkers.43, 44 The context in which they could be used needs to be 
investigated further. Another important mechanism in DILI is metabolic activation of 
the drug and subsequent adduct formation, therefore, measuring such adducts in 
plasma or urine could be a way of monitoring patients. For human APAP intoxication, 
adducts in plasma correlated well with liver injury.45 The possibility of using plasma 
drug-protein adducts as biomarkers of DILI caused by other drugs remains to be 
investigated. For hepatic fibrosis, several alternative methods have been developed 
to monitor patients, including measuring serum procollagen type III aminopeptide 
(PIIINP), multi-test algorithms, such as the Fibrotest score and Hepascore, and 
physical diagnostic methods, such as Fibroscan.48 However, the predictive potential 
of these methods is still not clear. Furthermore, microRNAs have emerged as 
potential biomarkers in the past few years. MicroRNAs are small, regulatory 
noncoding RNAs, which are thought to affect mRNA stability and protein translation.49 
It was demonstrated that liver-specific microRNAs, such as miR-122, are elevated 
in serum of mice with APAP-induced liver injury.48 Recently, it has been shown that 
this also occurs in human APAP intoxicants and preclinical data suggests that after 
hepatic injury miR-122 might be released earlier injury than ALT.50 Although miR-122 
shows a good correlation with APAP-induced liver injury, it is probably not sufficient 
as single biomarker for monitoring DILI in general, and research is now focused on 
establishing a panel of microRNAs that might be predictive and discriminative for 
the various types of DILI and their underlying pathologic mechanisms. Finally, the 
detection of key proteins in various biological samples has been investigated in the 
search for new biomarkers for DILI. Discovery of protein biomarkers predictive for 
DILI is achieved using proteomics techniques, which are discussed below in more 
detail. 
22
Chapter 1
1Proteomics in the search of DILI biomarkersProteomicsThe field of proteomics includes all technologies used to assess protein identification 
and quantification in biological samples. It has emerged as a quickly developing 
field and is used extensively in biomarker research.50, 51 There are many proteomics 
techniques based on different principles that can be applied to compare the 
proteome between samples for biomarker assessment. Two-dimensional difference 
gel electrophoreses (2D-DIGE) is based on the separation of proteins by charge 
firstly, and subsequently by mass. With 2D-DIGE the proteins of multiple samples 
can be compared within one gel, as the samples can be labeled with spectrally 
distinct, charge and mass-matched, fluorescent dyes (Cy2, Cy3 and Cy5). Often 
these separation techniques are followed by a mass spectrometry (MS) technique 
for protein identification, for instance matrix-assisted laser desorption/ionization 
(MALDI) MS, liquid chromatography (LC) MS or electrospray ionization (ESI) MS.51 
After protein digestion, these MS techniques cause fragmentation and ionization 
of the proteins in a sample allowing peptide identification using species-specific 
databases. Besides protein identification, MALDI time-of-flight (TOF) MS can 
also be used for protein profiling, often in combination with isolation of a specific 
protein fraction from the sample using (magnetic) beads.52 Surface-enhanced laser 
desorption/ionization (SELDI) TOF MS is another method used for protein profiling. 
With this technique, a specific protein fraction is isolated from the sample by using 
chip surfaces that allow selective binding of proteins with different physicochemical 
properties. Table 2 gives an overview of the progress made by these proteomics 
techniques in search for biomarkers of all types of drug- or chemical-induced liver 
injury.
Sample selection
In vitro hepatocyte models can be used to determine which proteins are modified 
upon drug treatment, but also which proteins are excreted as a result of cell 
damage.53 Liver tissue obtained from animal studies or biopsies in patients are used 
to identify proteins that change due to DILI in the target organ, whereas plasma 
biomarker research focuses on the change in protein composition of blood due to 
DILI.51 Likewise, urine is used to assess proteins related to DILI as non-invasive 
biomarkers.54 Proteomics can be used to identify biomarkers related to DILI, and 
also allows mechanistic insight in the processes involved in DILI by highlighting 
the pathways in which the identified proteins are involved. Moreover, proteomics 
techniques can reveal to what modifications proteins have been subjected to, for 
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1instance oxidation or adduct formation.
55
Cell-based models used in proteomics research for DILI
For in vitro research involving (idiosyncratic) DILI different models have been 
described, including cell lines, like HepG2, and primary hepatocytes of animal or 
human origin. Van Summeren et al. have treated HepG2 cells with APAP, cyclosporine 
A and amiodarone to study necrosis, cholestasis and steatosis, respectively.55 
They analyzed the difference in intracellular proteins using a combined 2DIGE 
and MALDI-TOF-TOF approach. Changes in protein expression were observed 
for carboxylesterase 1 with APAP treatment, serotransferrin with cyclosporine A 
and aldo-keto reductase with amiodarone. Hepatic necrosis, phospholipidosis and 
steatosis were studied in primary rat hepatocytes by 24 h incubation with APAP, 
amiodarone and tetracyclines, respectively.56 For APAP treatment an increase in 13 
proteins and a decreased expression of 33 proteins was demonstrated. Amiodarone 
treatment resulted in 18 up-regulated and 42 down-regulated proteins, whereas 
tetracycline treatment increased the expression of 13 proteins and reduced the 
expression of 34 proteins. 
These proteins were mostly related to oxidative stress, a process now recognized as 
an important feature of DILI. D-galactosamine-induced necrosis and apoptosis was 
studied in primary hepatocytes of human origin, showing changes in intracellular 
protein expression of fatty acid binding protein and superoxide dismutase 2.57
Besides analyzing changes in the intracellular proteome, in vitro assays have been 
used to study changes in the proteins secreted by hepatocytes upon DILI. Ethanol 
has been used as a model compound to study liver cirrhosis and HepG2/C3A cells 
treated with ethanol showed marked changes in the constitution and abundance of 
proteins secreted after treatment.58 Proteins that leak out of the hepatocyte could be 
candidate biomarkers for human DILI if they can be measured in blood or urine. Gao 
et al analyzed proteins excreted in the surrounding medium of human hepatocytes 
stably transfected with CYP3A4 by solid phase extraction and ion MS.59 They chose 
several PPARγ agonists, some of which were hepatotoxic, including troglitazone; a 
drug that was withdrawn from the market by the FDA due to idiosyncratic DILI.53 Two 
proteins were identified as being excreted by the hepatocytes upon treatment with 
the known hepatotoxic PPARγ agonists as compared to the nontoxic drugs.  
In vitro models have also been used to study the mechanisms of DILI. Jenkins et 
al. established a method using HepG2 cells transfected with human glutathione-
S-transferase pi (GSTP), a target for adduct formation, to investigate the potential 
of a reactive metabolite to form adducts.60 They used APAP as model compound 
to demonstrate the formation of an adduct of NAPQI with GSTP, which had been 
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1observed in vivo. To unravel the mitochondrial processes involved in APAP-mediated DILI, Stamper et al. isolated the mitochondrial proteins of immortalized murine TGF-α transgenic hepatocyte (TAMH) cells after incubation with APAP.61 MS analysis showed that many proteins, especially from the electron transport chain, were post-
translationally modified, indicating their involvement in the process of APAP-induced 
liver injury.
Proteomics of DILI using hepatic tissue
Proteomic analysis of liver tissue reveals the proteins that are affected by drug 
treatment in the target organ and, thus, closely links pathology to potential biomarkers 
or mechanisms. For APAP-induced liver injury, Fountoulakis et al. showed that the 
abundance of 35 proteins was altered after APAP treatment of C57Bl/6 mice.62 Some 
of these proteins were known targets for covalent modification by NAPQI, others 
were possibly related to the mechanisms that drive APAP-mediated DILI. Proteins 
changed in rat liver after APAP treatment were identified to be involved mainly in 
the following processes: cell proliferation, stress and cell damage response, and 
metabolism of glutathione, lipids, fatty acids, carbohydrates or amino acids.63 
The hepatic mitochondrial fraction of CD-1 mice demonstrated 20 proteins to 
be increased or reduced in any of the various time points (15-240 minutes) after 
APAP administration.64 Concerning hepatic mitochondrial protein modification by 
APAP, Andringa et al. showed that minor changes in protein thiols occurred, and 
that probably other modifications, such as nitration of tyrosine residues, are more 
important for APAP-induced liver injury.65 Treatment of Sod2+/- mice with troglitazone 
resulted in 70 mitochondrial proteins that were significantly changed in abundance 
compared to vehicle-treated mice, of which aconitase-2 appeared to be the most 
sensitive marker for mitochondrial oxidant stress.66 
Hepatic fibrosis was induced in rats by ethanol treatment, after which the plasma 
membrane fraction of liver cell homogenates was isolated for proteomics analysis.67 
In total, 16 plasma membrane proteins were changed in fibrotic liver, among which 
annexin-V and peroxiredoxin 1.
Protein changes in hepatic steatosis have been demonstrated in rat liver after 
treatment with a compound known to cause steatosis.68-69 Identification of these 
proteins suggested that the β-oxidation pathway was disrupted by the compound, 
leading to steatosis. Another way of investigating hepatic proteins involved in 
steatosis is to compare obese and control mice.70 These ob/ob mice develop fatty 
livers and many hepatic proteins showed a difference compared to wildtype; mostly 
proteins involved in oxidative stress, fatty acid oxidation, gluconeogenesis, amino 
acid metabolism and peroxisomal proteins.
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1Low et al. induced cirrhosis in rats by thioacetaamide (TAA) treatment to investigate the effect on hepatic proteins.71 They identified many proteins that were changed in abundance related to cirrhosis, which were classified in the following clusters: energy metabolism, iron and heme metabolism, metabolism of carbonyl compounds 
and glutathione related proteins. Mölleken et al. were able to obtain human liver 
material of seven patients with liver cirrhosis and performed proteomics analysis on 
the tissues. They discovered high protein abundance for 9 proteins related to cell 
structure, of which microfibril-associated glycoprotein-4 could be a potential serum 
biomarker.72   
Proteomics of DILI using serum or plasma
Plasma and serum biomarkers like ALT, AST, bilirubin, alkaline phosphatase, gamma-
glutamyl transferase, are often used to assess liver function.44 New plasma or serum 
biomarkers that are more predictive for DILI would thus easily fit in the battery of 
tests already used to monitor patients. In animal models it is possible to study the 
effect on the blood proteome of a single drug. Amacher et al. analyzed the proteins 
in rat serum after treatment with one of four different hepatotoxic compounds; APAP 
for hepatocellular injury, α-napthylisocyanate for cholestasis, and phenobarbital and 
WY-14,643 for hypertrophy.73 They identified 19 proteins that originated from the 
liver to be changed in serum abundance after liver injury induced by these drugs. 
Similarly, Merrick et al. identified 38 proteins in serum with increased or decreased 
protein abundances due to APAP-induced liver injury.74 Both studies had 5 proteins 
in common, including transthyretin, complement component 3, apolipoprotein E, 
apolipoprotein H and hemopexin. 
To study changes in the blood proteome associated with hepatic fibrosis, rats were 
treated with TAA, after which serum haptoglobin was reduced.70 In another study, 
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) was used to induce hepatic fibrosis 
in rats, which led to the identification of fibrinopeptide A in serum as potential 
biomarker.75
Analysis of human blood samples for DILI biomarkers can be very difficult because 
of interindividual variation of the blood proteome due to diet, underlying disease, 
genetic and gender differences and drug use.76 Moreover, it is a challenge to collect 
a sufficient number of samples to analyze changes in the blood proteome caused 
by DILI due to a single drug. Therefore, it is more effective to study changes in 
blood proteome after a specific type of liver injury, which might have been caused by 
an adverse drug reaction. Profiling of human serum in an alcohol-induced cirrhosis 
study resulted in the identification of fibrinogen and apolipoprotein A as potential 
biomarkers.77 Bell et al. have studied the serum proteome in 114 DILI patients caused 
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1by various drugs.
78 They were able to correlate serum proteins to the currently used 
serum biomarkers for liver function and compare the patients based on disease 
pattern, severity and causality assessments. Their findings led to the identification of 
proteins related to toxicity-specific pathways that could be used to assess different 
types of DILI, including apolipoprotein E and gelsolin. In addition, a similar study 
performed by Soga et al. identified various gamma-glutamyldipeptides as potential 
biomarkers for DILI.79 
Besides cases of typical drug-induced injury, also serum samples of patients with 
non-drug-induced hepatic injury have been studied in order to identify biomarkers for 
a specific type of liver injury. Liu et al. investigated changes in serum low-molecular 
weight proteins and peptides due to hepatitis using SELDI TOF MS.80 They found 
43 peptide mass peaks that discriminated between control and hepatitis serum 
samples, which they suggested to be related to coagulation processes. Serum 
protein biomarkers for steatosis were assessed in patients with non-alcoholic fatty 
liver disease (NAFLD).81 First, proteins that differed between control and NAFLD 
were identified from liver tissue, of which two candidate biomarkers, carbamoyl 
phosphatase synthase 1 and 78 kDa glucose-regulated protein, were assessed 
further in serum samples. Progression of steatosis can ultimately result in cirrhosis 
and, thus, NAFLD patients can also be used to identify biomarkers for cirrhosis. 
Indeed, in a study performed by Gray et al. it was found that serum apolipoproteins 
and CD51 were able to discriminate between various stages of NAFLD cirrhosis.82 
Hepatic cirrhosis and fibrosis can also be studied in patients with hepatitis C infection, 
as was done by Gangadharan et al.83 They identified complement factor C3 and C4 
as new markers for hepatic cirrhosis in serum.
Proteomics of DILI using urine
Compared to blood, urine has a much lower amount of proteins of which approximately 
70% originate from the kidney. Nevertheless, proteins related to other organ toxicities 
are detectable in urine.84 Therefore, the use of urinary biomarkers for urogenital and 
non-urogenital pathologies has emerged over the past few years.54 Regarding urinary 
biomarkers for hepatotoxocity, proteomics techniques have been implemented, but 
not as much as for serum or plasma. Urinary protein profiling using SELDI TOF of 
mouse urine with carbon tetrachloride-induced liver injury led to the discovery of 
superoxide dismutase 1 as potential urinary biomarker for hepatic necrosis in rats.85 
In a rat model for drug-induced hepatobiliary injury, urinary proteomics showed 
proteins to be detectable in urine in a time- and dose-dependent manner.86
Although proteomics techniques have not been used for urine to the same extent 
as for blood or tissue, other techniques have demonstrated that urinary biomarkers 
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1can be very useful to monitor DILI. Miller et al. have indicated the use of urinary cytochrome c as a biomarker of mitochondrial injury for DILI in rats using ELISA.87 Also metabolomics techniques have been used to identify urinary biomarkers predictive for DILI by constructing a fingerprint of the metabolites present. Urine 
is particularly suitable as biofluid for metabolomics studies, because it is a rich 
source of proteins and metabolites and easily accessible.88 Hasegawa et al. made 
a metabolomics fingerprint in urine of rats with TAA-induced cirrhosis that appeared 
to be related to macrophage infiltration in the injured liver.89 Specific metabolomes 
were identified from urine of rats with DILI caused by valproic acid, which correlated 
well with the serum biomarker used to assess the liver injury induced, α-glutathione 
S-transferase.90 Recently, distinct urinary metabolite profiles have been demonstrated 
for hepatotoxicity in rats induced by APAP, carbon tetrachloride and methotrexate.91 
MicroRNAs as biomarkers for DILI have been extensively studied in serum, but are 
also present in urine. Yang et al have demonstrated a panel of ten microRNAs to 
appear in rat urine after hepatotoxicity caused by APAP and carbon tetrachloride.92 
Additionally, they found treatment-specific urinary microRNAs enabling discrimination 
between the two hepatotoxicants. These findings are promising for urine as medium 
for biomarker evaluation, including the use of proteomics.  
Translational biomarker research for idiosyncratic DILI
Identifying biomarkers predictive for idiosyncratic DILI has proven to be difficult 
because of the poorly understood underlying mechanisms. Much of the research in 
this field has focused on fine-tuning in vitro and animal models to mimic elements 
of human idiosyncratic DILI. However, for biomarker identification often a complete 
organism is required, especially if these biomarkers should be measured in plasma 
or urine. Moreover, since idiosyncratic DILI is a condition that specifically affects 
humans, biomarker identification and ultimately validation should be performed 
in human samples. Because the incidence of idiosyncratic DILI is relatively low, 
biomarker research in humans is difficult and progresses slowly. Therefore, a 
translational approach using proteomic tools at different biological levels, as 
described above, will be necessary to find human biomarkers for idiosyncratic DILI. 
One approach is to focus first on the identification of common predictive biomarkers 
for normal types of DILI that can be investigated by combining in vitro, in vivo and 
clinical research. There are a large number of model compounds known to cause 
hepatotoxicity for all types of hepatic injury. Using such model compounds, proteins 
related to a specific type of liver injury can be identified, which can then be validated 
as predictive biomarkers. Because also idiosyncratic DILI presents as any of the 
known types of liver injury, the next step would be to assess whether the biomarkers 
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1that were identified for the various types of normal DILI also relate to idiosyncratic DILI. This could be achieved by measuring the presence of the protein biomarkers for normal DILI in samples of patients with idiosyncratic DILI. For a translational approach in biomarker identification urine would be an ideal source, as it is easily 
accessible in both animals and humans. 
Aim of this thesis
The research described in this thesis was focused on the assessment and 
identification of non-invasive biomarkers that are predictive for (idiosyncratic) DILI. 
Model drugs can be used to investigate various types of liver injury in order to find 
biomarkers or get insight in the underlying disease mechanisms. We used APAP 
administration in mice to identify urinary biomarkers related to acute liver injury, but 
also to unravel the pathologic mechanisms that play a role in acute hepatotoxicity 
(Chapters 2 and 3). To find urinary biomarkers for mixed hepatocellular/cholestatic 
liver injury, mice were treated with DF, the results of which are described in Chapter 
4. Besides in vivo studies, we applied an in vitro model using precision-cut liver slices 
to investigate whether the proteins found in urine were released by liver tissue upon 
treatment with APAP and DF. The results of this study are described in Chapter 5. 
In Chapter 6 we performed proteomics studies on human urine samples of psoriasis 
patients to find biomarkers for MTX-induced hepatic fibrosis. 
A general discussion on models used for biomarker identification, mechanistic 
research concerning idiosyncratic DILI and future implications of our results is given 
in Chapter 7. 
References
1. Tujios, S. and R.J. Fontana, Mechanisms of drug-induced liver injury: from bedside 
to bench. Nat Rev Gastroenterol Hepatol, 2011. 8(4): p. 202-11.
2. Andrade, R.J., et al., Drug-induced liver injury: an analysis of 461 incidences 
submitted to the Spanish registry over a 10-year period. Gastroenterology, 2005. 
129(2): p. 512-21.
3. Fontana, R.J., Approaches to the study of drug-induced liver injury. Clin Pharmacol 
Ther, 2010. 88(3): p. 416-9.
4. Kleiner, D.E., The pathology of drug-induced liver injury. Semin Liver Dis, 2009. 
29(4): p. 364-72.
5. Ramachandran, R. and S. Kakar, Histological patterns in drug-induced liver 
disease. J Clin Pathol, 2009. 62(6): p. 481-92.
6. Chitturi, S. and G.C. Farrell, Drug-induced cholestasis. Semin Gastrointest Dis, 
2001. 12(2): p. 113-24.
7. Lee, C.H., J.D. Wang, and P.C. Chen, Increased risk of hospitalization for acute 
32
Chapter 1
1 hepatitis in patients with previous exposure to NSAIDs. Pharmacoepidemiol Drug Saf, 2010. 19(7): p. 708-14.8. Toghill, P.J., et al., Acute hepatic necrosis following an overdose of paracetamol. Gastroenterology, 1969. 56(4): p. 773-6.9. Bercoff, E., et al., Ketoconazole-induced fulminant hepatitis. Gut, 1985. 26(6): p. 
636-8.
10. Black, M., et al., Isoniazid-associated hepatitis in 114 patients. Gastroenterology, 
1975. 69(2): p. 289-302.
11. Weinstein, A., et al., Low-dose methotrexate treatment of rheumatoid arthritis. 
Long-term observations. Am J Med, 1985. 79(3): p. 331-7.
12. Langman, G., P.M. Hall, and G. Todd, Role of non-alcoholic steatohepatitis in 
methotrexate-induced liver injury. J Gastroenterol Hepatol, 2001. 16(12): p. 1395-
401.
13. Olson, M.J., J.A. Handler, and R.G. Thurman, Mechanism of zone-specific hepatic 
steatosis caused by valproate: inhibition of ketogenesis in periportal regions of the 
liver lobule. Mol Pharmacol, 1986. 30(6): p. 520-5.
14. Osman, K.A., M.M. Osman, and M.H. Ahmed, Tamoxifen-induced non-alcoholic 
steatohepatitis: where are we now and where are we going? Expert Opin Drug Saf, 
2007. 6(1): p. 1-4.
15. Stirnimann, G., K. Kessebohm, and B. Lauterburg, Liver injury caused by drugs: an 
update. Swiss Med Wkly, 2010. 140: p. w13080.
16. Daly, A.K., Drug-induced liver injury: past, present and future. Pharmacogenomics, 
2010. 11(5): p. 607-11.
17. Kaplowitz, N., Drug-induced liver injury. Clin Infect Dis, 2004. 38 Suppl 2: p. S44-8.
18. Manyike, P.T., et al., Contribution of CYP2E1 and CYP3A to acetaminophen 
reactive metabolite formation. Clin Pharmacol Ther, 2000. 67(3): p. 275-82.
19. Bartolone, J.B., et al., Selective acetaminophen metabolite binding to hepatic and 
extrahepatic proteins: an in vivo and in vitro analysis. Toxicol Appl Pharmacol, 
1989. 99(2): p. 240-9.
20. McGill, M.R., et al., The mechanism underlying acetaminophen-induced 
hepatotoxicity in humans and mice involves mitochondrial damage and nuclear 
DNA fragmentation. J Clin Invest, 2012. 122(4): p. 1574-83.
21. Hinson, J.A., D.W. Roberts, and L.P. James, Mechanisms of acetaminophen-
induced liver necrosis. Handb Exp Pharmacol, 2010(196): p. 369-405.
22. Fredriksson, L., et al., Diclofenac inhibits tumor necrosis factor-alpha-induced 
nuclear factor-kappaB activation causing synergistic hepatocyte apoptosis. 
Hepatology, 2011. 53(6): p. 2027-41.
23. Itoh, K., et al., Regulatory mechanisms of cellular response to oxidative stress. 
Free Radic Res, 1999. 31(4): p. 319-24.
24. Nguyen, T., C.S. Yang, and C.B. Pickett, The pathways and molecular mechanisms 
regulating Nrf2 activation in response to chemical stress. Free Radic Biol Med, 
2004. 37(4): p. 433-41.
25. Salamone, F., et al., Silibinin modulates lipid homeostasis and inhibits nuclear 
factor kappa B activation in experimental nonalcoholic steatohepatitis. Transl Res, 
2012. 159(6): p. 477-86.
26. Seki, E., D.A. Brenner, and M. Karin, A liver full of JNK: signaling in regulation of 
cell function and disease pathogenesis, and clinical approaches. Gastroenterology, 
2012. 143(2): p. 307-20.
27. Walgren, J.L., M.D. Mitchell, and D.C. Thompson, Role of metabolism in drug-
induced idiosyncratic hepatotoxicity. Crit Rev Toxicol, 2005. 35(4): p. 325-61.
28. Adams, D.H., et al., Mechanisms of immune-mediated liver injury. Toxicol Sci, 
2010. 115(2): p. 307-21.
29. Ju, C. and T. Reilly, Role of immune reactions in drug-induced liver injury (DILI). 
Drug Metab Rev, 2012. 44(1): p. 107-15.
30. Jaeschke, H., M.R. McGill, and A. Ramachandran, Oxidant stress, mitochondria, 
33
General introduction
1and cell death mechanisms in drug-induced liver injury: lessons learned from acetaminophen hepatotoxicity. Drug Metab Rev, 2012. 44(1): p. 88-106.31. Zhang, X., et al., Involvement of the immune system in idiosyncratic drug reactions. Drug Metab Pharmacokinet, 2011. 26(1): p. 47-59.32. Boelsterli, U.A., Diclofenac-induced liver injury: a paradigm of idiosyncratic drug 
toxicity. Toxicol Appl Pharmacol, 2003. 192(3): p. 307-22.
33. Higuchi, S., et al., Metabolic activation and inflammation reactions involved in 
carbamazepine-induced liver injury. Toxicol Sci, 2012.
34. Pichler, W.J., et al., Pharmacological interaction of drugs with immune receptors: 
the p-i concept. Allergol Int, 2006. 55(1): p. 17-25.
35. Lavergne, S.N., B.K. Park, and D.J. Naisbitt, The roles of drug metabolism in 
the pathogenesis of T-cell-mediated drug hypersensitivity. Curr Opin Allergy Clin 
Immunol, 2008. 8(4): p. 299-307.
36. Amacher, D.E., The primary role of hepatic metabolism in idiosyncratic drug-
induced liver injury. Expert Opin Drug Metab Toxicol, 2012. 8(3): p. 335-47.
37. Chalasani, N. and E. Bjornsson, Risk factors for idiosyncratic drug-induced liver 
injury. Gastroenterology, 2010. 138(7): p. 2246-59.
38. Boelsterli, U.A. and C.J. Hsiao, The heterozygous Sod2(+/-) mouse: modeling the 
mitochondrial role in drug toxicity. Drug Discov Today, 2008. 13(21-22): p. 982-8.
39. Cosgrove, B.D., et al., Synergistic drug-cytokine induction of hepatocellular death 
as an in vitro approach for the study of inflammation-associated idiosyncratic drug 
hepatotoxicity. Toxicol Appl Pharmacol, 2009. 237(3): p. 317-30.
40. Roth, R.A. and P.E. Ganey, Intrinsic versus idiosyncratic drug-induced 
hepatotoxicity--two villains or one? J Pharmacol Exp Ther, 2010. 332(3): p. 692-7.
41. Graham, D.J., C.R. Drinkard, and D. Shatin, Incidence of idiopathic acute liver 
failure and hospitalized liver injury in patients treated with troglitazone. Am J 
Gastroenterol, 2003. 98(1): p. 175-9.
42. Hunter, E.B., et al., Bromfenac (Duract)-associated hepatic failure requiring liver 
transplantation. Am J Gastroenterol, 1999. 94(8): p. 2299-301.
43. Watkins, P.B., Biomarkers for the diagnosis and management of drug-induced liver 
injury. Semin Liver Dis, 2009. 29(4): p. 393-9.
44. Ozer, J., et al., The current state of serum biomarkers of hepatotoxicity. Toxicology, 
2008. 245(3): p. 194-205.
45. Watkins, P.B., et al., Using controlled clinical trials to learn more about acute drug-
induced liver injury. Hepatology, 2008. 48(5): p. 1680-9.
46. Nathwani, R.A., et al., Serum alanine aminotransferase in skeletal muscle 
diseases. Hepatology, 2005. 41(2): p. 380-2.
47. Amacher, D.E., Serum transaminase elevations as indicators of hepatic injury 
following the administration of drugs. Regul Toxicol Pharmacol, 1998. 27(2): p. 119-
30.
48. Chladek, J., et al., Assessment of methotrexate hepatotoxicity in psoriasis patients: 
a prospective evaluation of four serum fibrosis markers. J Eur Acad Dermatol 
Venereol, 2012.
49. Au, J.S., V.J. Navarro, and S. Rossi, Review article: Drug-induced liver injury--its 
pathophysiology and evolving diagnostic tools. Aliment Pharmacol Ther, 2011. 
34(1): p. 11-20.
50. Starkey Lewis, P.J., et al., Serum microRNA Biomarkers for Drug-Induced Liver 
Injury. Clin Pharmacol Ther, 2012. 92(3): p. 291-3.
51. Merrick, B.A., Toxicoproteomics in liver injury and inflammation. Ann N Y Acad Sci, 
2006. 1076: p. 707-17.
52. Fiedler, G.M., et al., Standardized peptidome profiling of human urine by magnetic 
bead separation and matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry. Clin Chem, 2007. 53(3): p. 421-8.
53. Van Summeren, A., et al., Proteomics in the search for mechanisms and 
biomarkers of drug-induced hepatotoxicity. Toxicol In Vitro, 2012. 26(3): p. 373-85.
34
Chapter 1
154. Decramer, S., et al., Urine in clinical proteomics. Mol Cell Proteomics, 2008. 7(10): p. 1850-62.55. Merrick, B.A., The plasma proteome, adductome and idiosyncratic toxicity in toxicoproteomics research. Brief Funct Genomic Proteomic, 2008. 7(1): p. 35-49.56. Yamamoto, T., et al., Identification of oxidative stress-related proteins for predictive 
screening of hepatotoxicity using a proteomic approach. J Toxicol Sci, 2005. 30(3): 
p. 213-27.
57. Rodriguez-Ariza, A., et al., Altered protein expression and protein nitration pattern 
during d-galactosamine-induced cell death in human hepatocytes: a proteomic 
analysis. Liver Int, 2005. 25(6): p. 1259-69.
58. Lewis, J.A., et al., Analysis of secreted proteins as an in vitro model for discovery of 
liver toxicity markers. J Proteome Res, 2010. 9(11): p. 5794-802.
59. Gao, J., et al., Identification of in vitro protein biomarkers of idiosyncratic liver 
toxicity. Toxicol In Vitro, 2004. 18(4): p. 533-41.
60. Jenkins, R.E., et al., Glutathione-S-transferase pi as a model protein for the 
characterisation of chemically reactive metabolites. Proteomics, 2008. 8(2): p. 301-
15.
61. Stamper, B.D., et al., Proteomic analysis of acetaminophen-induced changes in 
mitochondrial protein expression using spectral counting. Chem Res Toxicol, 2011. 
24(4): p. 549-58.
62. Fountoulakis, M., et al., Two-dimensional database of mouse liver proteins: 
changes in hepatic protein levels following treatment with acetaminophen or its 
nontoxic regioisomer 3-acetamidophenol. Electrophoresis, 2000. 21(11): p. 2148-
61.
63. Yamamoto, T., et al., Investigation of proteomic biomarkers in in vivo hepatotoxicity 
study of rat liver: toxicity differentiation in hepatotoxicants. J Toxicol Sci, 2006. 
31(1): p. 49-60.
64. Ruepp, S.U., et al., Genomics and proteomics analysis of acetaminophen toxicity in 
mouse liver. Toxicol Sci, 2002. 65(1): p. 135-50.
65. Andringa, K.K., et al., Mitochondrial protein thiol modifications in acetaminophen 
hepatotoxicity: effect on HMG-CoA synthase. Toxicol Lett, 2008. 177(3): p. 188-97.
66. Lee, Y.H., et al., Troglitazone-induced hepatic mitochondrial proteome expression 
dynamics in heterozygous Sod2(+/-) mice: two-stage oxidative injury. Toxicol Appl 
Pharmacol, 2008. 231(1): p. 43-51.
67. Jia, X., et al., A dynamic plasma membrane proteome analysis of alcohol-induced 
liver cirrhosis. Proteome Sci, 2012. 10(1): p. 39.
68. Meneses-Lorente, G., et al., A proteomic investigation of drug-induced steatosis in 
rat liver. Chem Res Toxicol, 2004. 17(5): p. 605-12.
69. Meneses-Lorente, G., et al., Identification of early proteomic markers for hepatic 
steatosis. Chem Res Toxicol, 2006. 19(8): p. 986-98.
70. Douette, P., et al., Steatosis-induced proteomic changes in liver mitochondria 
evidenced by two-dimensional differential in-gel electrophoresis. J Proteome Res, 
2005. 4(6): p. 2024-31.
71. Low, T.Y., et al., A proteomic analysis of thioacetamide-induced hepatotoxicity and 
cirrhosis in rat livers. Proteomics, 2004. 4(12): p. 3960-74.
72. Molleken, C., et al., Detection of novel biomarkers of liver cirrhosis by proteomic 
analysis. Hepatology, 2009. 49(4): p. 1257-66.
73. Amacker, D. E., et al., Use of proteomic methods to identify serum biomarkers 
associated with rat liver toxicity or hypertrophy. Clin Chem, 2005. 51(10):p. 1796-
803.
74. Merrick, B.A., et al., Alterations in the rat serum proteome during liver injury from 
acetaminophen exposure. J Pharmacol Exp Ther, 2006. 318(2): p. 792-802.
75. Chen, X., et al., Changes in fibrinopeptide A peptides in the sera of rats chronically 
exposed to low doses of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Environ 
Toxicol Pharmacol, 2012. 33(2): p. 191-6.
35
General introduction
176. Winnike, J.H., et al., Use of pharmaco-metabonomics for early prediction of acetaminophen-induced hepatotoxicity in humans. Clin Pharmacol Ther, 2010. 88(1): p. 45-51.77. Nomura, F., et al., Identification of novel and downregulated biomarkers for alcoholism by surface enhanced laser desorption/ionization-mass spectrometry. 
Proteomics, 2004. 4(4): p. 1187-94.
78. Bell, L.N., et al., Serum proteomic profiling in patients with drug-induced liver injury. 
Aliment Pharmacol Ther, 2012. 35(5): p. 600-12.
79. Soga, T., et al., Serum metabolomics reveals gamma-glutamyl dipeptides as 
biomarkers for discrimination among different forms of liver disease. J Hepatol, 
2011. 55(4): p. 896-905.
80. Liu, X., et al., An approach to the characterization of serum low-molecular weight 
proteins/peptides in liver injury using SELDI-TOF MS and factor analysis. Clin 
Biochem, 2007. 40(16-17): p. 1266-71.
81. Rodriguez-Suarez, E., et al., Non-alcoholic fatty liver disease proteomics. 
Proteomics Clin Appl, 2010. 4(4): p. 362-71.
82. Gray, J., et al., A proteomic strategy to identify novel serum biomarkers for liver 
cirrhosis and hepatocellular cancer in individuals with fatty liver disease. BMC 
Cancer, 2009. 9: p. 271.
83. Gangadharan, B., et al., New approaches for biomarker discovery: the search for 
liver fibrosis markers in hepatitis C patients. J Proteome Res, 2011. 10(5): p. 2643-
50.
84. Thongboonkerd, V., Urinary proteomics: towards biomarker discovery, diagnostics 
and prognostics. Mol Biosyst, 2008. 4(8): p. 810-5.
85. Smyth, R., et al., Identification of superoxide dismutase as a potential urinary 
marker of carbon tetrachloride-induced hepatic toxicity. Food Chem Toxicol, 2008. 
46(9): p. 2972-83.
86. Adler, M., et al., Assessment of candidate biomarkers of drug-induced hepatobiliary 
injury in preclinical toxicity studies. Toxicol Lett, 2010. 196(1): p. 1-11.
87. Miller, T.J., et al., Cytochrome c: a non-invasive biomarker of drug-induced liver 
injury. J Appl Toxicol, 2008. 28(7): p. 815-28.
88. Zhang, A., et al., Urine metabolomics. Clin Chim Acta, 2012. 414C: p. 65-69.
89. Hasegawa, M., et al., Urinary metabolic fingerprinting for thioacetamide-induced 
rat acute hepatic injury using fourier transform-ion cyclotron resonance mass 
spectrometry (FT-ICR MS), with reference to detection of potential biomarkers for 
hepatotoxicity. Toxicol Pathol, 2007. 35(4): p. 570-5.
90. Lee, M.S., et al., Metabolomics study with gas chromatography-mass spectrometry 
for predicting valproic acid-induced hepatotoxicity and discovery of novel 
biomarkers in rat urine. Int J Toxicol, 2009. 28(5): p. 392-404.
91. Kumar, B.S., et al., Discovery of common urinary biomarkers for hepatotoxicity 
induced by carbon tetrachloride, acetaminophen and methotrexate by mass 
spectrometry-based metabolomics. J Appl Toxicol, 2012. 32(7): p. 505-20.
92. Yang, X., et al., Identification of urinary microRNA profiles in rats that may diagnose 
hepatotoxicity. Toxicol Sci, 2012. 125(2): p. 335-44.
93. Ramachandran, A., et al., The impact of partial manganese superoxide dismutase 
(SOD2)-deficiency on mitochondrial oxidant stress, DNA fragmentation and liver 
injury during acetaminophen hepatotoxicity. Toxicol Appl Pharmacol, 2011. 251(3): 
p. 226-33.
94. Smilkstein, M.J., et al., Acetaminophen overdose: a 48-hour intravenous 
N-acetylcysteine treatment protocol. Ann Emerg Med, 1991. 20(10): p. 1058-63.
95. James, R., et al., The differential localization of various drug metabolizing systems 
within the rat liver lobule as determined by the hepatotoxins allyl alcohol, carbon 
tetrachloride and bromobenzene. J Pharmacol Exp Ther, 1981. 217(1): p. 127-32.
96. Hunter, A.L., M.A. Holscher, and R.A. Neal, Thioacetamide-induced hepatic 
necrosis. I. Involvement of the mixed-function oxidase enzyme system. J 
36
Chapter 1
1 Pharmacol Exp Ther, 1977. 200(2): p. 439-48.97. Ledda-Columbano, G.M., et al., Induction of two different modes of cell death, apoptosis and necrosis, in rat liver after a single dose of thioacetamide. Am J Pathol, 1991. 139(5): p. 1099-109.98. Dugan, C.M., et al., A mouse model of severe halothane hepatitis based on human 
risk factors. J Pharmacol Exp Ther, 2010. 333(2): p. 364-72.
99. Satoh, M., et al., Midzonal necrosis of the liver after concanavalin A-injection. 
Tohoku J Exp Med, 1996. 180(2): p. 139-52.
100. Miyamoto, Y., et al., Cisplatin (CDDP)-induced acute toxicity in an experimental 
model of hepatic fibrosis. J Toxicol Sci, 2007. 32(3): p. 311-9.
101. Belinsky, S.A., et al., Hepatotoxicity due to allyl alcohol in deermice depends on 
alcohol dehydrogenase. Hepatology, 1985. 5(6): p. 1179-82.
102. Ndikum-Moffor, F.M., T.R. Schoeb, and S.M. Roberts, Liver toxicity from norcocaine 
nitroxide, an N-oxidative metabolite of cocaine. J Pharmacol Exp Ther, 1998. 
284(1): p. 413-9.
103. Katoh, T., et al., Dose-dependent effects of dichloropropanol on liver histology and 
lipid peroxidation in rats. Ind Health, 1998. 36(4): p. 318-23.
104. Stachlewitz, R.F., et al., Glycine and uridine prevent D-galactosamine 
hepatotoxicity in the rat: role of Kupffer cells. Hepatology, 1999. 29(3): p. 737-45.
105. Boverhof, D.R., et al., Temporal and dose-dependent hepatic gene expression 
patterns in mice provide new insights into TCDD-Mediated hepatotoxicity. Toxicol 
Sci, 2005. 85(2): p. 1048-63.
106. Mansouri, A., et al., Tacrine inhibits topoisomerases and DNA synthesis to cause 
mitochondrial DNA depletion and apoptosis in mouse liver. Hepatology, 2003. 
38(3): p. 715-25.
107. Finnie, J.W., S.H. Read, and J.G. Swift, Apoptosis in liver damage produced by 
tunicamycin. Aust Vet J, 2004. 82(1-2): p. 87-90.
108. Zhong, W., et al., Chronic alcohol exposure stimulates adipose tissue lipolysis 
in mice: role of reverse triglyceride transport in the pathogenesis of alcoholic 
steatosis. Am J Pathol, 2012. 180(3): p. 998-1007.
109. Lee, M.H., et al., Gene expression profiles of murine fatty liver induced by the 
administration of methotrexate. Toxicology, 2008. 249(1): p. 75-84.
110. Natarajan, S.K., et al., Oxidative stress in experimental liver microvesicular 
steatosis: role of mitochondria and peroxisomes. J Gastroenterol Hepatol, 2006. 
21(8): p. 1240-9.
111. Cole, L.K., R.L. Jacobs, and D.E. Vance, Tamoxifen induces triacylglycerol 
accumulation in the mouse liver by activation of fatty acid synthesis. Hepatology, 
2010. 52(4): p. 1258-65.
112. Bramow, S., et al., Cholestasis and regulation of genes related to drug metabolism 
and biliary transport in rat liver following treatment with cyclosporine A and 
sirolimus (Rapamycin). Pharmacol Toxicol, 2001. 89(3): p. 133-9.
113. Chen, X., et al., Altered integrity and decreased expression of hepatocyte tight 
junctions in rifampicin-induced cholestasis in mice. Toxicol Appl Pharmacol, 2009. 
240(1): p. 26-36.
114. Yamamoto, Y., et al., Estrogen receptor alpha mediates 17alpha-ethynylestradiol 
causing hepatotoxicity. J Biol Chem, 2006. 281(24): p. 16625-31.
115. Amatsu, T., etal., Endoplasmic reticulum proliferates without an increase in 
cytochrome P-450 in hepatocytes of mice treated with phenobarbital and cobalt 
chloride. Eur J Cell Biol, 1995. 68(3): p. 256-62.
116. Boitier, E., et al., A comparative integrated transcript analysis and functional 
characterization of differential mechanisms for induction of liver hypertrophy in the 
rat. Toxicol Appl Pharmacol, 2011. 252(2): p. 85-96.
117. Fujimoto, N., et al., Estrogen and androgen receptor status in hepatocellular 
hypertrophy induced by phenobarbital, clofibrate, and piperonyl butoxide in F344 
rats. J Toxicol Sci, 2012. 37(2): p. 281-6.
37
General introduction
1118. Lamacchia, C., et al., Mice deficient in hepatocyte-specific IL-1Ra show delayed resolution of concanavalin A-induced hepatitis. Eur J Immunol, 2012. 42(5): p. 1294-303.119. Kobayashi, M., et al., Th2 cytokine-mediated methimazole-induced acute liver injury in mice. J Appl Toxicol, 2012. 32(10): p. 823-33.
120. Dugan, C.M., et al., Natural killer cells mediate severe liver injury in a murine model 
of halothane hepatitis. Toxicol Sci, 2011. 120(2): p. 507-18.
121. Krizhanovsky, V., et al., Senescence of activated stellate cells limits liver fibrosis. 
Cell, 2008. 134(4): p. 657-67.
122. Santra, A., et al., Hepatic damage caused by chronic arsenic toxicity in 
experimental animals. J Toxicol Clin Toxicol, 2000. 38(4): p. 395-405.
123. Hall, P.D., M.A. Jenner, and M.J. Ahern, Hepatotoxicity in a rat model caused by 
orally administered methotrexate. Hepatology, 1991. 14(5): p. 906-10.
124. Tan, X.F., et al., Science letters: Proteomic analysis of differentially expressed 
proteins in mice with concanavalin A-induced hepatitis. J Zhejiang Univ Sci B, 
2010. 11(3): p. 221-6.
125. Witzmann, F.A., et al., Two-dimensional electrophoretic analysis of compartment-
specific hepatic protein charge modification induced by thioacetamide exposure in 
rats. Fundam Appl Toxicol, 1996. 31(1): p. 124-32.
126. Wong, L.L., et al., Identification of liver proteins and their roles associated with 
carbon tetrachloride-induced hepatotoxicity. Hum Exp Toxicol, 2011. 30(9): p. 1369-
81.
127. Shimada, T., et al., Potential implications for monitoring serum bile acid profiles 
in circulation with serum proteome for carbon tetrachloride-induced liver injury/
regeneration model in mice. J Proteome Res, 2010. 9(9): p. 4490-500.
128. Amacher, D.E., et al., Use of proteomic methods to identify serum biomarkers 
associated with rat liver toxicity or hypertrophy. Clin Chem, 2005. 51(10): p. 1796-
803.
129. Henkel, C., et al., Changes of the hepatic proteome in murine models for toxically 
induced fibrogenesis and sclerosing cholangitis. Proteomics, 2006. 6(24): p. 6538-
48.
130. Van Summeren, A., et al., Proteomics investigations of drug-induced hepatotoxicity 
in HepG2 cells. Toxicol Sci, 2011. 120(1): p. 109-22.
131. Liu, S.L., et al., Discovery of serum biomarkers of alcoholic fatty liver in a rodent 
model: C-reactive protein. J Biomed Sci, 2011. 18: p. 52.
132. Cho, Y.E., et al., In-depth identification of pathways related to cisplatin-induced 
hepatotoxicity through an integrative method based on an informatics-assisted 
label-free protein quantitation and microarray gene expression approach. Mol Cell 
Proteomics, 2012. 11(1): p. M111 010884.

2Identification of novel translational urinary biomarkers for acetaminophen-induced acute liver injury using proteomic profiling in mice
Rachel P. L. van Swelm 1
Coby M. M. Laarakkers 2
Ellen C. van der Kuur 3
Eva Morava-Kozicz 4
Ron A. Wevers 2
Kevin D. Augustijn 5
Daan J. Touw 6
Maro H. Sandel 7
Rosalinde Masereeuw 1
Frans G. M. Russel 1
Published in PLOS ONE (2012); 7(11):e54924
1. Department of Pharmacology and Toxicology, Radboud University Nijmegen Medical Centre,     
    Nijmegen, the Netherlands
2. Department of Laboratory Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, 
    the Netherlands
3. Streekziekenhuis Koningin Beatrix Ziekenhuis, Winterswijk, the Netherlands
4. Department of Pediatrics, Radboud University Nijmegen Medical Centre, Nijmegen, the  
    Netherlands
5. Department of Chemistry and Pharmacochemistry, Vrije Universiteit, Amsterdam, 
    the Netherlands
6. Apotheek Haagse Ziekenhuizen, Den Haag, the Netherlands
7. Hagaziekenhuis, Den Haag, the Netherlands
40
Chapter 2
2
Abstract
Drug-induced liver injury (DILI) is the leading cause of acute liver failure. Currently, 
no adequate predictive biomarkers for DILI are available. This study describes 
a translational approach using proteomic profiling for the identification of urinary 
proteins related to acute liver injury induced by acetaminophen (APAP). Mice were 
given a single intraperitoneal dose of APAP (0-350 mg/kg bw) followed by 24 h urine 
collection. Doses of ≥275 mg/kg bw APAP resulted in hepatic centrilobular necrosis 
and significantly elevated plasma alanine aminotransferase (ALT) values (p<0.0001). 
Proteomic profiling resulted in the identification of 12 differentially excreted proteins 
in urine of mice with acute liver injury (p<0.001), including superoxide dismutase 1 
(SOD1), carbonic anhydrase 3 (CA3) and calmodulin (CaM), as novel biomarkers 
for APAP-induced liver injury. Urinary levels of SOD1 and CA3 increased with rising 
plasma ALT levels, but urinary CaM was already present in mice treated with high dose 
of APAP without elevated plasma ALT levels. Importantly, we showed in human urine 
after APAP intoxication the presence of SOD1 and CA3, whereas both proteins were 
absent in control urine samples. Urinary concentrations of CaM were significantly 
increased and correlated well with plasma APAP concentrations (r = 0.97; p<0.0001) 
in human APAP intoxicants, who did not present with elevated plasma ALT levels. 
In conclusion, using this urinary proteomics approach we demonstrate CA3, SOD1 
and, most importantly, CaM as potential human biomarkers for APAP-induced liver 
injury.
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Introduction
Drug-induced liver injury (DILI) is the leading cause of acute liver failure and remains 
difficult to predict due to the lack of adequate biomarkers.1 Monitoring of hepatic 
function in patients receiving drugs of risk is mainly based on measuring serum 
liver enzymes such as alanine aminotransferase (ALT).2 These enzymes are not 
accurately predictive for DILI, because they can be detected only after damage has 
been instigated 3. In addition, some drugs can increase plasma liver enzymes without 
actually causing liver damage, such as diclofenac and methotrexate.4-5 Therefore, 
there is a need for biomarkers that can detect DILI at the onset and can be used as 
a tool during drug development and monitoring of patients.6 Biomarkers predictive 
for DILI that can be detected in urine could be of great value to monitor patients on 
a regular basis in a non-invasive way. The urinary proteome mirrors the protein pool 
present in blood, and proteins related to pathologies, such as acute liver injury, can 
be detected in urine.7-8 Compared to blood, urine is well suited for proteomic profiling 
as it contains less high abundant proteins that can hamper biomarker detection.9 
Nevertheless, human sample collection for biomarker assessment is difficult, 
because the overall incidence of DILI is 10-15 cases in 100 000 patient years and 
the incidence for any particular drug can range from 1 case in 10.000 to 1.000.000 
patient years.10  
Acetaminophen (APAP) is an interesting model compound for searching biomarkers 
related to acute DILI. APAP is metabolized to its reactive metabolite N-acetyl-
p-benzoquinone imine (NAPQI), which is detoxified by conjugation to GSH. With 
high dosages of APAP, the GSH pool is depleted allowing NAPQI to bind to cellular 
macromolecules. Binding of NAPQI to mitochondrial proteins initiates the formation 
of reactive oxygen species and peroxynitrite. It has been demonstrated that oxidative 
stress leads to lipid peroxidation, mitochondrial dysfunction, disruption of calcium 
homeostasis and eventually necrotic cell death.11-12 Previous proteomics studies 
using rodent plasma and liver tissue showed marked changes in the expression 
levels of various proteins as a result of APAP-induced hepatotoxicity 13-15, including 
proteins involved in lipid/fatty acid metabolism, energy metabolism, oxidative stress, 
calcium homeostasis and inflammation.
The goal of this study was to identify proteins in human urine related to acute DILI. 
To this end, we implemented a translational approach to identify urinary biomarkers 
for human DILI. By first identifying proteins related to liver injury in urine of mice 
exposed to the drug of interest, and subsequently searching for the orthologous 
proteins in human urine, we aim to more efficiently use the limited availability of 
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human urine samples for biomarker assessment. Here, we show carbonic anhydrase 
3 (CA3), superoxide dismutase 1 (SOD1) and calmodulin (CaM) as potential urinary 
biomarkers for APAP-induced liver injury in both mouse and human. 
Materials and methods
Ethics statement
All experiments were approved by the local Animal Welfare Committee of the 
Radboud University Nijmegen (RU-DEC 2008-142 and RU-DEC 2009-101), in 
accordance with the guidelines of the Principles of Laboratory Animal Care (NIH 
publication 86-23, revised 1985).
Human sample collection was evaluated by the ethical committee of the Radboud 
University Nijmegen Medical Centre and the Hagaziekenhuis (Den Haag, the 
Netherlands) and they concluded that the performed research was not conducted 
under the regulations of the Act on Medical Research Involving Human Subjects, 
because sample collection included non-invasive sampling of urine and use of 
leftover plasma samples, taken for clinical analysis. Moreover, samples were 
collected anonymously and no clinically relevant or incriminating information were 
used. Written informed consent, therefore, was not compulsory; however, oral 
informed consent was obtained for all volunteers, patients and the parents of the 
underage patient with acetaminophen intoxication, which was not recorded to keep 
the procedure anonymous. 
Animal experiment
Male FVB mice (Charles River, Germany; 22-28 g bw) were housed under controlled 
conditions and randomly assigned to a single i.p. injection of vehicle (saline, n=19)) 
or 100 (n=6), 225 (n=18), 275 (n=33) or 350 (n=6) mg/kg bw APAP (A500 Sigma-
Aldrich Chemie B.V., Zwijndrecht, the Netherlands). As a negative control, mice (n=6) 
were treated with 350 mg/kg bw 3-acetamidophenol (AMAP; A7205, Sigma-Aldrich). 
After injection, mice were placed individually in metabolic cages (Techniplast, 
Germany GmbH) to collect 24 h urine samples, with water and pulverized standard 
chow ad libitum. Protease inhibitors (Complete Mini, Roche Diagnostics, Almere, 
the Netherlands) were added to the urine, which was then centrifuged at 3000 x 
g for 10 min at 4°C. Subsequently, blood plasma was collected in lithium-heparin 
tubes by eye extraction under isoflurane anesthesia and animals were sacrificed 
by cervical dislocation. Urine creatinine and plasma ALT levels were assessed by 
routine assays.
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Table 1. Demographics acute DILI patients
Parameter Refe-
rence 
value
APAP 
intoxi-
cants
DILI 1 DILI 2
Sex 
•	 Female
•	 Male
7
1
Female Female
Age 39 (± 17) 66 85
Plasma ALT (U/L) > 35 19 (± 7) 217 269
Plasma creatinine 
(µmol/L)
60-120 54 (± 18) 64 144
Use of alcohol 
•	 Yes
•	 No
1
7
No No
Use of other 
drugs 
•	 Yes
•	 No
3
5
Yes Yes
Other drugs used Diaze-
pam
Ibuprofen
Coffeine
Amoxicillin and 
clavulanic acid
Omeprazol
Alprazolam
Zoldipem
Alendronic acid
Co-trimoxazol
Pantoprazol
Lercanidipine
Dipyridamol
Acetylsalicylic acid
Furosemide
Metoprolol
Mean values for the APAP intoxicants are represented as mean ± SD. 
Human sample collection
First, a control master pool was created consisting of 24 urine samples of both 
male and female volunteers between 18-65 years of age. Next, we were able to 
collect urine of a severe APAP intoxication, concerning a 5 year old girl of 12.5 kg 
bw that ingested approximately 12 tablets of 500 mg APAP. We received one urine 
sample collected upon hospital admission (urine sample 1) and one pooled urine 
sample composed of urine collected previous to, during, and after N-acetyl cysteine 
treatment (urine sample 2). Plasma liver enzymes were determined at hospital 
admission (plasma sample 1) and within 24 h after admission (plasma sample 2). 
Plasma liver enzyme values of both plasma samples were substantially increased. 
Enzyme concentrations in sample 1 and sample 2 were: ALT 8475 U/L and 9265 U/L 
(reference value <35), aspartate aminotransferase 16850 U/L and 18420 U/L (ref 
<40), lactate dehydrogenase 16010 U/L and 17730 U/L (ref 110-295) and gamma 
glutamyl transpeptidase 63 U/L and 60 U/L (ref >35), respectively.
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In addition, plasma and urine samples were collected from 10 patients with 
suspected drug-induced acute liver injury that were admitted to the emergency 
room at Radboud University Nijmegen Medical Centre (Nijmegen, the Netherlands) 
and the Hagaziekenhuis (Den Haag, the Netherlands). The demographics of these 
patients are shown in Table 1.
Histology
Hematoxylin and eosin staining was performed on liver paraffin sections. Liver 
damage was evaluated by a qualified pathologist and scored blinded of 10 images 
taken from each liver section (10x magnification). For each image the degree of 
centrilobular necrosis was assessed by overlaying the images with a grid (Image 
J, 3700^2 pixels) and counting the intersections in necrotic areas. Liver injury was 
reported as mean percentage of centrilobular necrosis. Kidney paraffin sections 
were stained using Periodic Acid Schiff staining.
Urine protein profiling with MALDI-TOF MS
Urine samples were normalized according to creatinine values to reduce sample 
protein variation.16 Based on the method of Fiedler et al., urine samples were 
subsequently pretreated using affinity beads to isolate specific fractions of the urine 
proteome, before MALDI-TOF MS analysis.17 We used weak cation exchange (WCX) 
Macro-Prep® carboxymethyl support beads (Bio-Rad Laboratories, Hercules, CA, 
USA) and Magnetic Beads based Hydrophobic Interaction Chromatography 8 beads 
(C8; Bruker Daltonics GmbH, Bremen, Germany), that bind positively charged 
proteins and hydrophobic proteins, respectively. Synthetic hepcidin-24 (Peptide 
International Inc., Louisville, KY, USA) was used as internal standard (IS) to enable 
comparison between samples. Of the prepared sample, 1 μl was applied to a MSP 
96 polished steel MALDI target plate under nitrogen flow, followed by two times 
0.5 μl of 5 mg/mL α-cyano-4-hydroxy-cinnamic acid in 50% ACN and 0.5% TFA. 
Mass-to-charge (m/z) spectra were generated using MALDI-TOF MS (Microflex LT 
with software flexControl Version 3.0, Bruker Daltonics) in positive, linear ion mode 
and 350 laser shots. Initial laser power; 50% for 1-20 kDa and 60% for 10-160 kDa 
measurements, Laser Attenuator; Offset 25% and Range 20%. Pulsed ion extraction 
was set to 250 ns. Samples prepared with the WCX support beads were measured 
in the 1-20 kDa mass range and those prepared with the C8 beads were measured 
in both the 1-20 kDa and 10-160 kDa mass range. Calibration was performed using 
protein calibration standard I for 1-20 kDa measurements and protein calibration 
standard II (both Bruker Daltonics) for 10-160 kDa measurements.
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Peptide and protein identification
Proteins were identified by using a MALDI linear ion trap mass spectrometer (vMALDI 
LTQ; Thermo Fisher Scientific) and LC-MS/MS (nLC LTQ FT Ultra MS; Thermo Fisher 
Scientific) as described elsewhere.18-19 Single C8 pretreated urine samples were used 
to identify specific protein masses smaller than 4 kDa directly with vMALDI LTQ. 
Proteins larger than 4 kDa were identified using 1D-gelelectrophoresis with a 15% 
SDS gel and silver-blue staining. Bands were excised and subjected to reduction, 
alkylation and trypsin digestion before being measured on the vMALDI-LTQ. For 
LC-MS/MS two pooled urine samples were used to identify differentially excreted 
proteins between control (n=5) and APAP-induced liver injury (n=5; plasma ALT > 
5000 U/L). Urine samples were in-solution digested, after reduction and alkylation. 
The digested samples were loaded on stagetips for desalting and concentrating, 
and eluted to a final volume of 20 µL, 8 µL of which was used for analysis. To avoid 
contamination with polymers, an extra strong cation exchange purification step was 
performed.
Database searches were performed using the Mus musculus RefSeq36 protein 
database supplemented with known contaminant proteins. For vMALDI LTQ the data 
search was performed using SEQUEST (v. 28 BioworksTM), for LC-MS/MS protein 
identifications were extracted from the data by means of the search program Mascot 
(v2.2; Matrix Science). The following modifications were allowed in the search: 
carbamidomethylation of cysteines (fixed), oxidation of methionine (variable) and 
acetylation of the N-terminus (variable). When appropriate, searches specified 
tryptic specificity, allowing a single missed cleavage site. Additional parameters for 
vMALDI LTQ were 1.4 Da precursor ion mass tolerance and 1 Da fragment ion mass 
tolerance. For LC-MS/MS precursor ion mass tolerance was set to 10 ppm, and 
fragment ion mass tolerance was set to 0.8 Da. Proteins identified using vMALDI 
LTQ were considered significant with a peptide probability > 1e-002, and a protein 
probability > 1e-003. Validation of proteins identified using LC-MS/MS was performed 
by an in-house developed script (PROTON) as described elsewhere.19
Immunoprecipitation
Urine samples were pretreated with C8 beads and incubated overnight with PBS 
and 0.1% Triton containing 2 mM CaCl2 and CaM antibody at 4ºC. Subsequently, 
magnetic beads that bind IgG (MagnabindTM Protein G Magnetic beads, Thermo 
scientific, Rockford USA) were added and incubated for 2 h at RT. After removal 
of the unbound fraction, proteins were eluted from the beads using 50% ACN and 
0.5% TFA. The eluted fraction was measured using MALDI-TOF MS, as described. 
To correct for non-specific binding to the magnetic IgG beads, a urine sample was 
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Figure 1. APAP-induced liver injury and kidney histology in mice
Hematoxylin and eosin staining of representative liver slides from a vehicle-treated mouse (A 
and C) and an APAP-treated mouse (B and D). Panels A and B show a 10x magnification and 
a 20x magnification of the framed area is given in panels C and D respectively. Centrilobular 
necrosis can be observed in liver slides after APAP treatment. Plasma ALT levels (E) and 
the percentage of centrilobular necrosis (F) increased significantly in mice receiving 275 
and 350 mg/kg APAP. Periodic acid-Schiff staining of representative kidney slides from a 
vehicle-treated mouse (G and I) and an APAP-treated mouse (H and J) show no difference in 
histology. Panels G and H demonstrate a 20x magnification and a 40x magnification is given 
for the framed areas in panels I and J. The scalebar represents 200 µm in the slides with 10x 
magnification, 100 µm with 20x magnification and 50 µm with 40x magnification. 
** p < 0.01, *** p < 0.001 compared to vehicle treated mice. 
analyzed as described without CaM antibody. 
Western blot
Urine samples were normalized to creatinine (mouse samples) or protein 
concentration (human samples) before loading on a SDS gel. Antibodies against 
CA3 (1:100), SOD1 (1:2000) and CaM (1:1000) were purchased from Abcam 
(Cambridge, UK). The following positive controls were used: recombinant human 
CA3 protein (Abcam), bovine SOD1 protein (Bruker Daltonics), and recombinant 
Xenopus laevis CaM 20. Image J software (1.42q, National Institutes of Health, USA) 
was used to measure signal intensities on Western blot.
ELISA assay
CaM concentration in human urine samples was determined using an ELISA assay 
(E90640Hu, Uscn Life Science, China) according to manufacturer’s protocol. CaM 
concentrations were normalized to urine creatinine concentration. Samples were 
measured in duplicate.
Statistical analysis
Statistics were performed using GraphPad Prism 5.02 (La Jolla, USA), unless 
indicated otherwise. A p-value of less than 0.05 was considered statistically 
significant. Data was compared between groups using one-way ANOVA with a post 
hoc multiple comparisons test, when possible. Spectra generated with MALDI-TOF 
MS were analyzed using flexAnalysis Version 3.0 and ClinProTools Version 2.2 
software (both; Bruker Daltonics). Protein masses that differed significantly between 
the treatment groups were indicated using a Student’s t-test or Wilcoxon rank test, 
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Figure 2. Urinary protein profiles of APAP-induced liver injury in mice
Representative urine protein profiles of m/z values versus peak intensity illustrate an APAP 
dose-related increase in urinary protein excretion (A). ALT-dependent increases in protein 
peaks were observed in urine samples pretreated with WCX beads or C8 beads (B). The 
protein masses of 15.9 kDa and 16.8 kDa are indicated by (I) and (II), respectively. Double 
charged forms are indicated by (+2H). The correlation between the relative peak intensity of 
two representative urinary CA3 fragments (C & D), SOD1 (E), and CaM (F) and plasma ALT 
was determined using the Spearman’s rank correlation coefficient (r) in mice with APAP dose 
≥ 275 mg/kg body weight.
depending on normal distribution. Relative peak intensities were calculated by 
dividing protein peak intensity by the peak intensity of the IS. 
Results
Dose-dependent acute liver injury by APAP
Exposing mice to APAP resulted in dose-dependent hepatotoxicity, defined 
histologically as centrilobular necrosis (Figure 1A-D). The percentage of necrosis 
and the plasma ALT values were significantly increased after APAP administration 
compared to control and AMAP (Figure 1E and 1F). There was substantial 
interindividual variability in the toxic response to the highest doses of APAP reflected 
by the range in ALT values (40-29000 U/L) and percentage of necrosis (0-87%). 
Hence, ALT values and necrosis showed a strong intra-individual correlation. Renal 
tissue was analyzed histologically to rule out APAP-induced nephrotoxicity as a 
possible cause of altered urine proteome composition. We did not observe any 
histological changes that indicated kidney injury (Figure 1G-J).
Presence of SOD1, CA3 and CaM in urine is related to APAP-induced liver 
injury in mice 
After urine profiling, an increased abundance in protein peaks was observed for mice 
treated with 275 and 350 mg/kg APAP compared to control and AMAP (Figure 2A). 
In total, 66 protein peaks in the WCX beads spectra, and 75 protein peaks in the C8 
beads spectra were detected as significantly different between all APAP treatments 
and control. These proteins presented with increasing peak intensities in urine of 
mice with elevated plasma ALT values (Figure 2B). Most protein peaks were only 
detectable in urine of mice with relatively severe APAP-induced liver injury. However, 
two proteins of 15.9 and 16.8 kDa, later identified as SOD1 and CaM, respectively, 
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Figure 3. Identification of CA3, SOD1 and CaM in mouse urine 
Western blots show the relation between urinary SOD1 and CA3, and plasma ALT levels 
in individual mice (n=13; panel A), of which urinary SOD1 intensity on Western blot was 
analyzed by linear regression analysis (B). Immunoprecipitation  demonstrated the specific 
protein profile of CaM, i.e. the mass peak for CaM at 16.8 kDa (CaM+H) and its double and 
triple charged form (CaM+2H and CaM+3H), in mouse urine after APAP treatment (C). 
51
Novel urinary biomarkers for acetaminophen-induced liver injury
2
Table 2. Proteins identified with vMALDI-LTQ
Protein Pro-
tein 
Mass 
(Da)
P (pro) Peptide sequence [M+H]1+ 
(Da)
D-dopachrome 
tautomerase
13068.8 3.5e-007 R.FFPLEAVVQIGK.K
K.FLTEELSLDQDR.I
R.LCAATATILDKPEDR.V
K.STEPCAHLLVSSIGVVGTAEQNR.T
1335.7096
1465.7169
1673.8527
2425.2140
Fatty acid  
binding protein 
1 liver
14236.5 3.3e-007 K.AIGLPEDLIQK.G 
K.YQLQSQENFEPFMK.A
K. SVTELN#GDTITNTMTLGDIVYK.R
1196.6885
1788.8261
2386.1694
PRED. Sim to 
superoxide 
dismutase 1
15974.8 9.7e-007 R.HVGDLGNVTAGK.N
R.VISLSGEHSIIGR.T
K.GDGPVQGTIHFEQK.A
1167.6117
1367.7641
1512.7441
Peroxiredoxin 
precursor 5
21883.5 1.2e-006 K.ATDLLLDDSLVSLFGNR.R 1848.9702
Glutathion-S- 
transferase π1
23594.1 7.8e-007 R.EAAQMDMVNDGVEDLR.G
K.FEDGDLTLYQSNAILR.H
K.ALPGHLKPFETLLSQN#QGGK.A
1792.7840
1854.9232
2136.1448
Glutathion-S- 
transferase α3
25344.3 1.5e-006 K.SHGQDYLVGNR.L
R.ADIALVELLYHVEELPPGVVDN#FPLLK.A
1245.5971
3022.6023
Glutathion-S- 
transferase µ3
25685.0 2.9e-004 K.VTYVDFLAYDILDQ#YR.M 1994.9746
Glutathion-S- 
transferase µ1
25953.1 1.1e-006 R.YTMGDAPDFDR.S
R.MLLEYTDSSYDEKR.Y
1287.5310
1749.8000
Carbonic       
anhydrase 3
29347.7 1.0e-007 R.VVFDDTYDR.S
K.GEFQILLDALDK.I
K.YAAELHLVHWNPK.Y
R.EKGEFQILLDALDK.I
K.HDPSLQPWSASYDPGSAK.T
K.YN#TFGEALKQPDGIAVVGIFLK.I
R.SLFSSAEN#EPPVPLVGNWRPPQPVK.G
1129.5160
1361.7311
1577.8223
1618.8687
1942.8930
2381.2751
2746.4199
Ketohexoki-
nase
32719.5 3.4e-004 K.HLGFQSAVEALR.G
K.VVHIEGR.N
1327.7117
910.4894
Regucalcin 33385.5 4.4e-007 R.WDTVSNQVQR.V
R.VAVDAPVSSVALR.Q
R.HQGSLYSLFPDHSVK.K
R.HQGSLYSLFPDHSVKK.Y
R.YFAGTMAEETAPAVLER.H
1232.6018
1283.7318
1714.8547
1842.9497
1855.8895
For each protein identified by vMALDI-LTQ the protein mass and the protein probability 
(P(pro)) are given. The peptide sequences by which the protein was identified are listed with 
their corresponding monoisotopic mass ([M+H]1+). PRED: predicted.
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Table 3. Proteins identified with LC-MS/MS
Protein Reference emPAI
APAP/C
Peptides 
APAP/C
D-dopachrome tautomerase* gi|6753618|ref|NP_034157.1| 6.7 7
Fatty acid binding protein liver 
1*
gi|8393343|ref|NP_059095.1| 214.4 6
Superoxide dismutase 1 gi|45597447|ref|NP_035564.1| 5.9 2
Peroxiredoxin precursor 5 gi|6755114|ref|NP_036151.1| 48.6 8
Glutathion-S-transferase π1* gi|10092608|ref|NP_038569.1| 3.6 5
Glutathion-S-transferase α3* gi|31981724|ref|NP_034486.2| 3.0 5
Glutathion-S-transferase µ1* gi|6754084|ref|NP_034488.1| 10.5 11
Carbonic anhydrase 3* gi|31982861|ref|NP_031632.2| 4.2 7
Ketohexokinase* gi|31982229|ref|NP_032465.2| 0.8 4
Regucalcin* gi|6677739|ref|NP_033086.1| 3.9 9
Calmodulin gi|6753244|ref|NP_033920.1| 2.3 2
For each protein the ratio in protein abundance (emPAI) and number of unique peptides 
between mice with APAP-induced liver injury (APAP) and control (C) are given. Proteins 
completely absent in the control urine sample are indicated with *, in which case only the 
value for APAP is given. 
were observed in the C8 beads spectra at low plasma ALT levels. 
The eleven differentiating proteins that were identified using vMALDI LTQ are 
depicted in Table 2. LC-MS/MS analysis confirmed the presence of these proteins 
and additionally retrieved the identity of the 16.8 kDa protein, which was not found 
using vMALDI-LTQ (Table 3). Besides SOD1 and CaM, also peak intensities of 
fragments of CA3 correlated closely with plasma ALT values (Figure 2C-F), and 
therefore these 3 proteins were investigated further.  
To confirm the presence of CA3 and SOD1 in urine by a specific antibody, we used 
Western blot analysis, as shown in Figure 3A. Whereas CA3 could be detected only 
in urine of mice with high plasma ALT (>3500 U/L) values, SOD1 was associated 
with minor elevations in plasma ALT (>100 U/L) and it gradually amplified with 
increasing plasma ALT values. After measuring the intensities of the SOD1 signal in 
the Western blot, linear regression analysis showed a significant correlation between 
urinary SOD1 and plasma ALT levels (Figure 3B). The third potential biomarker, 
CaM, was confirmed with an immunocapture assay, by which the 16.8 kDa peak was 
precipitated from C8 beads pretreated urine (Figure 3C), using a specific antibody 
against CaM.
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Urinary biomarkers identified in mice show potential for human acute DILI
To assess the biomarker potential of the proteins identified in relation to APAP-
induced liver injury in mice, we analyzed urine samples of a patient with a severe 
APAP intoxication for the presence of CA3, SOD1 and CaM. Western blot analysis 
identified in both urine samples CA3 and SOD1, whereas both proteins were absent 
in the masterpool control sample (Figure 4A). Note that the positive control for 
SOD1 is of bovine origin and has a lower molecular weight than human SOD1. The 
concentration of urinary CaM, as determined by ELISA assay, was 75 ± 15 pg/mmol 
creatinine (mean ± SD) in the masterpool control sample and increased to 150 ± 5 
pg/mmol creatinine in urine sample 1 and 3400 ± 250 pg/mmol creatinine in urine 
sample 2. Of all urinary proteins identified in mouse urine, CaM was the only protein 
found in urine of mice treated with a high dose of APAP that did not have elevated 
plasma ALT. Therefore, CaM could serve as an early biomarker for acute DILI. To 
further evaluate the potential of urinary CaM as novel biomarker for human acute DILI, 
we collected urine samples of patients that were admitted to the emergency room 
with suspected acute DILI. We collected urine of 8 patients with APAP intoxication 
and 2 patients with acute liver injury caused by other drugs, not including APAP (DILI 
1 and DILI 2; Table 1). Although the patients with APAP intoxications did not show 
elevated plasma ALT levels, urinary CaM concentration was increased compared 
to the masterpool control sample and this increase correlated significantly with 
plasma APAP concentration (Figure 4B). Furthermore, urinary CaM concentration 
was increased in both patients with acute DILI not caused by APAP, to 140 pg/mmol 
creatinine in DILI 1 and 257 pg/mmol creatinine in DILI 2. These two patients, unlike 
the APAP intoxicants, did have elevated plasma ALT levels. To rule out acute kidney 
injury, plasma creatinine concentrations were measured, which were not increased 
in the APAP intoxicants and DILI 1, and only slightly elevated in DILI 2 (Table 2).
Discussion
The present study was designed to identify novel biomarkers in urine for acute 
DILI by using APAP as model compound. Applying multiple proteomics techniques 
allowed us to identify twelve proteins related to APAP-induced liver injury. For the 
first time, we report the presence of CA3, SOD1 and CaM in urine to be related to 
APAP-induced liver injury, of which CaM had never been linked to liver injury before. 
Of these proteins, principally SOD1 and CaM closely associated with plasma ALT, 
as observed by proteomic profiling and antibody-based methods. CA3 fragments 
showed a good correlation with plasma ALT with proteomic profiling but this could not 
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Figure 4. Detection of SOD1, CA3 and CaM in human urine samples
Presence of CA3 and SOD1 was assessed by Western blot in urine samples of masterpool 
control (I), severe APAP intoxication sample 1 (II) and 2 (III) and a positive control (IV) (panel 
A). Using an ELISA assay, the urinary concentration of CaM was correlated with plasma APAP 
concentrations using the Pearson correlation (r) test in patients with an APAP-intoxication, 
but without elevated plasma ALT values (B). The open data point represents the masterpool 
control urine sample.
be confirmed using Western blotting with a specific antibody for the whole protein. 
However, CA3 as well as SOD1 and CaM were present in human urine samples 
after APAP intoxication, and are, therefore, proposed as potential urinary biomarkers 
for APAP-induced liver injury. Urinary CaM concentration was increased in human 
APAP intoxications and correlated well with plasma APAP concentration, whereas 
plasma ALT was not increased. This suggests that CaM might be an early marker 
compared to plasma ALT. Urinary CaM concentration was also elevated in two cases 
55
Novel urinary biomarkers for acetaminophen-induced liver injury
2
of human DILI caused by drugs other than APAP, indicating that CaM is not specific 
to APAP-induced liver injury, but rather to acute hepatocellular injury. 
High doses of APAP caused liver damage as indicated by an increase in plasma ALT 
and centrilobular hepatic necrosis. Despite the use of inbred mice, our data indicate 
that the animals showed a differential response to APAP. This is most likely caused 
by a variation in glutathione stores in individual mice, since our mice were not fasted 
before APAP administration.21 The variation in hepatotoxic response allowed us to 
correlate urinary protein levels to plasma ALT, a conventional biomarker of liver injury. 
A major advantage of our experimental design was that we could profile proteins 
in urine collected in a controlled animal study. Urine samples from patients are 
difficult to profile in search for biomarkers, because they vary in many features. 
For example, nutritional status, disease condition, and/or use of other drugs may 
affect the urinary proteome. Using a translational approach, we were able to identify 
potential biomarkers for APAP-induced liver injury in mice and confirm the presence 
of these proteins in human urine samples after APAP intoxication and DILI caused 
by other drugs.
In mice, urine was collected during 24 h after APAP administration, and plasma and 
liver tissue samples at 24 h after exposure. We measured urine at one time point 
after APAP administration, but still observed a strong association between plasma 
ALT values and both SOD1 and CaM levels in urine samples. Yet, we could not 
assess if these potential biomarkers are excreted in urine early after the onset of 
injury. Nevertheless, SOD1 has previously been reported to appear in rat urine as 
early as 12 h after treatment with CCl4, another known hepatotoxic chemical.
22 A 
disadvantage of urine collection during 24 h could be that potentially interesting 
proteins are difficult to detect because of dilution, particularly those excreted shortly 
after the onset of injury. In addition, some proteins may be unstable in urine and only 
fragments rather than intact proteins can be detected. This has likely occurred for 
CA3 in the present study. 
Obviously, the kidney has a major influence on urine content and approximately 70% 
of the proteins in urine originate from this organ.23 Since most proteins identified in 
this study are not liver-specific, we investigated whether potential kidney injury by 
APAP could have been a confounding factor. No signs of kidney injury were observed 
after APAP treatment as determined by histology and the absence of kidney injury 
markers (kidney injury molecule-1 and neutrophil gelatinase associated lipocalin; 
data not shown). We, therefore, assume that the proteins found in urine after APAP-
induced liver injury were not the result of kidney injury, but were from liver into blood 
and subsequently excreted by the kidney. Most of the proteins identified in this study 
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were only found in mice with high plasma ALT values and do not seem to be suitable 
as biomarker. Urinary CA3 and SOD1 showed a good correlation with plasma ALT 
and probably are also leakage markers of injured hepatocytes. The advantage 
over plasma ALT is that these markers can be measured in patients non-invasively. 
CaM proved to be the most promising biomarker, because the protein was found in 
urine of mice treated with a high dose of APAP that did not show elevated plasma 
ALT levels. This was also observed in urine samples of human APAP intoxicants. 
Although plasma ALT levels were not increased in these patients, plasma APAP 
concentrations were high enough that liver injury was a concern as indicated by 
the Rumack-Matthew normogram.24 These data indicate that CaM has potential as 
predictive biomarker for acute DILI and that a mechanism of hepatocyte release 
other than leakage may be involved. 
Most of the proteins that we detected in urine are involved in intracellular processes 
related to APAP-induced liver injury (Table 1 and 2).25-28 These process are not specific 
to APAP and, accordingly, the biomarkers identified in this study are most likely not 
specific to APAP, but rather to acute hepatocellular injury. In line with this, urinary CaM 
concentration was also increased in human cases of DILI not caused by APAP. Since 
oxidative stress, mitochondrial damage and disrupted calcium homeostasis play an 
important role in APAP-mediated hepatotoxicity, it is not exceptional that we identified 
SOD1 and CaM as proteins with biomarker potential. The involvement of superoxide 
dismutases in APAP-induced liver injury has previously been demonstrated by the 
increased toxicity of APAP in mice with reduced activity of SOD2.29-30 The exact role 
of SOD1 in APAP-mediated hepatotoxicity remains controversial as both protective 
and damaging effects have been reported, but SOD1 nitration and reduction in 
SOD1 activity appear to be involved.31 A role for CaM in APAP-induced liver injury 
has not been clearly described, however, CaM does play a key role in maintaining 
intracellular calcium balance. Binding of NAPQI to mitochondrial proteins can cause 
mitochondrial permeability transition, after which mitochondrial Ca2+  is released into 
the cytosol.32 The cytosolic Ca2+ concentration is tightly regulated and any excess 
Ca2+ will be effluxed via the plasma membrane Ca2+ ATPase transporter (PMCA), 
using CaM as ultimate cofactor.33 However, the peroxynitrite formed during APAP-
induced oxidative stress can oxidize specific methionine positions of CaM, after 
which CaM is no longer able to activate PMCA, which results in reduced excretion of 
cytosolic Ca2+.34 Previous studies showed decreased activity of PMCA during APAP-
induced liver injury.35 With sustained high cytosolic Ca2+ concentrations, Ca2+ will 
be translocated to the nucleus by CaM, where it will cause DNA fragmentation and 
ultimately lead to cell death.36 CaM is thus involved in the initiating events of APAP-
induced liver injury and may, therefore, be a potential early biomarker. 
57
Novel urinary biomarkers for acetaminophen-induced liver injury
2
Based on these data, the next step would be to investigate the dynamics of the 
suggested biomarkers on hepatic regulation and excretion in urine with DILI, by 
including multiple time points of measurement after drug administration. This will 
also allow better comparison of the urinary proteins as non-invasive biomarkers 
with the conventional plasma ALT measurements, including the predictive value for 
DILI. Continuous urine sample collection of patients with APAP-induced liver injury 
and DILI caused by other drugs is needed to assess further the suitability of the 
biomarkers suggested for acute DILI in general.    
In summary, using a translational approach we identified CA3, SOD1 and CaM 
as novel urinary biomarkers in relation to APAP-induced liver injury in both mouse 
and human urines. These results allow further clinical validation to assess their 
applicability as non-invasive biomarkers for acute DILI.
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Abstract
Acetaminophen (APAP), a major cause of acute liver injury in the western world, is 
mediated by metabolism and oxidative stress. Recent studies have suggested a role 
for iron in potentiating APAP-induced liver injury, although its regulatory mechanism 
is not completely understood. The current study was designed to unravel the iron-
regulating pathways in mice after APAP-induced hepatotoxicity. Mice with severe 
injury showed a significant increase in liver iron concentration and oxidative stress. 
Concurrently, the plasma concentration of hepcidin, the key regulator in iron 
metabolism, and hepatic hepcidin antimicrobial peptide (Hamp) mRNA expression 
levels were significantly reduced. We showed that hepcidin transcription was inhibited 
via several hepcidin-regulating factors, including the bone morphogenetic protein 
/ small mother against decapentaplegic (BMP/SMAD) pathway, CCAAT/enhancer-
binding protein α (C/EBPα) and possibly also via erythropoietin (EPO). Down-
regulation of the BMP/SMAD signaling pathway was most likely caused by hypoxia-
inducible factor 1α (HIF-1α), which was increased in mice with severe APAP-induced 
liver injury. HIF-1α stimulates cleaving of hemojuvelin, the cofactor of the BMP receptor, 
thereby blocking BMP-induced signaling. In addition, gene expression levels of 
C/ebpα were significantly reduced and Epo mRNA expression levels were significantly 
increased after APAP intoxication. These factors are regulated through HIF-1α during 
oxidative stress and suggest that HIF-1α is a key modulator in reduced hepcidin 
transcription after APAP-induced hepatotoxicity. In conclusion, acute APAP-induced 
liver injury leads to activation of HIF-1α which results in a down-regulation in hepcidin 
expression through a BMP/SMAD signaling pathway and through C/EBPα inhibition. 
Eventually, this leads to hepatic iron loading associated with APAP cytotoxicity. 
63
Decreased hepcidin synthesis in acetaminophen-induced liver injury
3
Introduction
Acetaminophen (APAP) is a widely used over-the-counter drug and accounts 
for most cases of drug-induced liver injury.1 When used at therapeutic dosages, 
APAP is mostly conjugated in the liver by sulfation and glucuronidation reactions. 
A small part is metabolized in the liver by cytochrome P450 (CYP) enzymes to its 
reactive metabolite N-acetyl-p-benzoquinone imine (NAPQI), which is detoxified by 
conjugation to glutathione. With high dosages, more APAP is converted to NAPQI 
and eventually the glutathione pool becomes depleted, which allows NAPQI to cause 
liver injury.2 Oxidative stress as a result of APAP metabolism and mitochondrial 
damage is one of the most extensively studied mechanisms of APAP-induced liver 
injury. CYP2E1 is the predominant enzyme involved and during the course of its 
catalytic cycle hydrogen peroxide and superoxide are formed. Uncoupling of CYP2E1 
can lead to the escape of the superoxide anion radicals, thereby causing cellular 
damage.3 Moreover, accumulation of glutathione disulfide in the mitochondrial matrix 
leads to enhanced formation of superoxide and peroxynitrite within the mitochondria. 
Increased production of reactive oxygen and nitrogen species causes mitochondrial 
DNA damage which ultimately triggers mitochondrial permeability transition.4 
Although APAP-induced liver injury is thought to be mediated primarily by oxidative 
stress, the exact intracellular mechanisms that contribute to hepatic damage are not 
completely understood. 
Recent in vitro studies have shown that iron mobilization in hepatocytes potentiates 
APAP-induced liver injury.5-6 Cytosolic iron overload can result in the generation 
of reactive oxygen species mediated by the Fenton reaction, a process that could 
aggravate the oxidative stress already induced by APAP.7 Enhanced formation of 
reactive oxygen and iron species causes organ injury by damaging a wide range of 
cellular processes, including peroxidation of the cellular membranes and organelle 
lipids.8 However, the role of iron in APAP-induced liver injury in vivo has, as yet, not 
been fully elucidated. We previously demonstrated a decreased plasma hepcidin 
concentration in mice that had been treated with a high dose of APAP.9 Hepcidin 
is a hormone essential for maintaining the body iron homeostasis. It can bind to 
cellular iron exporter ferroportin, inducing its internalization and degradation, thereby 
reducing iron absorption from the intestine or iron release from macrophages.10 To 
control iron homeostasis, expression of hepcidin is tightly regulated. This key iron 
regulating hormone is reduced by hypoxia and anemia, and induced by inflammation 
and iron loading.11 A disproportional decrease in hepcidin expression can lead to iron 
loading, as seen with patients suffering from juvenile hemochromatosis, alcoholism 
and chronic hepatitis C.12-14 For alcohol loading and hepatitis C it has been shown 
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that the reduction in hepcidin is greatly influenced by oxidative stress.15-16 Oxidative 
stress can decrease hepcidin expression through multiple factors that regulate 
hepcidin expression, such as hypoxia inducible factor 1α (HIF-1α), signal transducer 
and activator of transcription 3 (STAT3) and CCAAT/enhancer-binding protein α (C/
EBPα).17-19 HIF-1α expression is induced early after administration of a toxic APAP 
dose to mice 20, and it was found that liver injury was delayed in HIF-1α-deficient 
mice.21 Moreover, APAP-mediated induction of HIF-1α is most likely an adaptive 
response to oxidative stress rather than hypoxia.22 
We hypothesized that decreased hepcidin expression in APAP-induced liver injury 
is induced by oxidative stress. This, subsequently, results in increased hepatic iron 
concentration that could potentiate liver injury. In this study, we investigated hepatic 
iron concentration and regulation of hepcidin expression in mice with APAP-induced 
liver injury. 
Materials and methods
Animal study
All experiments were approved by the local Animal Welfare Committee of the 
Radboud University Nijmegen, in accordance with the guidelines of the Principles 
of Laboratory Animal Care (NIH publication 86-23, revised 1985). Male FVB mice 
(Charles River, Germany; 22-28 g bw) were housed under controlled conditions and 
randomly assigned to a single i.p. injection of vehicle (saline, n=17)) or 100 (n=6), 
225 (n=18), 275 (n=32) or 350 (n=5) mg/kg bw APAP (A500 Sigma-Aldrich Chemie 
B.V., Zwijndrecht, the Netherlands). Standard chow was provided ad libitum during 
the experiment. After 24 h, blood plasma was collected in lithium-heparin tubes by 
eye extraction under isoflurane anesthesia and animals were sacrificed by cervical 
dislocation. Plasma alanine aminotransferase (ALT) levels were assessed by NOTOX 
B.V (‘s-Hertogenbosch). Liver tissue was collected and homogenized using a Mikro 
dismembrator U (Sartorius Stedim, Nieuwegein, the Netherlands). One half of liver 
homogenate was used for protein extraction by Tris-sucrose buffer and protein 
concentration was determined using Biorad protein assay (Bio-Rad Laboratories, 
Hercules, CA, USA). The other part of homogenate was used for RNA extraction 
using TRIzol (Invitrogen) according to manufacturer’s protocol. RNA concentrations 
were measured using a Nanodrop spectrophotometer (Wilmington, USA). 
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Plasma hepcidin determination
Hepcidin concentration in mouse plasma was determined using Surface-Enhanced 
Laser Desorption/Ionization (SELDI) Cu2+ affinity-capture time-of-flight (TOF) MS as 
described previously.9 
Measurement of thiobarbituric acid reactive substances (TBARs)
The TBAR assay is based on the formation of adducts between malondialdehyde 
and thiobarbituric acid, which can be measured with fluorometry. We adapted the 
method from Shlafer et al. for tissue homogenates in sucrose buffer.23 In short, to 
100 µL of standard or sample, 20 µL 8.1% (w/v) sodium dodecyl sulfate, 150 µL 
20% (v/v) acetic acid, 150 µL 1% (w/v) thiobarbituric acid and 0.01% (w/v, final 
concentration) butylated hydroxytoluene was added. The volume was adjusted to 
500 µL using water and incubated at 95°C for 1 h. Samples were cooled back to RT 
(21°C) and centrifuged for 15 min at 3000 rpm at RT. To the supernatant 1:1 (v/v) 
of n-butanol was added and samples were vortexed thoroughly for 1-2 min. After 
another centrifugation step of 5 min at 10.000 x g at RT, 200 µL of the supernatant 
was placed in a 96-wells plate. Absorbance was measured at 532 nm with a BioRad 
plate reader. The standard curve was made using tetramethoxypropane.
Ferrozine assay
Hepatic iron concentrations were determined by the ferrozine assay adapted from 
Riemer at al.24 In short, 100 µL liver homogenate was incubated with 100 µL 10 mM 
HCl and 100 µl iron releasing agent for 2 h at 60ºC to convert all iron to Fe(II). Next, 
30 µL of iron-detecting agent was added and incubated for 30 min at RT. Absorbance 
was determined at 550 nm. FeSO4 was used to make a standard curve. 
Quantitative PCR
For quantitative PCR (qPCR), we used forward and reversed primers (Biolegio, 
Nijmegen, the Netherlands) in combination with Sybr Green PCR mix (Applied 
Biosystems, Nieuwerkerk a/d IJssel, the Netherlands), and primer-probe sets in 
combination with Taqman PCR mastermix (both; Applied Biosystems). All primers 
used are listed in Table 1. QPCR analysis was performed using an ABI Prism 7900 
HT Fast Real time PCR system and data was analyzed using the SDS 2.3 software 
(both; Applied Biosystems). To compare mRNA expression between groups, we 
normalized expression levels of genes of interest to β-actin as housekeeping gene 
and represented mRNA expression levels as fold induction compared to the control 
group. 
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Western blot
Activation of small mothers against decapentaplegic (SMAD)1/5/8 and SMAD2/3 
was assessed using antibodies against the phosphorylated form of these protein 
complexes, according to the method of Blaney Davidson et al.25 The antibody 
against  hemojuvelin (HJV) was purchased from Abcam (Cambridge, UK) and 
used in a 1:1000 dilution in combination with a fluorescent donkey-anti-mouse 
Alexa 680 antibody (1:10.000 dilution; Invitrogen); antibody against HIF-1α (Enzo 
Lifescience, Antwerp, Belgium) was used in a 1:1000 dilution in combination 
with a HRP-conjugated goat-anti-mouse antibody (1:3000; Dako, Enschede, the 
Netherlands). As loading control we used antibody against β-actin (Sigma-Aldrich) 
in a 1:100.000 dilution in combination with a fluorescent donkey-anti-rabbit IRdye 
800 antibody (1:10.000; Rockland, Gilbertsville, USA) or HRP-conjugated goat-anti-
rabbit antibody (1:3.000; Sigma-Aldrich). Liver homogenates were normalized to 
protein concentration and loaded with Laemmli buffer on a 7.5-10% SDS gel. Gels 
were blotted on nitrocellulose using the iBlot protein transfer system (Invitrogen, the 
Netherlands). Signals were visualized on an Odyssey scanner (version 2.1 LICOR®, 
Table 1. Mouse primers used for qPCR
SYBR Green
Gene Primer Sequence 5’-3’
Β-actin Forward GCTATGCTCTCCCTCACGCCA
Β-actin Reverse CTCTTTGATGTCACGCACGAT
Hamp Forward TTGCGATACCAATGCAGAAG
Hamp Reverse GGATGTGGCTCTAGGCTATGTT
C/ebpα Forward CAAGAACAGCAACGAGTACCG
C/ebpα Reverse GTCACTGGTCAACTCCAGCAC
Pai Forward ACGTCGTGGAACTGCCCTAC
Pai Reverse CAGCGATGAACATGCTGAGG
Chop Forward ATGAAGGAGAAGGAGCAGGAGAA
Chop Reverse CTTGGTGCAGGCTGACCATG
Primer-probe
Gene Catalog number
Β-actin 4352933E
Smad4 Mm03023996_m1
Stat3 Mm01219775_m1
Smad7 Mm00433126_m1
Bmp6 Mm01332882_m1
Epo Mm00433126_m1
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Biosciences, Lincoln, USA) or luminescent image analyzer LAS3000 (version 2.2 
Fuji Photo Film, Rotterdam, the Netherlands). Image J software (1.42q, National 
Institutes of Health, USA) was used to measure signal intensities on Western blot.
Statistical analysis
Data was analyzed using one-way ANOVA, or unpaired Student’s t-test, using 
GraphPad Prism 5.02 (La Jolla, USA) unless indicated otherwise. In case the one-
way ANOVA showed no significant difference between groups, the group with highest 
liver injury was compared to control using the unpaired Student’s t-test. A p-value of 
less than 0.05 was considered statistically significant.
Results
APAP treatment decreased hepcidin transcription and caused hepatic oxidative 
stress and iron loading 
Treatment of mice with dosages >275 mg/kg APAP caused liver injury, indicated by 
significantly increased plasma ALT values, which, however, ranged from no injury to 
severe injury (Table 2). Liver injury correlated well with ALT values but not so much 
with APAP dose, therefore, APAP-treated mice were divided into categories of liver 
injury: plasma ALT ≤ 60 U/L (no injury; n=28), plasma ALT 60-1000 U/L (liver injury; 
n=10) and >1000 U/L (severe liver injury; n=21). Plasma hepcidin concentration was 
significantly reduced only in mice with severe liver injury (Figure 1A). In addition, 
Hamp (hepcidin antimicrobial peptide) mRNA expression levels were significantly 
down-regulated in the same group of mice, which gradually decreased with rising 
plasma ALT levels after APAP treatment (Figure 1B). Mice with severe liver injury 
also showed signs of oxidative stress, as evidenced by the significantly increased 
amount of TBARs, and increased hepatic iron concentration (Figures 1C and D). 
This suggests that the increase in liver iron concentration observed after APAP-
induced liver injury is caused by a decrease in hepcidin transcription, probably as a 
result of oxidative stress.
Hepcidin down-regulation due to reduced activity of the BMP/SMAD pathway 
and increased erythropoietin mRNA levels 
To investigate which pathway could be responsible for the down-regulation of 
hepatic Hamp mRNA expression, we determined hepatic mRNA expression levels 
of known hepcidin regulators in mice with severe APAP-induced liver injury (Figure 
2A). Hepatic mRNA expression of Smad4, activin-like kinase 3 (Alk3) and Bmp6, all 
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Figure 1. Changes in iron regulation and oxidative stress caused by APAP-induced 
liver injury
Plasma hepcidin concentration (n=4-9, panel A) and hepatic Hamp mRNA expression levels 
(n=6-19, panel B) were significantly decreased in mice with severe APAP-induced liver injury, 
whereas hepatic concentration of TBARs (n= 5-10, panel C) and total iron as determined 
by the ferrozine assay (n= 4-12, panel D) were significantly increased in these mice. Hamp 
mRNA expression was normalized against Β-actin mRNA expression and presented as fold 
increase compared to control. * p<0.05; *** p<0.001
Table 2. Plasma ALT values
APAP dose
(mg/kg bw)
N Plasma ALT
 (U/L) 
Control 19 < 60
100 5 < 60
225 18 90 ± 40
275 33 4700 ± 1200 ***
350 5 11000 ± 5000 **
Data are represented as mean ± 
SEM. Means within the range of 
baseline plasma ALT levels are 
represented as < 60 U/L. 
** p<0.01; *** p<0.0001 
compared to control (vehicle 
treated animals).
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part of the BMP/SMAD pathway, were significantly reduced in mice with severe liver 
injury compared to control. No change in mRNA expression of Stat3, an activator 
of hepcidin, nor in Smad7, a known inhibitor of hepcidin, was observed. The mRNA 
levels of erythropoietin (Epo), an inhibitor of hepcidin expression via STAT3 26, were 
significantly up-regulated in mice with severe liver injury (p < 0.001). These changes 
in mRNA expression levels suggested a decreased activity of the BMP/SMAD 
Figure 2. Hepatic mRNA expression levels and Western blot of hepcidin regulating fac-
tors.
Open bars represent control mice and closed bars mice with APAP-induced liver injury (ALT 
>1000 U/L; n= 5-10 per group). Hepatic mRNA expression levels were normalized against 
Β-actin mRNA expression and presented as fold increase compared to control. Smad4, Alk3 
and Bmp6 mRNA expression were significantly reduced in mice with severe APAP-induced 
liver injury (APAP; panel A). Expression levels of Stat3 and Smad7 were not changed and Epo 
mRNA expression level was strongly induced. Phosphorylated SMAD1/5/8 was reduced in 
liver homogenates of mice with APAP-induced liver injury (ALT >1000 U/L) compared to con-
trol (B). No change in phosphorylated SMAD2/3 protein was observed. * p<0.05; *** p<0.001
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pathway. This was explored further by Western blot analysis of phosphorylation 
of two complexes that interact with SMAD4. Phosphorylation of the SMAD1/5/8 
complex was decreased in mice with APAP-induced liver injury (Figure 2B). On the 
other hand, there was no change in phosphorylation of the SMAD2/3 complex, which 
plays a role in the transforming growth factor β-mediated regulation of hepcidin. 
Inhibition of the BMP/SMAD pathway was caused by HIF-1α via HJV cleavage 
To unravel further BMP/SMAD pathway in APAP-induced hepatotoxicity, we focused 
on the cofactor of the BMP6 receptor, HJV. Western blot analysis showed the 50 
kDa band for membrane HJV in liver homogenate of both control mice and APAP-
treated mice (Figure 3A), with a stronger signal in mice with APAP-induced liver 
Figure 3. Western blot of 
HJV and HIF-1α in mouse 
liver and gene expression 
of Pai.
Hepatic concentration of 
HJV (A) and HIF-1α (B) 
was increased in liver 
homogenates of mice with 
APAP-induced liver injury 
(APAP; ALT >1000 U/L) 
compared to control. In 
addition, these showed and 
increased amount of HJV 
cleavage products between 
50 and 25 kDa. Hepatic 
mRNA expression of Pai 
was significantly increased 
compared to control (n=5, 
panel C). Pai mRNA 
expression levels were 
normalized against Β-actin 
mRNA expression and 
presented as fold increase 
compared to control. *** 
p<0.001.
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injury. Moreover, in liver homogenates of mice with APAP-induced injury additional 
smaller bands were observed. These bands indicate cleavage of HJV, of which the 
fragments are typically between 20 and 50 kDa.27 Cleavage of HJV can be induced 
by HIF-1α via activation of matriptase-2 or furin. 28-29 Figure 3B shows that HIF-1α 
protein expression was nearly absent in control mice, but was clearly increased in 
mice with APAP-induced liver injury. In addition, we observed a 50-fold increase in 
mRNA expression of plasminogen activator inhibitor (Pai), a downstream target of 
HIF-1α activation 30-31, in mice with APAP-induced liver injury compared to control 
(Figure 3C). This indicates that increased hepatic protein expression of HIF-1α 
translates to increased activity, supporting its potential role in HJV cleavage.
Oxidative stress mediates hepcidin down-regulation in APAP-induced liver 
injury
If down-regulation of hepcidin is initiated by oxidative stress, this process can be 
mediated by more factors than EPO and the SMAD/BMP pathway, such as C/
EBPα. To verify that formation of oxidative stress plays a significant role in the 
down-regulation of hepcidin, we measured mRNA expression levels of C/ebpα and 
one of its inhibitors, C/EBP-homologous protein (Chop). C/ebpα mRNA expression 
showed a trend towards reduction in mice with increasing APAP-induced liver injury 
compared to control (Figure 4A). This was not accompanied by an increase in Chop 
mRNA expression (Figure 4B). These findings confirm that oxidative stress is a key 
mechanism in APAP-induced down-regulation of hepcidin. 
Figure 4. Hepatic mRNA expression levels of C/ebpα and Chop
Hepatic mRNA expression of C/ebpα was gradually reduced with increasing APAP-induced 
liver injury (n= 5-10, panel A). There was no change in Chop mRNA expression (n= 4-10, 
panel B) after APAP treatment.  Messenger RNA expression levels were normalized against 
Β-actin mRNA expression and presented as fold increase compared to control.
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Discussion
Oxidative stress is an initiating event and leading mechanism in APAP-induced 
liver injury, which could be aggravated by the accumulation of iron. In this study 
we demonstrated oxidative stress and iron loading in mice with severe APAP-
induced liver injury, which was accompanied by decreased hepatic Hamp mRNA 
expression. Moreover, multiple mechanisms that control hepcidin transcription, 
including the BMP/SMAD pathway, EPO and C/EBPα were affected by APAP, 
whereas the transforming growth factor β-mediated regulation of hepcidin is unlikely 
to be involved. Figure 5 summarizes the sequence of events potentially leading to 
a down-regulation of hepcidin. All these regulators identified can be influenced by 
HIF-1α, the expression of which was increased in mice with APAP-induced injury.28-29, 
32-33 Therefore, we concluded that oxidative stress caused by APAP inhibits hepcidin 
transcription, eventually leading to hepatic iron overload.  
Treatment of mice with APAP dosages above 275 mg/kg bw led to a significant 
increase in mean plasma ALT values, but with a high variation within the treatment 
groups; ranging from baseline ALT values to a 480-fold increase in the enzyme. This 
is might be caused by a variation in glutathione stores of individual mice, since our 
mice were not fasted before APAP administration.34 Taking this variation in response 
into account, we choose to present plasma ALT values rather than APAP dose. 
Various pathways have been reported to be involved in the regulation of hepcidin 11, 
however, not all of them were activated by APAP-induced liver injury. Hepatic mRNA 
expression levels of Stat3 and Smad7 were not changed, indicating that regulation 
of hepcidin by interleukin-6 was unlikely to be involved.35-36 On the other hand, mRNA 
expression of Epo was highly up-regulated possibly related to oxidative stress, since 
HIF-1α is a potent inducer of EPO.33 EPO acts through inhibition of STAT3 in down-
regulating hepcidin 26; however, Stat3 mRNA levels were unchanged 24 h after 
APAP administration, indicating that this pathway does not seem to play a major 
role in APAP-related hepatotoxicity. Reduced mRNA expression of Smad4, Alk3 and 
Bmp6 and decreased phosphorylation of SMAD1/5/8 indicated that the activity of 
the BMP/SMAD pathway in general was reduced.11 HJV is an essential cofactor for 
the BMP receptor.37 The observed increase in HJV fragments suggests activation 
of HJV-cleaving enzymes. Matriptase-2 and furin are both able to cleave HJV and 
thereby inhibit signaling via the BMP receptor on protein level.38 The cleavage of 
HJV by furin yields fragments of soluble HJV, which can bind BMP and thus act as 
a decoy receptor for BMP. Matriptase-2 cleaves and inactivates membrane HJV as 
cofactor for the BMP receptor. Although matriptase-2 and furin act in a different way 
73
Decreased hepcidin synthesis in acetaminophen-induced liver injury
3
Figure 5. Schematic overview of proposed pathways involved in APAP-induced hepci-
din down-regulation
Hepcidin transcription can be induced by BMP6 via the BMP/SMAD pathway, by C/EBPα and 
STAT3.26, 35 APAP-induced HIF-1α inhibits hepcidin transcription via the BMP/SMAD pathway 
by matriptase-2 or furin. Matriptase-2 can cleave HJV to prevent signal transduction via the 
BMP receptor. Furin produces sHJV by cleavage of HJV, which acts as a decoy receptor by 
binding BMP6.38 APAP also inhibits C/EBPα via HIF-1α, thereby reducing hepcidin transcrip-
tion. Induction of EPO by APAP might also contribute to reduced hepcidin transcription via 
STAT3. However, Stat3 mRNA expression levels were not found to be changed in this study.
and produce different HJV fragments, it remains difficult to distinguish between both 
enzymes based on HJV fragment sizes. It was reported that furin-mediated soluble 
HJV fragments are 42 and 33 kDa in size, and matriptase-2 resulted in 46 and/or 
36 kDa HJV fragments.39 Based on our Western blot data, we cannot differentiate 
between furin or matriptase-2 activities responsible for HJV cleavage. Both enzymes 
can be induced by HIF-1α 28-29, which is a key player in APAP-induced liver injury and 
its expression is induced by oxidative stress.22
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Our data showed that the increase in hepatic HIF-1α protein expression and activity, 
as suggested by an increase in Pai mRNA expression, are likely responsible for 
cleavage of HJV and an impaired BMP/SMAD pathway. This eventually leads to 
hepcidin down-regulation, and, subsequent hepatic iron loading. Although BMP6 
is thought to be expressed mainly in nonparenchymal cells 40, HIF-1α-mediated 
inhibition of the BMP receptor most likely occurs within the hepatocyte during APAP-
induced hepatotoxicity, similar to HIF-1α-mediated inhibition of hepcidin transcription 
in hypoxia28 In addition to the BMP/SMAD pathway, also the hepcidin-regulating factor 
C/EBPα can be inhibited in oxidative stress 18, regulated by HIF-1α.32 We determined 
the mRNA expression of C/ebpα and an endoplasmatic reticulum (ER) stress-
induced inhibitor of hepcidin, Chop, which does not require HIF-1α for activation.41 
As expected, mRNA expression levels of C/ebpα were gradually reduced in mice 
with increasing APAP-induced liver injury and Chop remained unchanged. Our data 
suggest a pivotal role for HIF-1α in APAP-induced hepatotoxicity, which is in line with 
previous studies that demonstrated an up-regulation of hepatic HIF-1α early after 
APAP administration in mice.20-22 
Together these findings are supportive for hepcidin down-regulation and subsequent 
iron loading as a result of oxidative stress in APAP-induced liver injury. Although other 
mechanisms, such as ER stress or induction of interleukin-6, have been reported to 
play a role in APAP-induced liver injury, we did not find evidence for their involvement 
in modulating hepcidin levels within the first 24 h after APAP administration.
In the present study, a single time point, i.e. 24 h, was evaluated. To investigate the 
dynamics of the proposed mechanisms in more detail, further research is needed 
which includes multiple time points after APAP administration. Furthermore, to show 
the functional relevance of the proposed mechanisms, key factors of the involved 
pathways could be modulated, for instance using gene silencing methods in an in 
vitro assay. However, such a cellular model should be selected carefully, as not all 
liver cell lines are suitable for investigating APAP-induced mechanisms of toxicity.42 
For this purpose, use of animals deficient in one of the key factors involved in 
hepcidin regulation (e.g. HIF-1α) could be considered, as well as use of antioxidants 
(e.g. N-acetylcysteine). 
APAP intoxication in vivo caused an increase in total hepatic iron concentration 
in mice with severe liver injury, rather than mobilization or sequestration of iron in 
the hepatocyte.6 This suggests a rapid redistribution of body iron stores. Increased 
absorption of iron from the intestine is unlikely because of the short time frame of 
24 h in which the APAP-induced hepatic iron loading occurred. Therefore, release 
of iron from other iron-handling and storing cells or organs should be considered. 
The liver and reticulo-endothelial (RE) macrophages, which are mostly located in 
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the spleen, function as major iron stores.43 Most of the body iron is recycled from 
senescent erythrocytes by the RE-macrophages, and returned to the bone marrow 
for incorporation in erythroid precursors. Release of iron from these RE macrophages 
is mediated by ferroportin.44 Thus, with a decrease of plasma hepcidin levels, iron 
will be released from RE-macrophages and redistributed to the liver. Fully consistent 
with this mode of action of hepcidin, low serum hepcidin levels have been found 
to be an excellent determinant of low spleen iron levels.9 Furthermore, it has been 
shown that there is an inverse correlation between splenic and hepatic iron stores. 
To confirm this mechanism of iron redistribution from the spleen in APAP-induced 
hepatotoxicity, splenic iron concentration should be measured in future experiments.
The data presented in this study were derived from an animal model and the next step 
would be to investigate the effect of APAP-induced liver injury on hepcidin regulation 
in humans. Liver injury and hepatic iron loading caused by other compounds or 
pathologies in humans, such as alcohol, chronic hepatitis C and hemochromatosis 
are mediated by similar mechanisms as we found for APAP-induced hepcidin down-
regulation in mice.12-14 Decreased activity of C/EBPα as a result of oxidative stress is 
the primary mechanism of hepcidin down-regulation with chronic hepatitis C infection 
and alcohol loading.16, 45 The molecular basis for the different types of hereditary 
hemochromatosis are mutations in proteins centered around the regulation of 
hepcidin 46, but any defect in the normal hepcidin regulatory factors may cause 
secondary hemochromatosis.47 Ultimately, iron overload can result in the formation 
of reactive iron and oxygen species leading to damage of major organs, including 
liver, heart, pancreas and endocrine organs.8 Because physiological regulation of 
hepcidin and iron metabolism is very complex, it is not unlikely that other drugs may 
also have an effect on the pathways that are involved in this regulation, which could 
have clinical implications on drug use by patients with a disturbed iron balance. 
In conclusion, we propose that APAP-induced hepatotoxicity leads to activation of 
HIF-1α, which results in a down-regulation in hepcidin expression through BMP/
SMAD signaling and C/EBPα inhibition. Eventually, this leads to hepatic iron loading 
associated with APAP cytotoxicity.
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Abstract
Diclofenac (DF) is a widely used non-steroidal anti-inflammatory drug for treatment 
of rheumatic disorders, but is often associated with liver injury. We applied urinary 
proteomic profiling using matrix-assisted laser desorption/ionization time-of-
flight mass spectrometry (MALDI-TOF MS) to identify biomarkers for DF-induced 
hepatotoxicity in mice. Female CH3/HeOUJIco mice were treated with 75 mg/kg 
bw DF by oral gavage and 24 h urine was collected. Proteins identified in urine of 
DF-treated mice included epidermal growth factor, transthyretin, kallikrein, clusterin, 
fatty acid binding protein 1 and urokinase, which are related to liver regeneration 
but also to kidney injury. Both organs showed enhanced levels of oxidative stress 
(TBARS, p<0.01). Kidney injury was confirmed by histology and increased Kidney 
injury molecule-1 (Kim1) and Interleukin-6 (Il-6) mRNA expression levels (p<0.001 
and p<0.01). Liver histology and plasma alanine aminotransferase (ALT) levels in 
DF-treated mice were not different from control, but mRNA expression of Signal 
transducer and activator of transcription 3 (Stat3; p<0.001) and protein expression 
of proliferating cell nuclear antigen (PCNA; p<0.05) were increased, indicating liver 
regeneration. In conclusion, urinary proteome analysis revealed that DF treatment 
in mice induced kidney and liver injury. Within 24 h, however, the liver was able to 
recover by activating tissue regeneration processes. Hence, the proteins found in 
urine of DF-treated mice represent kidney damage rather than hepatic injury. 
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Introduction
Diclofenac (DF) is a phenylacetic acid derivative that is widely used as a non-
steroidal anti-inflammatory drug for rheumatic disorders, including rheumatoid 
arthritis and ankylosing spondylitis.1 It acts by inhibiting prostaglandin production 
via the inhibition of cyclooxygenase. 2 DF is metabolized in the hepatocyte mainly 
by multiple cytochrome P450 enzymes to diclofenac-2,5-quinone imine, and by 
cytochrome P450 2C9 and uridine disphosphate glucuronosyltransferase 2B7 to 
4’-OH-diclofenac acylglucuronide, and the latter is transported out of the hepatocyte 
by the ATP-dependent transporter multidrug resistance protein 2.3 Adverse reactions 
associated with DF treatment mostly affect the gastrointestinal system, the kidney 
and the skin.4 Another rare, yet serious, adverse effect of DF is hepatic injury leading 
to hospital referral in 6.3 per 100.000 users.5 Hepatic injury caused by DF is classified 
as an idiosyncratic reaction, as mechanisms are not completely understood and 
individual susceptibility appears to play an important role.6 DF-induced liver injury 
can be classified as both hepatocellular and cholestatic injury. Although the exact 
mechanisms underlying DF-induced liver injury have not been resolved, multiple 
processes seem to play a role, including an immune response, formation of reactive 
oxygen species (ROS) and mitochondrial stress.1
Because of the idiosyncratic nature of liver injury caused by DF, monitoring of 
patients for this adverse effect proves to be difficult. The conventional biomarker 
for liver injury, plasma alanine aminotransferase (ALT), seems not suitable since 
plasma ALT is elevated in about 15% of the individuals that take DF on a regular 
basis, whereas actual liver injury occurs less frequently.7 Therefore, an alternative 
predictive and preferably non-invasive biomarker is desirable. Proteomics methods 
can be applied to identify proteins that appear in urine as a result of such injury 8, and 
thus, potential biomarkers for hepatotoxicity caused by DF might be found. Using 
protein profiling by means of matrix-assisted laser desorption/ionization time of flight 
mass spectrometry (MALDI-TOF MS), protein masses that differ between conditions 
or treatments can be readily assessed with a small sample volume.9 Due to the rare 
incidence of DF-induced liver injury, collection of sufficient human sample is difficult 
and animal models have been implemented. However, the validity of these models 
is under discussion, because the idiosyncratic nature of this type of adverse drug 
reaction is difficult to imitate in animals.1, 10 Treatment of animals with a low dose of 
lipopolysaccharide (LPS) to boost the immune system prior to drug administration 
is a method used to mimic idiosyncratic drug reactions.10, 11 Other studies, however, 
reported a mild acute liver injury as a result of DF treatment in mice without the use 
of LPS.12, 13
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Here, we treated mice with DF alone, or in combination with LPS, to identify the 
proteins subsequently excreted in urine in search of potential biomarkers for DF-
induced liver injury.     
Methods
Animal study
All experiments were approved by the local Animal Welfare Committee of the 
Radboud University Nijmegen (RU DEC 2009-113 and RU DEC 2011-115), in 
accordance with the guidelines of the Principles of Laboratory Animal Care (NIH 
publication 86-23, revised 1985). Female CH3/HeOUJIco mice (Charles River, 
Germany; 22-28 g bw) were housed under controlled conditions and randomly 
assigned to a single administration of solvent or 75 mg/kg DF (Sigma-Aldrich, 
Zwijndrecht, the Netherlands) by oral gavage, with or without pretreatment with 25 
μg/kg LPS (E. Coli OIII:B4; Invivogen, Toulouse, France)  i.p. 8 h prior to oral dosing 
(n=15 per group). After injection, mice were placed individually in metabolic cages 
(Techniplast, Germany GmbH) to collect 24 h urine samples, with access water and 
pulverized standard chow ad libitum. Protease inhibitors (Complete Mini tablets, 
Roche Diagnostics, Almere, the Netherlands) were added to the urine, which was 
then centrifuged at 3000 x g for 10 min at 4°C to remove debris. Subsequently, blood 
plasma was collected in lithium-heparin tubes by eye extraction under isoflurane 
anesthesia and animals were sacrificed by cervical dislocation. Urine and plasma 
were divided in aliquots and stored at -80°C until further use. Liver and kidney tissue 
samples were collected in 10% formalin for routine histology, or snap frozen with 
liquid nitrogen and stored at -80°C. 
Clinical chemistry
Plasma liver enzyme values of ALT were determined by routine assays at NOTOX b.v. 
(‘s-Hertogenbosch, the Netherlands). They also determined plasma concentrations 
of IL-6 and TNFα using an ELISA kit (mouse IL-6 ELISA Ready-SET-Go and 
mouse TNFα ELISA Ready-SET-Go; eBioscience, Vienna, Austria) according to 
manufacturers’ protocol.
Protein profiling
Urine samples were diluted to equal creatinine concentrations with water to reduce 
sample protein variation.14 Urine samples were subsequently pretreated with affinity 
beads to isolate proteins before analysis using MALDI-TOF MS according to the 
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method of Fiedler et al.15 We used Magnetic Beads based Hydrophobic Interaction 
Chromatography 8 beads (C8; Bruker Daltonics GmbH, Bremen, Germany), that 
bind hydrophobic proteins. Synthetic hepcidin-24 (Peptide International Inc., 
Louisville, KY, USA) was used as internal standard (IS) to enable protein profile 
comparisons between samples. Of the prepared sample, 1.5 μl was applied to a 
MSP 96 polished steel MALDI target plate under nitrogen flow, followed by 1.5 μl 
of 5 mg/mL α-cyano-4-hydroxy-cinnamic acid in 50% ACN and 0.5% TFA. Mass-
to-charge (m/z) spectra were generated using MALDI-TOF MS (Microflex LT with 
software flexControl Version 3.0, Bruker Daltonics) in positive, linear ion mode and 
350 laser shots. Initial laser power; 50% for 1-20 kDa and 60% for 10-160 kDa 
measurements, Laser Attenuator; Offset 25% and Range 20%. Pulsed ion extraction 
was set to 250 ns. Calibration was performed using protein calibration standard I for 
1-20 kDa measurements and protein calibration standard II (both Bruker Daltonics) 
for 10-160 kDa measurements. Protein profiles generated with MALDI-TOF MS 
were analyzed using flexAnalysis Version 3.0 and ClinProTools Version 2.2 software 
(both; Bruker Daltonics).
Protein identification
Samples for protein identification were obtained by using 1D gel electrophoresis 
in combination with in-gel protein digestion using trypsin. In addition, in-solution 
protein digestion using LysC followed by trypsin was applied to a pooled control 
urine sample (n=5) and a pooled DF urine sample (n=5).16, 17 Urine samples were 
normalized to creatinine concentration prior to pooling, and after pooling pretreated 
with C8 beads as described above. All samples were passed through Stage Tips for 
peptide purification prior to analysis using mass spectrometry.18 Protein identification 
was performed at the Nijmegen Proteomics Facility (Nijmegen, the Netherlands) 
using an electrospray ionization mass spectrometer (ESI LTQ; Thermo Fisher 
Scientific, Rockford, USA) with a C18 reversed phase liquid chromatography column 
(Easy nano LC, Proxeon, Thermo Fisher Scientific) placed in front of the ESI probe. 
Peptide and protein identifications were extracted from the ESI data by means of the 
search program Mascot using a mus musculus RefSeq36 database supplemented 
with known contaminant proteins. The following modifications were allowed in the 
search: carbamidomethylation of cysteines (fixed), oxidation of methionine (variable) 
and acetylation of the N-terminus (variable). Peptide and fragment mass tolerances 
were set to 0.5 Da. Maximally one missed cleavage site was allowed. Finally, the 
peptides and proteins found by Mascot were validated with the in-house designed 
script PROTON, as described elsewhere.19 
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Tissue homogenization
Kidney and liver tissue were homogenized using a Mikro Dismembrator U (Sartorius 
Stedim, Nieuwegein, the Netherlands) for 30 sec at 2000 rpm. One part of 
homogenized tissue was dissolved in tris-sucrose buffer and centrifuged for 30 min 
at 10.000 x g for protein isolation. Protein concentration was determined with the Bio-
Rad Protein Assay (Veenendaal, the Netherlands). The other part of homogenized 
tissue was taken up in TRIzol for RNA isolation. RNA concentration was determined 
using the Nanodrop (Thermo Fisher Scientific).
Measurement of thiobarbituric reactive substances (TBARs)
The TBAR assay is based on the formation of adducts between malondialdehyde 
and thiobarbituric acid, which can be measured with fluorometry. We adapted the 
method from Kikugawa et al. and Shlafer et al. for tissue homogenates in sucrose 
buffer.20, 21ERROR: requested citation index out of range In short, to 100 µL of 
standard or sample, 20 µL 8.1% (w/v) sodium dodecyl sulfate, 150 µL 20% (v/v) 
acetic acid, 150 µL 1% (w/v) thiobarbituric acid and 0.01% (w/v, final concentration) 
butylated hydroxytoluene was added. The volume was adjusted to 500 µL using mQ 
and incubated at 95°C for 1 h. Samples were cooled back to RT and centrifuged for 
15 min at 3000 rpm at RT. To the supernatant 1:1 (v/v) of n-butanol was added and 
samples were vortexed thoroughly for 1-2 min. After another centrifugation step of 
5 min at 10.000 x g at RT, 200 µL of the supernatant was placed in a 96-wells plate. 
Absorbance was measured at 532 nm with a Bio-Rad plate reader. The standard 
curve was made using tetramethoxypropane.
Histology
Gross histology of liver and kidney tissue was assessed by light microscopy. 
Formalin fixed tissue was dehydrated and embedded in paraffin, of which sections 
of 5 µm were prepared. Hematoxylin and eosin (H&E) staining was performed on 
liver paraffin sections and Periodic Acid Schiff (PAS) staining was used on kidney 
paraffin sections. 
Quantitative PCR
Reversed transcriptase PCR was used to convert RNA to cDNA for quantitative PCR 
(qPCR). To 5 µL of RNA (200 ng/µL) was added: 4.46 µL sterile water, 4 µL first 
strand buffer (5x), 1 µL dNTPs (12.5 nM), 2.04 µL random primers, 2 µL 0.1 M DTT, 
0.5 µL RNAsin and 1 µL M-MLV. The PCR cycle contained 10 min at 20°C, 45 min 
at 42°C and 10 min at 95°C. The resulting cDNA was diluted to 10 ng/µL with sterile 
water.
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For quantitative PCR (qPCR), we used forward and reversed primers (Biolegio, 
Nijmegen, the Netherlands) in combination with Sybr Green PCR mix (Applied 
Biosystems, Nieuwerkerk a/d IJssel, the Netherlands), and primer-probe sets in 
combination with Taqman PCR mastermix (both; Applied Biosystems); all primers 
used are listed in Table 1. For Sybr Green qPCR, we added 6 µL of primermix 
(containing 5 µl of 10 mM forward and reversed primer in 490 µL sterile water) and 
10 µL Sybr Green mix to 4 µL of diluted cDNA. For qPCR using primer-probe sets, 
we added to 5 µL of diluted cDNA: 1.25 µL primer-probe mix (20x), 12.5 µL Taqman 
PCR mastermix and 6.25 µL sterile water.  QPCR analysis was performed using an 
ABI Prism 7900 HT Fast Real time PCR system and data was analyzed using the 
SDS 2.3 software (both; Applied Biosystems). PCR cycles were the same for all 
primers used and as follows: 2 min at 50°C, 10 min at 95°C, followed by 40 cycles of 
15 sec at 95°C and 1 min at 60°C. To compare mRNA expression between groups, 
we subtracted the CT values of the household gene from the CT values of the gene 
of interest, resulting in ΔCT values. The ΔCT values were used for statistical analysis 
of mRNA expression levels between groups. Subsequently, fold induction of the 
mRNA expression levels compared to the control group were calculated from the 
ΔCT values by subtracting the ΔCT of control group from the treatment groups (ΔΔCT) 
and using the following formula: 2^-ΔΔCT. 
22
Immunohistochemistry
Liver and kidney sections embedded in paraffin were stained for cell proliferation using 
a rabbit anti-PCNA antibody (Abcam, Cambridge, UK). Sections were heated at 57ºC 
for 2 h before removing the paraffin using 3 x 15 min xylene, 3 min 100% ethanol, 3 
Table 1. Primers used for quantitative PCR
SYBR Green
Gene Primer Sequence 5’-3’
Β-actin Forward GCTATGCTCTCCCTCACGCCA
Β-actin Reverse CTCTTTGATGTCACGCACGAT
Kim1 Forward CCTCCACTCCTCCAACATCTACA
Kim1 Reverse TGGGATGGGATTCCTGTCA
Primer-probe
Gene Catalog number Applied Biosystems
Il-6 Mm00446190_m1
Egf Mm00438696_m1
Egfr Mm00433023_m1
Stat3 Mm01219775 _m1
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min 96% ethanol and 3 min 70% ethanol, after which the sections were rinsed with tap 
water for 15 min. Subsequently, an antigen retrieval step was performed by placing 
the sections in boiling citrate buffer (pH 6.0) and cooling them down to 37ºC. The 
sections were incubated for 30 min with 3% H2O2 to block endogenous peroxidases, 
followed by 30 min incubation with 2% non immune goat serum (Invitrogen, Breda, 
the Netherlands). Next, the primary antibody was added in a 1:1000 dilution and 
incubated overnight at 4ºC. The secondary goat anti-rabbit HRP conjugated antibody 
(Dako, Heverlee, Belgium) was added in a 1:1000 dilution and incubated for 30 min 
at RT. The immunostaining was visualized using 3,3’-diaminobenzidine (Invitrogen) 
for 15 min. Hematoxylin was used as counterstaining. The sections were dehydrated 
using 3 min 70% ethanol, 3 min 96% ethanol, 2 x 3 min 100% ethanol and 3 min 
xylene, and mounted with Pertex. The number of nuclei positive for PCNA staining 
were counted throughout the entire section and represented as percentage of control 
for DF treatment. 
Western blot
The protein fractions isolated from liver and kidney homogenates were normalized 
according to protein concentration as determined with the Bio-Rad protein assay. 
Protein samples were incubated with Laemmli buffer and incubated for 1 h at 37ºC 
before loading onto a SDS gel. Rabbit-anti-PCNA antibody (Abcam) was used in a 
1:1000 dilution in combination with a goat-anti-rabbit Alexa 680 (1:10000; Invitrogen) 
secondary antibody. As loading control we used a mouse-anti-β-actin antibody 
(Sigma-Aldrich) in a 1:20000 dilution with a goat-anti-mouse IRdye 800 secondary 
antibody (1:10000; Bio-Connect, Huissen, the Netherlands). Blots were visualized 
using an Odyssey scanner (version 2.1 LICOR®, Biosciences, Lincoln, USA) and 
pixel intensity was measured using ImageJ software (1.42q, National Institutes of 
Health, USA).
 
Statistical analysis
Data was analyzed according to one-way ANOVA with post-hoc Tukey’s multiple 
comparison test or unpaired Student’s t-test using GraphPad Prism 5.02 (La Jolla). 
A p-value of less than 0.05 was considered statistically significant. 
Results
DF caused a differential urinary proteome without acute hepatotoxicity
Twenty-four hours after treatment with DF alone or in combination with LPS, 
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plasma ALT levels were not changed in mice indicating that a single oral dose of 
75 mg/kg DF did not cause acute liver injury. However, plasma interleukin-6 (IL-6) 
concentration was significantly increased in mice treated with DF (Fig. 1A). Since 
DF decreases plasma IL-6 levels when used at therapeutic doses 23, the increased 
plasma IL-6 levels could be the result of an adverse event. Treatment with LPS 
alone did not affect plasma IL-6 concentration, whereas LPS administration prior to 
DF treatment resulted in a significant decrease of IL-6 concentrations as compared 
to DF alone. Plasma TNFα values were determined as a marker for possible DF-
induced gastrointestinal injury. Fig 1B demonstrates that there was no difference 
between control and DF-treated mice, and we, therefore, assumed that any potential 
gastrointestinal damage would not have contributed much to the urinary protein 
profile.
Protein profiling of urine samples using MALDI-TOF MS showed a differential profile 
as a result of DF treatment, of which a representative figure is shown in gelview in 
Fig. 1C. Differences between the urinary protein profiles of control and DF-treated 
mice were mostly observed in the lower m/z range. For better comparison, relative 
peak intensities of the most discriminating protein masses between control and DF-
treated mice are presented in Fig. 1D. LPS treatment alone did not result in significant 
changes in the urinary protein profile. The protein profile of mice treated with LPS 
prior to DF was similar to that of mice treated with DF alone, but with lower peak 
intensities. Because LPS pretreatment did not have an additional effect compared to 
DF treatment alone in terms of plasma ALT values, plasma IL-6 concentration and 
the proteins excreted in urine, mice treated with LPS alone or in combination with DF 
were left out of further analysis. 
Proteins in urine after DF treatment relate to kidney injury and liver regeneration 
Protein profiling clearly demonstrated differences in the urinary proteome composition 
after DF treatment. Because we were not able to identify the differentiating peptides 
observed with MALDI-TOF MS directly, we used 1D gel electrophoresis followed by 
in-gel digestion and in-solution digestion of pooled urine samples of control mice and 
DF-treated mice to identify the proteins that distinguished between control and DF-
treatment using ESI LTQ. The proteins that could be identified exclusively in urine of 
DF-treated mice are listed in Table 2. All proteins identified could be related to either 
kidney injury alone (i.e. transthyretin, kallikrein and clusterin) or kidney injury and 
liver regeneration (i.e. epidermal growth factor (EGF), fatty acid binding protein 1 
and plasminogen activator urokinase). 
To evaluate if indeed both organs were affected by DF, a TBAR assay was used 
to assess oxidative stress in liver and kidney tissue homogenates. The amount of 
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Figure 1. DF-induced changes in plasma IL-6 and urine protein profile
DF treatment increased plasma IL-6 concentration, which was diminished by pretreatment 
with LPS (A). No difference in plasma TNFα concentration between control and DF-treated 
mice (B). MALDI-TOF MS profiles of urinary endogenous peptides presented as gelview (C). 
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TBARs were significantly increased after DF treatment in liver and kidney tissue 
(Fig. 2A), indicating that DF caused oxidative stress in both organs. To confirm these 
results, the effect of DF on the liver and kidney was investigated further in more 
detail.
DF-induced mild kidney injury
Liver histology demonstrated no changes in morphology (Fig. 2B, C), whereas 
histology of the kidney indicated signs of mild injury after DF treatment (Fig. 2D-
G). The characteristics of kidney injury included the presence of apoptotic nuclei, 
detachment of tubular epithelial cells, loss of nuclei in tubular epithelial cells and 
an increase in interstitial monocytic inflammatory cells. Increases in plasma IL-6 
concentration could be attributable to either liver regeneration or kidney injury 24, 
25, therefore, we determined IL-6 expression in both organs after DF. Hepatic IL-6 
mRNA expression levels remained unchanged after DF treatment, whereas renal 
expression levels were significantly increased (Fig. 3A). In agreement with the 
occurrence of acute kidney injury, renal mRNA expression of kidney injury molecule-1 
(Kim1), another biomarker of renal injury, was significantly elevated in mice treated 
with DF (Fig. 3B). 
Liver regeneration after DF treatment
Although there were no signs of acute liver injury, the proteins present in urine of 
DF-treated mice together with the increased TBARs, suggested that the liver had 
been affected by DF treatment. The increased urinary concentration of EGF could 
be related to changes in liver pointing to tissue regeneration or survival in addition 
to its association with kidney injury. Therefore, hepatic mRNA expression levels of 
Egf and the EGF receptor, Egfr, were examined, which did not show any differences 
between control and DF-treated mice. However, hepatic mRNA expression levels of 
Signal transducer and activator of transcription 3 (Stat3) (Fig. 3C), a key mediator 
in liver regeneration and EGF-stimulated survival, were significantly increased after 
DF treatment. 
A different pattern is observed after DF treatment, either with or without LPS pretreatment, 
compared to control. Band intensity represents peak intensity according to the scale shown 
at the right Y-axis of the gelview. The internal standard (IS) is indicated at 2674 Da. LPS 
treatment alone did not change the urine protein profile. From these protein profiles several 
mass peaks were observed with higher peak intensity in DF-treated mice compared to control, 
which, for clarity, are presented in panel (D). Open bars represent control mice and closed 
bars represent DF-treated mice. *** p<0.001 compared to control; ### p<0.001 compared to 
DF. 
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To confirm liver regeneration, we used immunohistochemistry to stain for proliferating 
cell nuclear antigen (PCNA), a marker for cell nuclei division. An increase in the 
number of nuclei was found in the liver after DF treatment, whereas PCNA staining 
of the kidney showed a decrease in positive nuclei (Fig. 4A). Quantification of the 
number of PCNA positive nuclei in both tissues revealed a statistically significant 
difference (Fig. 4B). In addition, we performed a Western blot for PCNA in liver and 
kidney homogenates. The PCNA band at 29 kDa showed a higher intensity in liver 
homogenates of mice treated with DF, but a decreased signal in kidneys compared 
to solvent-treated mice (Fig. 4C). Semi-quantification revealed statistically significant 
differences in PCNA abundance, indicating increased cell proliferation in the liver 
and loss of proliferative activity in the kidney after DF treatment.  
Discussion
Among other adverse reactions, DF is known to cause idiosyncratic liver injury and 
this study was designed to identify potential urinary biomarkers for DF-induced 
liver injury in mice with protein profiling methods. Administration of 75 mg/kg DF 
as a single oral dose alone, or preceded by a low dose of LPS, potentially led to 
acute liver injury. After 24 h, however the urinary proteome reflected processes of 
liver regeneration and acute kidney injury, which could be confirmed with additional 
assays.
The DF dose selected in this study was based on a recent study that investigated 
hypersensitivity reactions to DF in relation to drug-induced liver injury (DILI).26 In that 
study, immune-related parameters were increased after a single oral dose of 75 mg/
kg bw DF and the CH3/HeOUJIco mice strain appeared to be most suitable to study 
DF-induced changes on the immune system. We did not observe acute liver injury 
as determined by histology and plasma ALT values 24 h after DF administration, 
which has been previously reported with an even lower dose of DF.13 However, 
another study had shown that liver enzyme values peaked at 6 h post DF dosing and 
returned to pre-dose levels after 17 h.12 Most likely, such a mild insult also preceded 
the regeneration process observed after 24 h in the present study. Indeed, TBARs 
in liver homogenates were increased, indicating that ROS formation was probably 
involved in the 24h following DF administration. 
Liver regeneration was assessed by measuring hepatic Stat3 mRNA expression 
levels, which have previously been reported to be increased after DF treatment in 
Balb/C mice.27 In that study, increased Stat3 mRNA levels were related to Th17-
mediated liver injury by DF. We hypothesize that the increased Stat3 mRNA levels 
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Figure 2. Oxidative stress in liver and kidney, and histologically assessed kidney injury 
after DF treatment
Increased amount of TBARs were observed in liver and kidney homogenates after DF 
treatment compared to control (A), indicating oxidative stress in both organs. H&E staining 
did not indicate any deviations in histology in liver tissue (10x magnification) of DF-treated 
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mice (C) compared to control mice (B). Kidney tissue of control mice (D, F) and DF-treated 
mice (E, G) was microscopically examined after PAS staining. Panels D and E show a 20x 
magnification and panels F and G a 40x magnification of the framed area in the corresponding 
D and E panels. Mild kidney injury was observed in DF-treated mice as infiltration of 
monocytic inflammatory cells (closed arrow heads), apoptotic nuclei (arrows), detachment 
of epithelial cells from the basement membrane (open arrow head) and loss of nuclei in the 
tubules (asterisk). The scalebars indicate 200 µm with 10x magnification, 100 µm with 20x 
magnification and 50 µm with 40x magnification slides.  ** p<0.01 compared to control.
could be associated with liver regeneration, because of the presence of EGF in 
urine. Stat3 and EGF both play key roles in the process of liver regeneration 28, which 
was confirmed in the livers of DF-treated mice by PCNA immunohistochemistry and 
Western blotting. 
From this study we observed that, although the liver did not show acute damage 24h 
after DF administration, it was affected in such a way that regeneration of liver tissue 
was initiated. Thus, the liver is a potential target organ for DF-induced injury, but it 
appears that other stimuli or individual characteristics are necessary before acute 
injury is elicited. The mechanisms that play a role in idiosyncratic drug reactions have, 
as yet, not been elucidated, but may include various processes that are orchestrated 
in such a way that it evokes an adverse response in a susceptible individual.29 Besides 
patient-specific factors, such as genetic variation and the sensitivity of the immune 
system 30, 31, also the pharmacokinetic and pharmacodynamic characteristics of a 
particular drug could play a role.32, 33 
Pretreatment of mice with a low dose of LPS did not enhance the toxic potential of 
DF, but rather attenuated the DF-induced effects. Although pretreatment with LPS 
to elicit an idiosyncratic-like response in animals is used for multiple drugs, timing 
of LPS administration seems to be critical to achieve the intended result.10 Notably, 
also opposite effects have been reported in which pretreatment with LPS attenuated 
cytokine release, such as Il-6, and leukocyte activation.34 Moreover, LPS pretreatment 
resulted in preconditioning of the liver in hepatic ischemic reperfusion injury in rats, 
which is thought to be established by inhibition of the pathways that lead to hepatic 
injury, including the c-Jun N-terminal kinase (JNK) pathway.35 Recent investigations 
have demonstrated that this pathway also plays a key role in liver injury caused by 
DF.36 This is in accordance with our findings where a low dose of LPS may have 
preconditioned the liver and, consequently, attenuated the hepatotoxic effect of DF. 
Although acute liver injury was the anticipated effect of DF;  urine protein profiling 
demonstrated that kidney injury was more apparent 24 h after DF administration 
as  most of the proteins found in urine of DF-treated mice have been reported to be 
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Figure 3. DF increased renal mRNA expression of Il-6 and Kim1 and hepatic mRNA 
expression of Stat3
Expression levels of mRNA are depicted as fold increase compared to control. The ΔCt 
values are given in the legend as mean ΔCt ± SD. Hepatic Il-6 mRNA expression remained 
unchanged (panel A; control 15.2 ± 0.9; DF 14.9 ± 1.1), whereas renal Il-6 mRNA expression 
increased after DF treatment (control 16.7 ± 0.6; DF 15.1 ± 1.1), which is indicative of kidney 
injury. In line with kidney injury, Kim1 mRNA expression was significantly increased in kidney 
tissue of DF-treated mice compared to control (panel B; control 4.2 ± 0.5; DF 3.5 ± 0.5). In liver 
tissue, DF treatment resulted in an increased mRNA expression of Stat3, a marker for liver 
regeneration (panel C; control 5.2 ± 0.7; DF 4.4 ± 0.4). ** p<0.01 and *** p<0.001 compared 
to control. 
associated with kidney injury. In agreement, plasma IL-6 and kidney Il-6 mRNA levels 
were significantly increased after DF treatment, which are indicative of early kidney 
injury.25 Moreover, mRNA expression of Kim1, a sensitive marker of nephrotoxicity 37, 
was increased and kidney histology showed anomalies of the tubular epithelial cells 
and basement membrane, presence of apoptotic nuclei and an increase in interstitial 
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monocytic inflammatory cells. Within the case of severe acute kidney injury, generally 
enhanced proliferative activity is observed as part of the regeneration processes.38 
In this study, we observed the opposite, i.e. decreased PCNA expression in kidney 
sections and kidney homogenates. This is probably due to the fact that we only 
found mild injury 24 h after DF administration, at which point regeneration has not 
yet commenced and the loss of PCNA expression was the result of renal damage. 
Kidney injury has been described before in animal models of DF-induced toxicity. 
Hickey et al. found signs of kidney injury in mice with the lowest dose of DF used, 
which was 100 mg/kg bw via i.p. injection.39 In another study, 200 mg/kg bw DF was 
dosed orally in Balb/C mice to inflict kidney injury.40 These findings demonstrate that 
kidney injury should be taken into consideration in mouse models used to study the 
hepatic adverse effects of DF.
DF-induced kidney injury has not only been reported in animal models, but also in the 
human clinical setting.41 Mechanisms of DF-associated kidney injury can be ascribed 
to inhibition of prostaglandins production and also mitochondrial targeting has been 
suggested.40, 42, 43 Our data confirms previous findings that ROS formation appears 
to be involved in DF-induced kidney injury 39, as TBARs in kidney homogenates 
were increased. Additionally, the elevation of Il-6 mRNA in the kidney suggests that 
leukocytes are involved in DF-induced kidney injury 25, which has been observed in 
renal biopsies of patients with DF-induced acute kidney injury.44 This animal study 
may have translational implications, as most proteins found in urine of DF-treated 
mice are markers for kidney function and drug-induced kidney injury, some of which 
are currently being evaluated for clinical application.45, 46 Additional studies, including 
multiple doses of DF and multiple time points of sampling are required to assess the 
dynamics, specificity and sensitivity of these proteins as biomarkers for kidney injury. 
In future, they may be used to non-invasively monitor patients that are treated with 
DF. 
In conclusion, a urinary proteome analysis revealed the biological processes involved 
in adverse reactions caused by DF treatment in mice, including kidney injury and liver 
regeneration rather than acute liver injury. The liver was affected by DF treatment, 
but recovered by activation of tissue repair processes. Hence, the proteins found 
in urine might be biomarkers related to DF-induced kidney injury rather than liver 
damage, which is a relevant adverse drug reaction in humans.
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Figure 4. PCNA protein levels increased in liver and decreased in kidney after DF 
treatment.
Immunostaining of liver sections for PCNA, a proliferation marker, indicated increased 
proliferation after DF treatment, compared to control (A). On the other hand, PCNA staining 
was reduced in kidney sections after DF treatment. Quantification of the immunostaining 
revealed a significantly increased number of PCNA positive nuclei in liver and decreased 
number of PCNA positive nuclei in kidney due to DF treatment (B). Open bars represent 
control mice, whereas closed bars represent DF-treated mice. Western blotting against PCNA 
demonstrated bands with higher intensity in liver of PCNA-treated mice (C). However, PCNA 
band intensity decreased compared to control in kidney of DF-treated mice. PCNA signal 
intensity of Western blot was semi-quantified by measuring pixel intensity of the PCNA bands 
99
Diclofenac-induced renal injury and hepatic regeneration
4
corrected for the loading control β-actin (D). Open bars show data of control mice and closed 
bars show data of DF-treated mice. Scalebar indicates 100 µm. * p<0.05 and *** p<0.001 
compared to control.
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Abstract 
Drug-induced liver injury (DILI) is among the leading causes of drug withdrawal. In this 
study, we investigated the applicability of protein profiling of the incubation medium 
of human, mouse and rat precision-cut liver slices (PCLS) exposed to DILI-inducing 
drugs for biomarker identification, using matrix-assisted laser desorption/ionization 
time-of-flight mass spectrometry. PCLS were incubated with acetaminophen 
(APAP), 3-acetamidophenol (AMAP), diclofenac (DF) and lipopolysaccharide (LPS) 
for 24-48h. PCLS medium from all species treated with APAP demonstrated similar 
changes in protein profiles as previously found in mouse urine after APAP-induced 
liver injury, including the same key proteins: superoxide dismutase 1, carbonic 
anhydrase 3 and calmodulin. Further analysis showed that the concentration of 
hepcidin, a hepatic iron-regulating hormone peptide, was reduced in PCLS medium 
after APAP treatment, resembling the decreased mouse plasma concentrations of 
hepcidin observed after APAP treatment. Interestingly, comparable results were 
obtained after AMAP incubation in rat and human, but not mouse PCLS. Incubation 
with DF, but not with LPS, resulted in the same toxicity parameters as observed for 
APAP, albeit to a lesser extent. In conclusion, proteomics can be applied to identify 
potential translational biomarkers using the PCLS system. 
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Introduction
The most common adverse drug reaction leading to drug withdrawal is drug-induced 
liver injury (DILI).1 The incidence for DILI has been estimated to be at least 10-
15 cases per 100,000 patient years.2 Despite the efforts to study DILI, for most 
drugs the underlying mechanisms have not been fully elucidated yet. In addition, 
particular drugs can cause a rare and severe form of DILI, without a straightforward 
dose-effect relationship or a relation with their therapeutic mode of action. These 
adverse reactions are, therefore, described as idiosyncratic. Currently, there are no 
adequate biomarkers to detect idiosyncratic DILI in patients, in preclinical animal 
studies or in in vitro models during drug development3 Because of this, identification 
of novel biomarkers for DILI is difficult and new methods to address this issue 
are being explored.4, 5 Although for non-idiosyncratic DILI more knowledge on 
potential mechanisms is available compared to idiosyncratic DILI, the prediction 
from preclinical data is limited and better preclinical prediction models with their 
accompanying biomarkers are needed.
Precision-cut liver slices (PCLS) of mouse, rat and human liver are being increasingly 
used to study the hepatotoxic effects of many compounds.5-9 The advantage of this 
ex vivo model over in vitro models, including cell cultures, is that the structure of the 
liver tissue is maintained in PCLS as well as the presence and interactions of all 
parenchymal and non-parenchymal cell types, including cell-matrix interaction.10, 11 
Moreover, PCLS retain the expression and activity of phase I and phase II metabolizing 
enzymes well, which is comparable to the in vivo situation.7, 12-15 Furthermore, it has 
been shown that rat PCLS demonstrate the same responses to toxic compounds as 
observed in vivo based on microarray data.6 
Recently, we have used matrix-assisted laser desorption/ionization time-of-flight 
mass spectrometry (MALDI-TOF MS) to assess and identify potential novel protein 
biomarkers for DILI.16 For this, mice were administered a single dose of acetaminophen 
(APAP) as a model compound for hepatocellular liver injury and 24 h urine samples 
were collected. From the urine samples, multiple proteins could be identified that 
were related to APAP-induced liver injury.  In the present study, we investigated 
whether the PCLS system could be used to identify proteomic biomarkers for DILI. 
We compared APAP-induced changes in protein profile in the medium of mouse 
PCLS with toxicity-related protein profiles previously observed in vivo. In addition to 
APAP, we also investigated the protein profiles in the PCLS medium after exposure 
to 3-acetamidophenol (AMAP), diclofenac (DF) and LPS, and investigated potential 
species differences. AMAP was shown previously to induce species-specific toxicity 
in PCLS of human and rat, but not of mouse.8 Diclofenac (DF) is a non-steroidal 
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anti-inflammatory drug that has been known to cause idiosyncratic DILI 17 and to 
induce acute hepatotoxicity similar to APAP 18, whereas LPS is known to induce 
inflammatory reactions in the liver.19
Methods
Animals for PCLS studies
Female C57BL/6 mice weighing 20-24 g and male Wistar rats (HsdCpb:WU) 
weighing 300-350 g were obtained from Harlan (Horst, the Netherlands). The mice 
and rats were housed on a 12-h light/dark cycle in a temperature- and humidity-
controlled room with food (Harlan chow no 2018, Horst, the Netherlands) and tap 
water ad libitum. The animals were allowed to acclimatize for at least seven days 
before experimentation. The experimental protocols were approved by the Animal 
Ethical Committee of the University of Groningen. Under isofluorane/O2 anesthesia, 
the liver was excised and placed into ice-cold University of Wisconsin (UW) organ 
preservation solution (DuPont Critical Care, Waukegab, IL, USA). 
Human liver tissue
Pieces of human liver tissue were obtained from patients undergoing partial 
hepatectomy for the removal of carcinoma or from liver tissue remaining as surgical 
waste after split liver transplantation, as described previously.7, 11 The experimental 
protocols were approved by the Medical Ethical Committee of the University Medical 
Center Groningen.
Preparation of the PCLS
PCLS were made as described previously.5, 8, 20 In brief, cylindrical liver cores were 
made using a 5mm biopsy punch (Kai Industries, Seki, Japan). These cores were 
sliced with a Krumdieck tissue slicer (Alabama R&D, Munford, AL, USA) in ice-cold 
Krebs-Henseleit buffer saturated with carbogen (95% O2 and 5% CO2). PCLS (5 mm 
diameter, 200-300 µm thick and ca. 4.5-5.5 mg wet weight) were stored in ice-cold 
UW solution until incubation. 
Incubation of the PCLS
Incubation of PCLS in 12-well plates (Greiner bio-one GmbH, Frickenhausen, 
Austria) was performed as described before.20 In brief, PCLS were pre-incubated 
at 37°C for 1 h individually in 1.3 ml Williams’ medium E with glutamax-1 (Gibco, 
Paisley, UK), supplemented with 25 mM D-glucose and 50 µg/ml gentamicin (Gibco, 
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Paisley, UK) (WEGG medium) in a 12-well plate with shaking (90 times/min) under 
saturated carbogen atmosphere. Pre-incubation allows the PCLS to restore their 
ATP levels. After pre-incubation, PCLS were transferred to fresh WEGG medium 
and incubated with vehicle (final concentration of DMSO during incubation ≤0.5%), 
APAP, AMAP, DF or LPS further for 24h. The human PCLS were incubated with 
APAP or AMAP for 48 h instead of 24 h, as no changes were observed after 24 h in 
protein profiles compared to control slices. A concentration of the compounds were 
selected because of their minor to moderate induction of damage, as determined by 
histology and PCLS viability using the ATP assay. Minor damage was defined as a 
<20% decrease in ATP concentration compared to control and moderate damage 
as a 20-50% decrease compared to control. For APAP and AMAP, dose response 
studies were performed previously 8, from which we selected 1 mM APAP and 3 
mM AMAP for mouse, 5 mM APAP and AMAP for rat and 3 mM APAP and AMAP 
for human PCLS. For DF, dose response studies are represented in supplementary 
figure S1 and doses of 200 μM for mouse, 350 μM for rat and 500 μM for human 
PCLS were selected. The dose of LPS was based on the study of Hadi et al. 5 to 
induce minimal toxicity, but to elicit an inflammatory response as assessed by the 
release of cytokines. The medium was collected, snap frozen in liquid nitrogen and 
stored at -80°C until further use.
ATP content of PCLS
Viability of PCLS was determined after incubation by measuring the ATP content 
of the PCLS according to the method described earlier 20. In brief, at the end of 
incubation, three replicate PCLS were collected individually in 1 ml 70% ethanol 
(v/v) containing 2 mM EDTA (pH 10.9) and snap-frozen in liquid nitrogen and stored 
at -80°C  until analysis. The samples were homogenized using a Mini-BeadBeater-8 
(BioSpec, Bartlesville, OK, USA) and centrifuged for 3 min at 13000 rpm and 4°C. 
The supernatant was diluted 10 times with 0.1 M Tris HCl containing 2 mM EDTA 
(pH 7.8) to reduce the ethanol concentration. The ATP content of the supernatant 
was measured using the ATP Bioluminescence Assay kit CLS II (Roche, Mannheim, 
Germany) in a black 96-well plate Lucy1 luminometer (Anthos, Durham, NC, USA) 
using a standard ATP calibration curve.
The protein content of the PCLS was determined by dissolving the remaining pellet 
after centrifugation in 200 µl of 5 M NaOH for 30 min. After dilution with water to a 
concentration of 1 M NaOH, the protein content of the samples was determined 
using the Bio-Rad DC Protein Assay (Bio-Rad, Munich, Germany) using bovine 
serum albumin (BSA) for the calibration curve. 
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Mouse urine samples
For validation of the PCLS model, urine samples obtained from a previously 
performed mouse study 16 were used. In short, male FVB mice were treated with 
a single i.p. dose of 0-350 mg/kg APAP and placed in a metabolic cage for 24 h to 
collect urine. After 24 h, liver tissue was collected and homogenized using a Mikro 
dismembrator U (Sartorius Stedim, Nieuwegein, the Netherlands).  
Protein profiling 
Proteins were isolated from urine, liver homogenates or PCLS medium using 
Magnetic Beads based Hydrophobic Interaction Chromatography 8 beads (C8; 
Bruker Daltonics GmbH, Bremen, Germany) that bind hydrophobic proteins.21 
Synthetic hepcidin-24 (Peptide International Inc., Louisville, KY, USA) was used 
as internal standard (IS) to enable comparison between samples. For protein 
profiling, MALDI-TOF MS (Microflex LT with software flexControl Version 3.0, Bruker 
Daltonics) was used. Of the prepared sample, 1 μl was applied to a MSP 96 polished 
steel MALDI target plate under nitrogen flow, followed by 1 μl of energy absorbing 
matrix, 5 mg α-Cyano-4-hydroxy-cinnamic acid (CHCA) in 1 ml 50% acetonitrile 
(ACN) and 0.5% trifluoro acetic acid (TFA). Mass-to-charge (m/z) spectra were 
generated using MALDI-TOF MS in positive, linear ion mode and 350 laser shots. 
Initial laser power; 50% for 1-20 kDa and 60% for 10-160 kDa measurements, 
Laser Attenuator; Offset 25% and Range 20%. Pulsed ion extraction was set to 250 
ns. Samples were measured in the 1-20 kDa mass range and 10-160 kDa mass 
range. Calibration was performed using protein calibration standard I for 1-20 kDa 
measurements and protein calibration standard II (both Bruker Daltonics) for 10-160 
kDa measurements. Spectra were analyzed by means of the ClinProTools software 
(Bruker). Relative peak intensities were calculated by dividing mass peak intensity 
by the peak intensity of the IS.
Protein identification
Protein identification was performed at the Nijmegen Proteomics Facility (Nijmegen, 
the Netherlands) using an electrospray ionization mass spectrometer (ESI LTQ; 
Thermo Fisher Scientific) with a liquid chromatography column placed in front of the 
ESI probe. Peptide and protein identifications were extracted from the ESI data by 
means of the search program Mascot using a mus musculus RefSeq36 database. 
Finally, the peptides and proteins found by Mascot were validated with the in-house 
designed script PROTON, as described elsewhere.22
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Hepcidin determination
The concentration of hepcidin in PCLS medium was determined using MALDI-TOF 
MS analysis as previously described.23 
Western blot
Antibodies against superoxide dismutase 1 (SOD1; 1:2000) and calmodulin (CaM; 
1:1000) were purchased from Abcam (Cambridge, UK) and the antibody against 
carbonic anhydrase 3 (CA3; 1:200) was obtained from Santa Cruz (Heidelberg, 
Germany). The secondary antibody used to detect SOD1 was a goat-anti-rabbit Alexa 
680 antibody (Invitrogen, Breda, the Netherlands; 1:10000) and for CA3, we used 
a donkey-anti-goat IRDye 800 antibody (Bio-Connect, Huissen, the Netherlands; 
1:10000). Signals for CA3 and SOD1 were visualized using an Odyssey scanner 
(LI-COR, Leusden, the Netherlands). CaM was detected using a goat-anti-rabbit 
horse radish peroxidase antibody (Abcam; 1:3000) in combination with an enhanced 
chemiluminescent scanner (LAS 3000; Fujifilm, Dusseldorf, Germany).
Statistical analysis
All experiments were performed in 3 slices of 5 (mouse and human) or 4 (rat) 
individual livers. Statistics were performed using GraphPad Prism 5.02 (La Jolla, 
USA), unless indicated otherwise. A p-value of less than 0.05 was considered 
statistically significant. Data were compared among groups using one-way ANOVA 
with a Dunnett’s post hoc multiple comparisons test.
Results
Protein profiles of PCLS medium resemble in vivo mouse urinary profiles of 
APAP-induced liver injury
The proteins in medium of mouse PCLS were profiled after APAP treatment and 
compared to the mouse urinary protein profile that was previously demonstrated 
to be associated with APAP-induced liver injury.16 Figure 1 demonstrates that a 
similar protein profile was observed in mouse PCLS medium after APAP treatment 
compared to the urinary protein profile after APAP intoxication. The toxicity profile 
is characterized by an increased number of protein peaks compared to control. 
The protein profiles of homogenized control mouse liver and mouse liver after 
APAP treatment show that the proteins observed in PCLS medium and urine after 
APAP toxicity are normally present in liver. Moreover, there is no difference in 
protein composition of mouse liver after APAP administration compared to control, 
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suggesting that the proteins detected in urine and PCLS medium are not specifically 
produced in liver upon APAP toxicity. Protein identification with ESI LTQ revealed 
that the same key proteins that differentiated between control and APAP-induced 
liver injury in mouse urine samples differed between control and APAP-treated PCLS 
medium (Table 1). 
Similar toxicity profiles in mouse, rat and human PCLS after APAP treatment
To compare toxicity between species, we profiled mouse and rat PCLS medium 
samples incubated with APAP or AMAP for 24 h and human PCLS medium incubated 
with APAP or AMAP for 48 h. Treatment with APAP resulted in comparable toxicity 
profiles in PCLS medium of all species. However, incubation with AMAP did not 
lead to a protein profile in mouse PCLS medium, whereas in rat and human PCLS 
medium, AMAP incubation  resulted in the same protein profiles as with APAP 
Figure 1. Protein profiles of mouse urine and liver homogenate, and mouse PCLS me-
dium after APAP treatment
Protein profiles of protein masses (m/z in Da) versus peak intensity (arbitrary units) of mouse 
urine, PCLS medium and liver homogenate of control and APAP treatment. Shaded areas 
indicate proteins that differ between control and APAP treatment. 
113
Biomarker detection for acute drug-induced liver injury using precision-cut liver slices 
5
incubation (Figure 2A). 
One potential marker associated with DILI is the iron-regulating hormone peptide 
hepcidin, for which it was demonstrated that hepatic and plasma levels were down-
regulated in mice with APAP-induced liver injury as a result of oxidative stress.24 To 
investigate whether acute APAP-induced hepatotoxicity in PCLS is mediated by a 
Table 1. Proteins identified in mouse urine and mouse PCLS medium after 
APAP administration
Protein Reference EmPAI (APAP/control)
Mouse 
urine
Mouse 
PCLS 
medium
Fatty acid binding protein 1, 
liver
gi|8393343|ref|NP_059095.1 APAP only 4.83
Peroxiredoxin 5 precursor gi|6755114|ref|NP_036151.1 48.65 APAP only
D-dopachrome tautomerase gi|6753618|ref|NP_034157.1 APAP only APAP only
Carbonic anhydrase III gi|31982861|ref|NP_031632.2 APAP only 3.27 
Regucalcin gi|6677739|ref|NP_033086.1 APAP only 2.08
Parkinson disease protein 7 gi|55741460|ref|NP_065594.2 APAP only APAP only
Peptidylprolyl isomerase A gi|6679439|ref|NP_032933.1 APAP only APAP only
Triosephosphate isomerase 1 gi|226958349|ref|NP_033441.2 APAP only APAP only
Quinoid dihydropteridine re-
ductase
gi|21312520|ref|NP_077198.1 APAP only APAP only
Peptidylprolyl isomerase C gi|6679441|ref|NP_032934.1 APAP only APAP only
Abhydrolase domain contain-
ing 14b
gi|171460960|ref|NP_083907.3 APAP only APAP only
Hemoglobin, beta adult minor 
chain
gi|17647499|ref|NP_058652.1 APAP only APAP only
Hemoglobin, beta adult major 
chain
gi|31982300|ref|NP_032246.2 APAP only APAP only
Arginase 1 gi|7106255|ref|NP_031508.1 APAP only 5.90
Calmodulin-like 3 gi|13386230|ref|NP_081692.1 2.33 APAP only
Aldolase B, fructose-bisphos-
phate
gi|21450291|ref|NP_659152.1 APAP only APAP only
SEC14-like 2 gi|21362309|ref|NP_653103.1 APAP only APAP only
Fumarylacetoacetate hydro-
lase
gi|240120112|ref|NP_034306.2 APAP only APAP only
EmPAI is a measure for protein abundance. APAP only indicates that the protein was only 
present after APAP treatment and not present in control sample, thus no EmPAI ratio could 
be determined.
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similar mechanism as observed in vivo, we measured the concentration of hepcidin 
in PCLS medium. Lipopolysaccharide (LPS)-treated PCLS were considered as a 
positive control in these experiments by showing increased hepatic hepcidin excretion 
by the PCLS, which is the physiological response to LPS.23 In concordance with the 
mouse in vivo data, hepcidin concentration was decreased in PCLS medium of all 
Figure 2. Protein profiles and hepcidin concentration of mouse, rat and human PCLS 
medium after APAP or AMAP treatment
 Protein profiles of protein masses (m/z in Da) versus peak intensity (arbitrary units) of 
medium from mouse, rat and human PCLS of control, APAP or AMAP treatment (A). Shaded 
areas indicate proteins that differ between control and APAP/AMAP treatments. Hepcidin 
concentrations in medium of control PCLS and after APAP or AMAP treatment for all species 
(B). Every line represents the hepcidin concentrations for a single PCLS in control situation 
and after APAP and AMAP treatment. * p < 0.05 compared to control
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species after APAP treatment (Figure 2B). AMAP treatment did not affect hepcidin 
concentration in mouse PCLS medium, but hepcidin concentration was decreased in 
rat and human PCLS after AMAP treatment. Hepcidin concentrations are known to 
vary substantially between individual patients 25, which hampers the assessment of 
statistical significant changes. To demonstrate that the effects of APAP and AMAP on 
hepcidin in PCLS of all individual donors were similar, we presented these data as 
line graphs that show the hepcidin concentration for all treatments in PCLS obtained 
in each mouse, rat or human liver slice.
DF treatment resembles the toxicity profile of APAP
Incubation of mouse PCLS with DF resulted in protein profiles of PCLS medium that 
resembled the toxicity profile of APAP, albeit with lower peak intensities (Figure 3). 
LPS had minimal effects on the protein profiles. The medium samples of rat and 
human PCLS treated with DF proved to be difficult to profile using MALDI-TOF MS 
and as a result the protein profiles were of insufficient quality, as they showed high 
background signals and low peak intensities. Therefore, we could not compare the 
protein profiles of rat and human PCLS medium samples after DF incubation with 
Figure 3. Comparison of PCLS medium protein profiles after incubation of APAP, DF 
or LPS
Profiles of protein masses (m/z in Da) versus peak intensities (arbitrary units) of medium from 
mouse PCLS of control and treatment with APAP, LPS and DF. Shaded areas indicate proteins 
that differ between control and APAP or DF treatment. 
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those of mouse PCLS. Instead, we compared the presence of some key proteins 
identified after APAP treatment in mouse PCLS medium  with medium of all species 
after all treatments by Western blot. Figure 4 shows that SOD1, CA3 and CaM are 
increased in mouse PCLS medium after APAP treatment compared to control, which 
confirmed the protein identification performed by ESI LTQ. Increased signals for 
these proteins were also observed for APAP and AMAP in rat and human PCLS, 
except for CA3 in human PCLS medium. In fact, we were not able to detect any CA3 
in human PCLS medium. In rat PCLS, AMAP treatment resulted in a higher protein 
signal on Western blot than APAP treatment, suggesting AMAP to be more toxic 
than APAP.  In concordance with the protein profiles AMAP treatment did not lead 
to increased protein expression of CA3 and CaM in mouse PCLS, although SOD1 
protein expression after AMAP treatment  was slightly higher compared to control. 
Incubation with DF demonstrated the same proteins to be present in PCLS medium 
of all species, but to a lesser extent than after APAP and/or AMAP incubation. 
Surprisingly, LPS incubation did not result in a protein profile that suggested toxicity, 
although Western blot analysis showed increased concentrations of SOD1 and 
CA3 in mouse PCLS medium and an increase of CaM in rat PCLS. In addition, 
hepcidin concentrations in PCLS medium samples were determined (Figure 5). 
Similar to the findings in mouse plasma and PCLS medium after APAP-induced 
hepatotoxicity, incubation with DF resulted in decreased hepcidin concentrations in 
the medium samples of mouse, rat and human PCLS. The effect of DF was not 
statistically significant in rat and human PCLS due to the high variation, but the 
line graphs demonstrate that DF treatment decreased the hepcidin concentrations 
Figure 4. Presence of SOD1, CA3 and CaM in PCLS medium
The presence of SOD1, CA3 and CaM in PCLS medium of all species was demonstrated by 
Western blotting of control medium (NC) and after incubation with APAP (AP), AMAP (AM), DF 
and LPS. CA3 was not detected in human PCLS medium, indicated as N.d.
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in each sample. Incubation with LPS increased the hepcidin concentration in all 
species, which is in agreement with a previously described effect of the endotoxin 
23. These findings confirm that PCLS have maintained their physiological regulation 
of hepcidin. 
Figure 5. Hepcidin concentration in PCLS medium after DF or LPS treatment
Hepcidin concentration in medium of mouse (A), rat (B) and human (C) PCLS after treatment 
with DF or LPS. * p < 0.05; ** p < 0.01 compared to control
Discussion
DILI remains a major problem in drug development, but also is a dangerous 
complication of drug treatment in patients.  Model systems to assess the potential 
of a drug to cause DILI, and to further investigate the underlying mechanisms, are 
needed to reduce the attrition rate in drug development and the number of adverse 
events. We demonstrated that the response of mouse PCLS to APAP treatment is 
comparable to what we have observed in vivo, with respect to theproteins that are 
released upon toxicity and the decrease in hepcidin concentration. These results 
could be further extended to rat and human PCLS, but also to another hepatotoxic 
drug, DF, underlining the translational aspects of the PCLS system as model for DILI. 
It has to be mentioned that the strain and gender of the mice used for the in vivo 
study are different from those used to generate the mouse PCLS. This was the 
result of the two procedures being performed by different labs at different moments 
and later compared to each other. The strain and gender differences might explain 
that some of the proteins present in mouse urine were not found in mouse PCLS 
medium and vice versa, but most likely they are due to the presence of extrahepatic 
proteins in urine. However, the key proteins that distinguished urinary profiles of mice 
with APAP-induced liver injury from control were present in mouse PCLS medium. 
118
Chapter 5
5
Besides similarities in effect on protein composition, the effect of APAP on hepcidin 
concentration was also comparable between the in vivo and PCLS experiments, 
which demonstrates that these parameters are robust enough to overcome variation 
introduced by strain and gender differences. This is especially of importance for the 
proteins that could be developed further as potential biomarkers.    
The advantage of the PCLS system is that liver slices of multiple species can be 
used and compared, enabling investigation of species differences. The proteins 
associated with APAP-induced liver injury in mouse PCLS and urine could also be 
found in rat and human PCLS incubated with APAP. The difference in toxicity caused 
by AMAP between the species, as demonstrated by the protein profiles, Western 
blot data and hepcidin measurements was in line with the previous observation, 
with other viability parameters such as ATP and morphology, that AMAP causes 
species-specific toxicity.8 In addition, from the protein profiles and Western blot data, 
it appeared that the same concentration of AMAP might be more toxic than APAP in 
rat PCLS, but not in human PCLS. Furthermore, we observed a species difference 
in response to LPS with Western blot analysis for SOD1 and CA3. Incubation of 
mouse PCLS with LPS resulted in increased medium concentrations of SOD1 and 
CA3 compared to control slices, whereas there was little or no effect of LPS on these 
protein concentrations in rat and human PCLS medium. This difference in response 
also demonstrates the necessity of an additional technique to confirm proteomics 
data, because the profiles of LPS treatment in mouse PCLS did not indicate any 
changes compared to control, whereas the Western blot data did. However, as 
LPS was used to demonstrate hepcidin regulation in the PCLS, we did not further 
investigate this finding.
Although CA3 could be detected in mouse and rat PCLS after APAP treatment, we 
were not able to detect CA3 in APAP- treated human PCLS medium by Western 
blot analysis, while it was shown before that CA3 is present in human urine after 
severe APAP intoxication.16 An explanation for this observation could be that the 
concentration of CA3 was below the detection limit of the Western blot technique or 
that the degree of APAP-induced injury we found in human PCLS was not severe 
enough for CA3 release. 
The proteins detected in mouse urine and PCLS medium after APAP treatment all 
play a role in processes known to be involved or affected in acute liver injury, such 
as oxidative stress, disruption of calcium homeostasis and mitochondrial dysfunction 
26-31, however, these proteins are not liver-specific. Overall, the kidney is the organ 
with the greatest influence on urine protein composition and therefore could be 
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responsible for the changes seen in urine after APAP treatment.32 However, in the in 
vivo mouse studies with APAP, we did not observe any sign of kidney injury 16, which 
was assessed by kidney histology and the determination in urine of kidney injury 
molecule-1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL). Since 
the liver was the only organ affected by APAP in this study, it was hypothesized that 
the proteins found in urine were released by the injured liver into the blood, similar 
to alanine aminotransferase. The proteins found in urine were small enough to be 
readily filtered by the glomerulus. The results of this study further strengthened this 
hypothesis as the proteins observed in mouse urine were shown to be released by the 
liver tissue, not only in mouse, but also by rat and human PCLS. This demonstrates 
that the PCLS system can contribute to studying the dynamics of potential protein 
biomarkers for DILI. Future studies will be directed to investigate the applicability of 
these biomarkers of human DILI and further validation in clinical studies. 
Besides APAP, which is often used as model compound to study acute liver injury, 
we were able to analyze the toxicity-induced protein profile of DF, which has been 
associated with idiosyncratic DILI, but also acute hepatotoxicity.17, 18 Because of the 
rare incidence of DF-induced liver injury 33, it has been difficult to study this adverse 
reaction in humans. With the PCLS system we were able to show the hepatotoxic 
properties of DF in human liver tissue. In line with previous studies that demonstrate 
a direct hepatotoxic effect of DF 18, we showed a protein profile in medium of PCLS of 
all species treated with DF that is similar to that after APAP incubation. The presence 
in PCLS medium of the same key proteins in PCLS medium was demonstrated 
by Western blotting. Furthermore, we also observed a decrease in hepcidin 
concentrations. This implies that, like APAP, DF-induced acute hepatotoxicity may 
be accompanied by oxidative stress. Many of the proteins identified in the medium 
of APAP-treated mouse PCLS are related to processes of oxidative stress, including 
SOD1 and CA3 which were also present after DF incubation.29-31, 34-36 Furthermore, 
it has been demonstrated in vivo that the decreased concentration of hepcidin after 
APAP-induced hepatotoxicity is mediated via oxidative stress.24 Besides acute liver 
injury, the PCLS system has been used in studying other pathologies of liver injury, 
whether or not caused by drugs, such as hepatic fibrosis and cholestasis 37-40 and 
idiosyncratic DILI.5 This suggests that drug-induced changes in protein profiles in 
PCLS medium could be useful for studying the pathological mechanisms that are 
involved in DILI.
In conclusion, this is the first proteomics study on DILI in medium of human, mouse 
and rat PCLS (ex vivo), demonstrating that similar toxicity-related protein profiles 
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were found as in mouse urine (in vivo). Hence, the PCLS system proves to be a 
promising, translational model for the identification of potential protein biomarkers, 
which could be developed as urinary biomarkers for human DILI, and provide insight 
into the mechanisms of these drug-induced adverse reactions.
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Supplementary figures
Supplementary figure 1. Dose response curves for DF incubation and ATP concentra-
tion in mouse, rat and human PCLS.
Viability was determined by means of ATP concentration after incubation with various concen-
trations of DF during 24h in mouse, rat and human PCLS. 
** p<0.01 compared to vehicle; *** p<0.001 compared to vehicle 
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Abstract
Hepatic fibrosis is an adverse drug reaction of methotrexate (MTX) seen after long-
term use in psoriasis patients. Currently, patients are monitored for MTX-induced 
hepatic fibrosis by performing liver biopsy, which is risky and burdensome for 
the patient, or by measuring plasma procollagen type III aminopeptide (PIIINP), 
which is not conclusive. The goal of this study was to identify novel predictive and 
preferably non-invasive biomarkers to monitor psoriasis patients for MTX-induced 
hepatic fibrosis. Urine samples were collected from 60 psoriasis patients treated 
with MTX and divided into two categories: low cumulative dose (<1500 mg MTX) 
and high cumulative dose (>1500 mg). Urinary proteins were profiled using matrix-
assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF 
MS) and identified using electrospray ionization LTQ. In urine of psoriasis patients 
with high cumulative MTX dose multiple proteins were identified that are associated 
with hepatic fibrosis, such as N-cadherin, inter-alpha-trypsin inhibitor heavy chain 
H4, haptoglobin and serotransferrin. These proteins may be candidate urinary 
biomarkers to monitor MTX-induced hepatic fibrosis. In conclusion, using urinary 
proteome analysis identified a profile of potentially predictive biomarkers for MTX-
induced hepatic fibrosis in psoriasis patients with high cumulative dose of MTX. 
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Introduction
Methotrexate (MTX) is a folic acid antagonist with anti-proliferative and anti-
inflammatory properties that has been used for the treatment of rheumatoid arthritis 
(RA) and psoriasis.1 Despite adverse reactions, including liver injury, MTX has been 
prescribed for decades because of its effectiveness.2 MTX-induced liver injury is 
characterized by hepatic fibrosis, which is reported more often in psoriasis patients 
than RA patients.3 Long-term low dose MTX treatment results in progression of liver 
disease in 33% of psoriasis patients, although a relation with non-alcoholic steatosis 
hepatitis (NASH), which in turn is related to diabetes mellitus and high body mass 
index (BMI), seems to be also present.4, 5 The risk of MTX-induced hepatic fibrosis 
increases with treatment duration and, typically, most cases of hepatic fibrosis 
present at a cumulative MTX dose between 1500 and 6000 mg.6 Risk factors for 
MTX-induced fibrosis are obesity and diabetes mellitus type 2, and to a lesser extent 
alcohol consumption.7 The number of patients with hepatic fibrosis is, however, very 
low in all cohorts investigated.8 To detect those patients that will progress to hepatic 
fibrosis at an early stage, a biomarker with good correlation to the disease condition 
is necessary.  
Monitoring psoriasis patients for MTX-induced hepatic fibrosis is difficult because the 
conventional biomarkers for liver injury, including plasma alanine aminotransferase 
(ALT), can transiently be increased in patients treated with MTX, even without the 
occurrence of liver injury.9 The golden standard for monitoring MTX-induced hepatic 
fibrosis has been by histological evaluation of a liver biopsy, which is not without risk 
and poses a burden to the patient.10 Less risky methods are increasingly used such as 
measuring plasma procollagen type III aminopeptide (PIIINP), however, this marker 
is also not conclusive in prediction of hepatic fibrosis in psoriasis patients.8  Therefore, 
research has focused on finding new biomarkers for MTX-induced hepatic fibrosis, 
which has led to the identification of a number of candidate plasma biomarkers, 
including tissue-inhibitor of metalloprotease-1 (TIMP-1), laminin, haptoglobin and 
matrix metalloproteinase-2 (MMP-2)10-12 Besides plasma biomarkers, indirect multi-
test algorithms, such as the Fibrotest score and Hepascore, and physical methods, 
including the Fibroscan, have been implemented to monitor MTX-induced hepatic 
fibrosis.13-15 In a recent study performed by Chládek et al. the Fibroscan and serum 
PIIINP proved to be superior to the Hepascore and hyaluronic acid as biomarker 
for hepatic fibrosis defined according to liver specificity and stability within various 
MTX treatment groups.16 However, conclusions as to their predictive potential could 
not be drawn from this study. Although these potential plasma biomarkers and other 
monitoring and diagnostic methods have emerged in the past few years, there is still 
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no adequate biomarker to predict MTX-induced hepatic fibrosis in psoriasis patients 
and the need for non-invasive predictive biomarkers remains.   
Proteomics techniques have been increasingly used for the detection of biomarkers 
in various body fluids, including urine.17 An advantage of urinary biomarkers is that 
it offers a non-invasive procedure to monitor patients on a routine basis. The goal of 
this study was to identify urinary proteins related to MTX-induced hepatic fibrosis in 
psoriasis patients as potential biomarkers. We identified multiple proteins associated 
with hepatic fibrosis in urine of psoriasis patients with a high cumulative dose of 
MTX, which potentially could be used as predictive biomarkers in future diagnostics.
Materials and methods
Human samples collection
Urine samples of psoriasis patients were collected at the Department of Dermatology 
at the Radboud University Nijmegen Medical Centre. Human sample collection 
was evaluated by the Dutch ethical committee involving human research and they 
concluded that the performed research did not have to be conducted under the 
regulations of the Act on Medical Research Involving Human Subjects, because 
sample collection included non-invasive sampling of urine and use of leftover plasma 
samples, taken for clinical analysis. Moreover, samples were collected anonymously 
and no clinically relevant or incriminating information were used. Written informed 
consent, therefore, was not compulsory; however, oral informed consent was obtained 
for all volunteers, which was not recorded to keep the procedure anonymously. 
Subjects were included if they were over 18 years of age and had been using the MTX 
(by weekly administration of a single bolus oral dose or 2-3 doses in 24 h) for more 
than three months. Protease inhibitors (Complete Mini tablets, Roche Diagnostics) 
were added to the collected urine samples and centrifuged for 10 minutes at 3000 x 
g. The supernatant was aliquoted in 1,5 mL polypropylene tubes to prevent multiple 
freeze/thaw cycles and stored at -80°C.
In total, 60 psoriasis patients were included and divided into two groups based on 
the cumulative dose of MTX; low cumulative dose (< 1500 mg) and high cumulative 
dose (>1500 mg) of MTX. After sample collection, 5 urine subjects were excluded 
for analysis due to uncertain cumulative MTX dose. The demographics of included 
subjects, recorded by a questionnaire, are presented in Table 1. We included use of 
other medication, high body mass index (BMI), diabetes mellitus type 2 and alcohol 
consumption as confounders of hepatic fibrosis and/or steatosis.18-21 
As a control, a masterpool of urine samples was created, which consisted of pooled 
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urines collected from 24 healthy volunteers, males and females at the age of 18-65 
years, and processed as described above.
Urine protein profiling
Urine sample volumes were normalized to creatinine values to reduce sample 
protein variation.22 Urine samples were subsequently pretreated with affinity beads 
to isolate specific fractions of the urine proteome 23, followed by analysis using matrix 
associated laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF 
MS). We used Magnetic Beads based Hydrophobic Interaction Chromatography 
8 beads (C8; Bruker Daltonics GmbH, Bremen, Germany), that bind hydrophobic 
proteins. Synthetic hepcidin-24 (Peptide International Inc., Louisville, KY, USA) was 
used as internal standard (IS) to enable comparison between samples. Protein 
profiles were analyzed using FlexAnalysis and ClinProTools (Bruker). 
Protein identification
To identify proteins differentially present between the groups, pooled samples were 
created for each group consisting of five to ten urine samples. These samples were 
pretreated with C8 beads and subjected to in-solution digestion using LysC, followed 
by trypsin as cleaving enzymes.24, 25 All samples were passed through Stage Tips for 
peptide purification prior to analysis using mass spectrometry.26 Protein identification 
was performed at the Nijmegen Proteomics Facility using an electrospray ionization 
mass spectrometer (ESI LTQ; Thermo Fisher Scientific) with a C18 reversed phase 
liquid chromatography column (Easy nano LC, Proxeon, Thermo Fisher Scientific) 
placed in front of the ESI probe. Peptide and protein identifications were extracted 
from the ESI data by means of the search program Mascot using a human RefSeq 
database. Finally, the peptides and proteins found by Mascot were validated with the 
in-house designed script PROTON, as described elsewhere.27 
Enzyme-linked immunosorbent assay
ELISA kits for N-cadherin (Cadherin-2, E91481Hu) and ITIH4 (E97776Hu) were 
ordered from Uscn Life Science Inc. (Huissen, the Netherlands) and executed 
according to manufacturers’ instructions. In short, 100 µL of the standard or samples 
was added in duplicate to each well and incubated for 2 h at 37ºC. Next, 100 µL 
of detection reagent A was added to each well and incubated for 1 h at 37ºC. After 
incubation, the solutions were aspirated and the wells were washed three times, 
where after 100 µL of detection reagent B was added. This was incubated for 30 
min at 37ºC. After aspiration, the wells were washed five times and 90 µL substrate 
solution was added and incubated for 25 min at 37ºC. Lastly, 50 µL of stop solution 
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was added and the optical density was immediately measured at a wavelength of 450 
nm. Concentrations were calculated using the standard curve. Not all samples could 
be measured on a single ELISA plate, thus we selected at random 12 urine samples 
from the low MTX group and 23 urine samples from the high MTX group. Finally, one 
sample from the high MTX group had to be discarded from the N-cadherin ELISA 
assay, because the read-out values were beyond the values included in the standard 
curve.
Statistical analysis
Patient demographics and ELISA results were statistically analyzed using GraphPad 
Prism 5.02 (La Jolla). The unpaired student’s t-test and chi-square test were used 
for demographics data and a non-parametric one-way ANOVA Kruskal-Wallis test for 
the ELISA data. A p-value of less than 0.05 was considered statistically significant. 
Results
Differential profiles of urinary proteins in patients after MTX use 
Psoriasis patients using MTX were divided into two groups based on the dose 
history of MTX, because it has been reported that liver injury mostly occurs above 
a cumulative threshold of 1500 mg.28 This way, we were able to discriminate 
between proteins that appear in urine relatively early after initiating MTX treatment 
and proteins that are present in urine with a cumulative dose of MTX that poses 
most risk for hepatic fibrosis. Demographic parameters other than cumulative MTX 
dose and duration of MTX intake were not different between MTX groups (Table 1), 
including psoriasis area and severity index (PASI), body mass index (BMI), diabetes 
and alcohol consumption. Some patients in the high cumulative MTX dose group 
underwent a liver biopsy in the past, which was classified according to the Roenigk 
scoring system. Most biopsies were classified as Roenigk score I, reflecting none 
to mild portal inflammation, fatty changes and nuclear pleomorphism.29 One case of 
Roenigk score II was observed, indicating moderate to severe portal inflammation, 
fatty changes and nuclear pleomorphism. However, in clinical practice these Roenigk 
scores are not perceived as indicative of fibrosis. 
Urinary protein analysis showed differential protein profiles between masterpool 
control and all patients using MTX. Furthermore, although there was substantial 
interindividual variation between the patients, distinct protein peaks could be 
observed that discriminated between the low and high cumulative MTX dose groups 
(Figure 1). 
131
Urinary biomarkers for methotrexate-induced hepatic fibrosis
6
Protein identification reveals urinary proteins related to hepatic fibrosis
For identification of the differentially excreted proteins, in-solution digestion followed 
by ESI LTQ analysis was used. To this end, we used a pooled urine sample for each 
patient group, selecting those with the most differentiating protein profiles. Protein 
identification revealed two proteins that were present in the urine pools of all MTX 
groups and not in control (Table 2). Nine proteins were specifically identified in the 
pooled urine samples of patients with a high cumulative MTX dose and may be 
related to long-term use of MTX. The next step was to confirm the presence of 
the proposed biomarkers using specific antibodies and in that way also determine 
urinary concentrations.
ELISA assays do not confirm differential presence of N-cadherin and ITIH4 in 
urine 
Cadherin-2 preproprotein (N-cadherin) and inter-alpha-trypsin inhibitor heavy chain 
Table 1. Patient demographics
MTX cum. dose 
< 1500 mg
MTX cum. dose 
> 1500 mg
Number of patients 31 24
PASI 7 (1-18; n=25) 6 (1-14; n=18)
BMI (kg/m2) 27 (19-46;) n=29) 29 (21-62; n=20)
Disease duration (yrs) 19 (4-43; n=30) 26 (3-68; n=23)
Cumulative dose (mg) 550 (20-1440; n=31) 4270 (1635-17850; 
n=24) ***
Duration MTX intake (months) 11  (3-48; n=31) 99 (27-384; n=24) ***
Mean MTX intake (mg/week) 12 (6-20; n=29) 12 (6-20; n=22)
Mean MTX intake per body 
weight (mg/week*kg)
0.15 (0.07-0.32; n=28) 0.20 (0.06-0.95; n=20)
Roenigk score (n I/II) NA 15/1 
Diabetes (Y/N/unknown) 1/27/3 5/19/0
Use of folic acid (Y/N) 28/3 20/4
Use of other medication (Y/N) 18/13 16/8
Alcohol consumption
 (glasses/week)
3  (0-17; n=30) 6 (0-28; n=20)
PIIINP concentration (ng/mL) 3.8 (1.5-7.7; n=29) 3.7 (2.1-5.6; n=22)
Data is represented as mean (range; n) unless indicated otherwise.
PASI: psoriasis area and severity index; BMI: body mass indez; MTX: methotrexate; PIIINP: 
procollagen type III aminopeptide; N: no; Y: yes 
*** p < 0.001 compared to low cumulative dose
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H4 (ITIH4) were selected to be measured using specific ELISA kits because they 
had been associated with hepatic fibrosis.30 Both proteins were measured in urine 
samples of masterpool control and both MTX groups, and normalized to urine 
creatinine concentration. Because the masterpool already consisted of multiple 
control urine samples, it was measured only in duplo for each assay. Unfortunately, 
both ITIH4 and N-cadherin did not discriminate between the high cumulative MTX 
dose group and the other groups. 
For ITIH4, there was no difference in urinary concentration between all groups (Figure 
2A; p=0.48). However, although most patients treated with MTX had a urinary ITIH4 
concentration comparable to the concentration measured in the masterpool, some 
individuals in both MTX groups clearly demonstrated ITIH4 concentrations high 
above average. Still, we could not explain these outliers by confounders for hepatic 
fibrosis, including use of other medication, high BMI, and alcohol. 
The urinary concentration of N-cadherin appeared to be slightly higher in all 
MTX treated patients versus masterpool control urine (Figure 2B), but this was 
not statistically significant (p=0.078). Similar to ITIH4, there were a few subjects 
Figure 1. Urinary protein profiles of MTX patients versus control
Representative urinary protein profiles generated by MALDI-TOF MS show protein mass 
(m/z) in Da versus peak intensity in arbitrary units. For visual comparison, the peak intensity 
of the internal standard (IS) was set at 50% of the Y-axes. The gray areas indicate the IS and 
the mass peaks that differ either in appearance or peak intensity between the MTX patient 
groups and control.
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demonstrating high N-cadherin concentrations in urine. However, these were 
different subjects than those presenting with high urinary ITIH4 concentrations, and 
the high N-cadherin concentrations were not related to any of the other parameters 
included in this study, such as PASI, alcohol intake, cumulative dose MTX , PIIINP 
concentration and folic acid supplementation.
Figure 2. Urinary concentrations of ITIH4 and N-cadherin
A) ITIH4 concentration in urine of MTX-treated patients was not different from the masterpool 
control. B) Similarly, N-cadherin concentration in urine did not differ between groups. The 
horizontal lines indicate the median concentration.
Discussion
Monitoring hepatic fibrosis induced by chronic use of MTX is a difficult, especially 
in psoriasis patients.31, 32 Current guidelines for baseline evaluations, monitoring 
and prevention of MTX-induced hepatotoxicity include performing a liver biopsy, 
measuring plasma liver enzymes and use of folic acid supplementation.10  In light of 
these guidelines, there is a need for better and preferably non-invasive biomarkers 
to monitor MTX-induced hepatic fibrosis. This study was designed to identify 
proteins related to MTX treatment and hepatic fibrosis in urine of psoriasis patients. 
Because MTX-induced hepatic fibrosis generally occurs above a cumulative dose of 
1500 mg 6, 28, we divided psoriasis patients into a low cumulative MTX dose group 
(cumulative dose <1500 mg) and a high dose group (cumulative dose >1500 mg). 
In urine samples of patients in the high dose group, we identified proteins related to 
hepatic fibrosis, which may be potential biomarkers to monitor the development of 
MTX-induced hepatic fibrosis.
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    In line with the protein profiles generated with MALDI-TOF MS, protein identification 
using ESI LTQ demonstrated proteins to be differentially present after MTX treatment 
versus control, and between high cumulative versus low cumulative MTX dose. 
Specifically, the proteins present only in urine of patients with high cumulative MTX 
dose were of interest as potential biomarkers for MTX-induced hepatic fibrosis, since 
the incidence of disease manifestation is relatively high in this dose group. Of these 
proteins, ITIH4 has previously been proposed as serum biomarker to predict hepatic 
fibrosis caused by hepatitis C 33, 34, N-cadherin has been associated with apoptosis 
of hepatic stellate cells in the process of liver fibrosis 35 and cadherin-1 preproprotein 
(E-cadherin) has been found to play a role in hepatic fibrosis.36 Genes for both 
N-cadherin and ITIH4 were differentially expressed in culture activated hepatic 
stellate cells.30 Furthermore, zinc-alpha-2-glycoprotein precursor and haptoglobin 
were identified, which, in addition to ITIH4, also have been described as candidate 
serum biomarkers for liver fibrosis.34 Gangadharan et al. showed that ITIH4 and zinc-
alpha-2-glycoprotein levels were altered in serum of patients with cirrhotic liver only, 
whereas serum concentrations of haptoglobin were already altered in patients with 
mild hepatic fibrosis.34 Finally, another protein related to hepatic fibrosis that was 
identified from patients with a high cumulative MTX dose was serotransferrin, which 
is associated with cell proliferation and liver fibrosis.37
There were no differences between the two groups of MTX-treated patients with 
regard to average weekly MTX intake or other treatment and disease-related 
parameters, except for duration of MTX treatment and the cumulative MTX dose. 
Despite urinary protein profiling showing substantial interindividual variability 
between psoriasis patients, differences in protein profiles between all groups could 
still be observed. Interindividual variation in urinary composition has been reported 
before and is influenced by many factors including diet and medication.38 To diminish 
variation in the urinary proteome and to enable protein identification, urine samples 
of each MTX group were pooled.
The pooled urine samples used for protein identification were created from the urine 
samples that showed the most differentiating protein profiles and, thus, included 
a small number of samples. We measured the urinary concentration of potentially 
discriminating proteins, i.e. ITIH4 and N-cadherin by ELISA. Both proteins had been 
reported to be involved in liver fibrosis in various previous studies. Unfortunately, 
their urinary concentrations did not discriminate between the treatment groups and 
between MTX treated patients and controls due to the high interindividual variability. 
Although there were no differences in BMI, alcohol consumption and diabetes 
mellitus type 2 between the MTX dose groups, it should be noted that we were not 
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able to correct for all confounders that might have influenced the fibrotic process and 
associated markers. We included the use of other drugs in our questionnaire, but 
lacked detailed information on the specific co-medication regimens.
Another limitation that has to be taken into account is the reported absence of 
hepatic fibrosis. Liver biopsies performed in the past in patients included in the 
high cumulative MTX dose group showed Roenigk scores of I and II, which are not 
regarded as fibrosis. Probably, most patients included in this study will not develop 
MTX-induced hepatic fibrosis, but the few patients with a higher urinary concentration 
of the proposed biomarkers may be at risk. If so, ITIH4 and N-cadherin might be 
early predictive biomarkers for fibrosis, as increased urinary concentrations were 
observed in the low cumulative MTX dose group.  For future studies, it is important 
to include patients with proven MTX-induced hepatic fibrosis, i.e. Roenigk score 
above III, and measure urinary concentrations of the proposed biomarkers in these 
patients. In addition, it would be interesting to monitor the patients with high urinary 
concentrations of ITIH4 and N-cadherin in time for progression to hepatic fibrosis. 
In any case, the value of ITIH4, N-cadherin, and the other identified urinary proteins 
as potential biomarkers predictive for MTX-induced hepatic fibrosis needs to be 
assessed by a prospective study, in which psoriasis patients are monitored from 
the start of MTX treatment. Urine samples collected at regular time intervals and 
synchronized with other monitoring methods, such as plasma PIIINP measurements 
or liver biopsy, will allow for the determination of their biomarker potential.  
 
In conclusion, the proteins identified in this study in urine of psoriasis patients with 
a high cumulative dose of MTX, are potential non-invasive biomarkers for MTX-
induced liver injury based on their reported roles in hepatic fibrosis. Future studies 
should include patients with proven MTX-induced hepatic fibrosis, multiple time 
points of sample collection and synchronization with currently used methods to 
monitor disease progression, to evaluate the potential of the proposed biomarkers to 
predict MTX-induced hepatic fibrosis. 
References
1. Shen, S., et al., The use of methotrexate in dermatology: a review. Australas J 
Dermatol, 2012. 53(1): p. 1-18.
2. Warren, R.B., et al., Methotrexate for psoriasis in the era of biological therapy. Clin 
Exp Dermatol, 2008. 33(5): p. 551-4.
3. Taylor, W.J., et al., Drug use and toxicity in psoriatic disease: focus on methotrexate. 
J Rheumatol, 2008. 35(7): p. 1454-7.
137
Urinary biomarkers for methotrexate-induced hepatic fibrosis
6
4. Whiting-O’Keefe, Q.E., K.H. Fye, and K.D. Sack, Methotrexate and histologic hepatic 
abnormalities: a meta-analysis. Am J Med, 1991. 90(6): p. 711-6.
5. Langman, G., P.M. Hall, and G. Todd, Role of non-alcoholic steatohepatitis in 
methotrexate-induced liver injury. J Gastroenterol Hepatol, 2001. 16(12): p. 1395-
401.
6. Berends, M.A., et al., Liver injury in long-term methotrexate treatment in psoriasis is 
relatively infrequent. Aliment Pharmacol Ther, 2006. 24(5): p. 805-11.
7. Montaudie, H., et al., Methotrexate in psoriasis: a systematic review of treatment 
modalities, incidence, risk factors and monitoring of liver toxicity. J Eur Acad Dermatol 
Venereol, 2011. 25 Suppl 2: p. 12-8.
8. Lindsay, K., et al., Liver fibrosis in patients with psoriasis and psoriatic arthritis on 
long-term, high cumulative dose methotrexate therapy. Rheumatology (Oxford), 
2009. 48(5): p. 569-72.
9. Visser, K. and D.M. van der Heijde, Risk and management of liver toxicity during 
methotrexate treatment in rheumatoid and psoriatic arthritis: a systematic review of 
the literature. Clin Exp Rheumatol, 2009. 27(6): p. 1017-25.
10. Barker, J., et al., Assessment and management of methotrexate hepatotoxicity in 
psoriasis patients: report from a consensus conference to evaluate current practice 
and identify key questions toward optimizing methotrexate use in the clinic. J Eur 
Acad Dermatol Venereol, 2011. 25(7): p. 758-64.
11. Fairris, G.M., B. Brooks, and A. Tanner, Elevated serum aminoterminal procollagen 
type III peptide in methotrexate-induced hepatic fibrosis. Br J Dermatol, 1986. 114(4): 
p. 520-1.
12. Maurice, P.D., et al., Monitoring patients on methotrexate: hepatic fibrosis not seen in 
patients with normal serum assays of aminoterminal peptide of type III procollagen. 
Br J Dermatol, 2005. 152(3): p. 451-8.
13. Ebinuma, H., et al., Evaluation of liver fibrosis by transient elastography using 
acoustic radiation force impulse: comparison with Fibroscan((R)). J Gastroenterol, 
2011. 46(10): p. 1238-48.
14. Kalantari, H., et al., Validation of hepascore as a predictor of liver fibrosis in patients 
with chronic hepatitis C infection. Hepat Res Treat, 2011. 2011: p. 972759.
15. Poynard, T., et al., Validation of liver fibrosis biomarker (FibroTest) for assessing liver 
fibrosis progression: Proof of concept and first application in a large population. J 
Hepatol, 2012. 57(3): p. 541-8.
16. Chladek, J., et al., Assessment of methotrexate hepatotoxicity in psoriasis patients: a 
prospective evaluation of four serum fibrosis markers. J Eur Acad Dermatol Venereol, 
2012.
17. Kentsis, A., Challenges and opportunities for discovery of disease biomarkers using 
urine proteomics. Pediatr Int, 2011. 53(1): p. 1-6.
18. Bosserhoff, A. and C. Hellerbrand, Obesity and fatty liver are ‘grease’ for the 
machinery of hepatic fibrosis. Dig Dis, 2011. 29(4): p. 377-83.
19. Spicak, J., et al., Alcoholic chronic pancreatitis and liver cirrhosis: Coincidence and 
differences in lifestyle. Pancreatology, 2012. 12(4): p. 311-6.
20. Wlazlo, N., et al., High prevalence of diabetes mellitus in patients with liver cirrhosis. 
Diabet Med, 2010. 27(11): p. 1308-11.
21. Stravitz, R.T. and A.J. Sanyal, Drug-induced steatohepatitis. Clin Liver Dis, 2003. 
7(2): p. 435-51.
22. Vanhoutte, K.J., et al., Biomarker discovery with SELDI-TOF MS in human urine 
associated with early renal injury: evaluation with computational analytical tools. 
138
Chapter 6
6
Nephrol Dial Transplant, 2007. 22(10): p. 2932-43.
23. Fiedler, G.M., et al., Standardized peptidome profiling of human urine by magnetic 
bead separation and matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry. Clin Chem, 2007. 53(3): p. 421-8.
24. Nielsen, M.L., et al., Iodoacetamide-induced artifact mimics ubiquitination in mass 
spectrometry. Nat Methods, 2008. 5(6): p. 459-60.
25. Kinter, A. and N.E. Sherman, Protein sequencing and identification using tandem 
mass spectrometry. JohnWiley & Sons, 2000: p. 161-163.
26. Rappsilber, J., Y. Ishihama, and M. Mann, Stop and go extraction tips for matrix-
assisted laser desorption/ionization, nanoelectrospray, and LC/MS sample 
pretreatment in proteomics. Anal Chem, 2003. 75(3): p. 663-70.
27. Wessels, H.J., et al., Liquid chromatography-mass spectrometry-based proteomics 
of Nitrosomonas. Methods Enzymol, 2011. 486: p. 465-82.
28. Wollina, U., K. Stander, and U. Barta, Toxicity of methotrexate treatment in psoriasis 
and psoriatic arthritis--short- and long-term toxicity in 104 patients. Clin Rheumatol, 
2001. 20(6): p. 406-10.
29. Berends, M.A., et al., Reliability of the Roenigk classification of liver damage after 
methotrexate treatment for psoriasis: a clinicopathologic study of 160 liver biopsy 
specimens. Arch Dermatol, 2007. 143(12): p. 1515-9.
30. Liu, X.J., et al., Association of differentially expressed genes with activation of mouse 
hepatic stellate cells by high-density cDNA microarray. World J Gastroenterol, 2004. 
10(11): p. 1600-7.
31. Aithal, G.P., Hepatotoxicity related to antirheumatic drugs. Nat Rev Rheumatol, 2011. 
7(3): p. 139-50.
32. Helliwell, P.S. and W.J. Taylor, Treatment of psoriatic arthritis and rheumatoid arthritis 
with disease modifying drugs -- comparison of drugs and adverse reactions. J 
Rheumatol, 2008. 35(3): p. 472-6.
33. Yang, L., et al., Novel biomarker candidates to predict hepatic fibrosis in hepatitis C 
identified by serum proteomics. Dig Dis Sci, 2011. 56(11): p. 3305-15.
34. Gangadharan, B., et al., Novel serum biomarker candidates for liver fibrosis in 
hepatitis C patients. Clin Chem, 2007. 53(10): p. 1792-9.
35. Hartland, S.N., et al., Active matrix metalloproteinase-2 promotes apoptosis of 
hepatic stellate cells via the cleavage of cellular N-cadherin. Liver Int, 2009. 29(7): p. 
966-78.
36. Cho, I.J., et al., E-cadherin antagonizes transforming growth factor beta1 
gene induction in hepatic stellate cells by inhibiting RhoA-dependent Smad3 
phosphorylation. Hepatology, 2010. 52(6): p. 2053-64.
37. Gressner, O.A., et al., Evaluation of serum percent trisialotransferrin as potential 
predictive biomarker of hepatocellular dedifferentiation in chronic liver disease. Clin 
Chim Acta, 2009. 403(1-2): p. 188-93.
38. Winnike, J.H., et al., Use of pharmaco-metabonomics for early prediction of 
acetaminophen-induced hepatotoxicity in humans. Clin Pharmacol Ther, 2010. 88(1): 
p. 45-51.
139
Urinary biomarkers for methotrexate-induced hepatic fibrosis
6

7General discussion
142
Chapter 7
7
143
General discussion
7
In this thesis, protein profiling by MALDI-TOF MS in combination with additional 
proteomics techniques was implemented for the detection and identification of urinary 
biomarkers that could be predictive for DILI. The workflow of this strategy is depicted 
in Figure 1. Furthermore, we gained more insight in the mechanisms that underlie 
these adverse drug reactions. In this chapter, the usefulness of urine proteomics for 
biomarker detection and unraveling molecular mechanisms, as well as the practical 
issues related to the use of urinary biomarkers in the clinic are discussed. Moreover, 
the necessity for translational research and the future perspectives in the field of 
idiosyncratic DILI are given.
The potential of proteomics techniques in identification of urinary biomarkers 
for DILI
Proteomics profiling with MALDI-TOF MS is an ideal technique to assess changes 
in protein composition of biological samples induced by various causes, such as 
disease, drug treatment and adverse drug reactions. This top-down approach results 
in an overview of all discriminating protein masses between two conditions, i.e. 
control and treatment, as it can cover a relatively large m/z range (up to 160 kDa). 
This approach can be very useful when there is no a priori knowledge on potentially 
differentiating proteins, such as for the detection of biomarkers for DILI. MALDI-TOF 
MS protein profiling was performed on urine samples, as urine contains fewer proteins 
than blood and less high-abundant proteins.1 Besides proteins, urine also contains 
salts that need to be removed prior to MALDI-TOF MS analysis, which was done by 
using affinity beads that capture a specific protein fraction based on their chemical-
physical properties (shown in Figure 1).2 After protein profiling, the proteins of interest 
were identified using additional techniques, for which we applied VMALDI LTQ, ESI 
LTQ and LC-MS/MS in our studies. The advantage of using VMALDI LTQ was that 
we could directly fragment and sequence mass peaks of < 4 kDa detected by MALDI-
TOF MS, and assign a protein to a particular mass peak. Proteins identified by ESI 
LTQ and LC-MS/MS could not be directly assigned to a single mass peak. For this, 
additional techniques involving protein-specific antibodies were implemented, such 
as immunocapture, which was performed for calmodulin (CaM) detection after APAP-
induced hepatotoxicity (Chapter 2). Originally, MALDI-TOF MS was designed for 
comparative analysis of protein patterns between samples.3 Once a specific pattern 
for tissue injury has been established, it is relatively straightforward to measure 
multiple samples and pinpoint toxicity. MALDI-TOF MS is ideally suited for assessing 
differences in protein profiles between control and disease conditions, but not for 
subsequent biomarker identification.4 Moreover, sample pretreatment is necessary for 
MALDI-TOF MS protein profiling, as a result of which only a fraction of the proteome 
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Figure 1. General workflow of urine proteomics profiling employed in this thesis
Human and mouse urine samples were collected in polypropylene tubes and centrifuged at 
3000 x g for 10 minutes to remove the debris. Proteins were isolated from urine by adding 
magnetic affinity beads to the sample. The protein-bound beads were isolated by placing 
the tube in a magnetic holder; the rest of the urine sample was removed. After washing, an 
elution solution was added to the beads to collect the protein fraction. Isolated proteins were 
spotted onto a MALDI target plate, dried under nitrogen flow and covered by an energy ab-
sorbing matrix. The target plate was placed in the Microflex apparatus (Bruker) in which a 
laser beam is directed to the plate surface. Proteins are desorbed and ionized from the plate 
surface by the laser beam and are passed through a vacuum tube to the mass analyzer. 
Protein reaching the mass analyzer are depicted as mass peaks in protein profiles, which 
can be compared between samples for biomarker assessment. Proteins of interest that were 
< 4kD could be directly identified from the target plate using VMALDI LTQ. Larger proteins 
were identified either by in-gel digestion after 1D gel pretreatment or in-solution digestion of 
samples pretreated with magnetic beads using LC-MS/MS or ESI LTQ.
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can be measured and analytical variation can be introduced.5 Another approach for 
biomarker identification is the use of 1D or 2D gel electrophoresis followed by in-gel 
digestion and MS analysis, which we applied in our studies on larger proteins that 
could not be identified using VMALDI LTQ. This technique requires less extensive 
sample pretreatment as compared to MALDI-TOF MS and allows a more accurate 
identification of differentially expressed proteins. The classical bottom-up approach 
of proteomics biomarker discovery is the use of HPLC separation coupled to MS/MS 
identification and quantification, which can be done either ‘label-free’ or with the use 
of isotope labeling.4 This technique allows for immediate protein identification and 
quantification, as demonstrated by Bell et al. who performed label-free quantitative 
proteomics using LC/MS/MS analysis for serum biomarker identification.6 The 
disadvantage of this platform is that it can become more expensive and less high-
throughput as precision of quantification and complexity increase. To confirm the 
proteins we identified with MALDI-TOF MS profiling and VMALDI LTQ in urine of 
APAP-treated mice, we also applied LC-MS/MS to pooled urine samples (Chapter 
2). As expected, more proteins could be identified with LC-MS/MS analysis as 
compared to MALDI-TOF MS, although the top ten of most differentiating proteins 
between control and APAP-treated mice was similar. The advantage of using both 
proteomics platforms was that we observed an interesting discriminating mass peak 
with MALDI-TOF MS profiling, which we could not identify with additional VMALDI 
LTQ or 1D gel electrophoresis in combination with ESI LTQ measurements. We 
were, however, able to retrieve the protein from the LC-MS/MS data, because of its 
unique mass. Although the protein was not within the top ten of most differentiating 
proteins, based on protein abundance the peak mass identified as CaM appeared to 
be a valuable biomarker.      
For acute hepatocellular hepatotoxicity caused by APAP, we observed a pattern of 
a few key protein mass peaks that were present in both human and mouse urine 
samples, but also in medium of PCLS that were incubated with APAP (Chapter 1 and 
5; Table 1). Moreover, MALDI-TOF MS protein profiling clearly demonstrated that 
the same pattern of mass peaks was present in PCLS medium after DF treatment, 
indicating that DF caused acute hepatocellular injury in this assay (Chapter 5). 
However, MALDI-TOF MS protein profiling alone is not sufficient for adequate 
biomarker discovery and to ensure optimal exploration of the urinary proteome and 
accurate protein identification, a combination of the different proteomics platforms is 
most desirable.
The potential of urinary proteins as biomarkers for DILI 
The usefulness of urinary biomarkers has already been established for kidney injury, 
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because the majority of urinary proteins reflect the processes that are ongoing in 
the kidney.7 But also for non-kidney related diseases, including pre-eclampsia, 
pancreatitis and coronary artery disease, urinary biomarkers have been identified, 
demonstrating their usefulness in detecting organ injury.8 The ultimate goal of this 
thesis was to identify urinary proteins that could be used in the process of drug 
development or clinical practice to predict and monitor DILI. We were able to identify 
a number of proteins related to liver injury caused by different hepatotoxic drugs 
and related to different pathologic mechanisms (Table 1). The vast majority of these 
potential biomarkers are not liver-specific, but many proteins correlated strongly with 
liver injury, as was observed with APAP (Chapter 2). 
Of the proteins identified in urine of mice with APAP-induced liver injury, CaM and 
superoxide dismutase 1 (SOD1) showed the strongest correlation with plasma 
ALT levels and could also be measured in human urine samples after APAP 
intoxication. In particular, CaM was found in samples of intoxicants that did not have 
elevated plasma ALT values and the protein levels correlated with plasma APAP 
concentrations. SOD1 had previously been investigated as urinary biomarker for 
CCL4-induced hepatotoxicity in rats in a dose- and time-dependent manner 
9, 10, 
whereas CaM was identified as a novel marker. In vitro experiments with human 
PCLS demonstrated that both proteins are released by human liver tissue after APAP 
incubation (Chapter 5), suggesting that they are good candidates as biomarkers for 
human hepatocellular DILI and should be investigated further. For both proteins, the 
detection in urine related to the degree of hepatic injury (as assessed by plasma 
ALT values and histology) at multiple time points after drug administration. Also, 
fragments of CA3 in urine correlated well with plasma ALT values in APAP-treated 
mice, whereas the whole protein did not. Full length CA3 could not be detected in 
medium from the human PCLS study, though CA3 was detected in urine of a severe 
APAP intoxicant. CA3 has been suggested as potential tissue biomarker for hepatic 
injury, i. e. hepatocellular carcinoma.11, 12 There seems to be an association between 
CA3 and hepatic injury, but in order to assess its potential as urinary biomarker, 
further preclinical studies should be performed to determine its dynamics. 
Besides the Top Institute Pharma consortium D3-201 that facilitated this study, there 
are several other consortia in Europe and the United States that are working on 
identification and validation of biomarkers for DILI, including the SAFE-T (Safer and 
Faster Evidence-based Translation) consortium funded by the Innovative Medicines 
Initiative (IMI) and the US Drug-induced Liver Injury Network (DILIN). The findings 
of our study partly correspond to the results obtained in these consortia and other 
academic research groups. For instance regucalcin and glutathione-S-transferase 
(GST) α have been listed as potential serum biomarkers by the SAFE-T consortium. 
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The latest status update indicated that regucalcin is ready to be analyzed in small 
sample sizes of DILI patients and GSTα is ready to be used for screening in a large 
number of serum samples of DILI patients. Liver fatty acid binding protein (L-FABP) 
has recently been studied in a small patient population as new diagnostic serum 
biomarker for liver injury due to hepatitis C infection.13 Therefore; L-FABP might also 
be a predictive serum or urine biomarker for DILI. Of the remaining proteins that 
were identified in this study, a role as potential biomarker for DILI has not been 
described in literature or has only been suggested in relation to other types of hepatic 
injury in in vitro and in vivo studies. Thus, these proteins remain to be investigated 
further at a preclinical level for potential biomarker properties. Ketohexokinase and 
D-dopachrome tautomerase have been assessed as potential tissue biomarkers 
in rats for hepatocellular carcinoma and alcoholic steatosis, respectively.12, 14 For 
peroxiredoxin precursor 5, no studies were found that describe its potential role 
in hepatic injury, although peroxiredoxin in general was suggested as potential 
biomarker for in vitro drug toxicity screening tests to predict hepatotoxicity in Hep3B 
cells.15 GSTπ1 and both GSTμ isoforms appear to be mechanistically involved in 
DILI (Table 1), but have not been investigated as biomarkers. Polymorphisms in the 
genes encoding for these proteins might play a role in susceptibility for DILI.16 
In psoriasis patients with high cumulative doses of MTX we identified proteins in urine 
that could relate to fibrosis (Chapter 6). Some of these proteins have been described 
as potential serum biomarkers for DILI in the US DILIN study, performed by Bell et 
al.6 In their study, lactotransferrin concentrations differed between control and serum 
samples from patients with DILI, prostaglandine-H2 D-isomerase discriminated 
between hepatocellular, cholestatic and mixed type DILI, and haptoglobin was 
differentially expressed between patients with moderate, severe or fatal DILI. 
Moreover, haptoglobin is part of the Fibrotest to predict hepatic fibrosis, which has 
been demonstrated as a useful diagnostic tool in a large population of patients 
with chronic hepatitis C, hepatitis B, non-alcoholic fatty liver disease and alcoholic 
fatty liver disease.17 Zinc-α-2-glycoprotein and inter-α-trypsin-inhibitor heavy chain 
H4 have been proposed as plasma biomarkers for hepatic fibrosis, because they 
were significantly increased in patients with hepatitis C.18 We did not find zinc-α-
2-glycoprotein itself, but its precursor protein. Similarly, Bell et al. demonstrated 
a differential presence of serotransferrin in serum of patients with hepatocellular, 
cholestatic and mixed DILI 6, whereas we found the serotransferrin precursor in 
urine of patients with a high cumulative dose of MTX. For both cadherin preprotein 
isoforms and apolipoprotein D precursor, we could not find any studies on their 
possible role as biomarker for DILI, although other isoforms of apolipoprotein have 
been linked to DILI.6 Because the proteins identified in our study have been found in 
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patients that are at risk of developing MTX-induced hepatic fibrosis, but did not have 
any adverse reaction yet, the most logical next step will be to verify whether these 
proteins can also be detected in urine of patients with established (MTX-induced) 
hepatic fibrosis. Preferably, patients starting MTX treatment should be followed over 
time with regular sampling intervals to assess the dynamics and predictive values of 
the proposed biomarkers. 
For DF we found proteins in urine that pointed towards regenerative processes in the 
liver, but also related to kidney injury (Chapter 4 and Table 1), of which all have been or 
are currently being evaluated in human patient samples as biomarker for renal injury, 
hepatic injury or both. In fact, epidermal growth factor (EGF), clusterin and L-FABP 
have been listed as potential biomarkers for kidney injury by the SAFE-T consortium. 
Clusterin has been proposed in particular as urinary biomarker for drug-induced 
kidney injury by multiple preclinical studies and is now being evaluated in patient 
samples by the SAFE-T consortium.19-21 Also kallikrein 1 has been investigated as 
urinary biomarker for renal injury in patients with acute kidney injury.22 Interestingly, 
some of the proteins might serve as biomarker for both liver and kidney injury. 
For instance, EGF has been proposed as tissue biomarker for chronic liver injury 
caused by CCL4 administration in mice 
23, and as mentioned before, L-FABP is also 
proposed as plasma biomarker for hepatic injury. Similarly, transthyretin has been 
investigated as urinary biomarker in patients with renal allograft injury, but also as 
serum biomarker in patients with fulminant hepatic failure.24, 25 Finally, plasminogen 
activator urokinase has been studied as urinary biomarker for the detection of renal 
allograft injury, but also as serum biomarker for hepatic injury in patients with chronic 
liver disease.26, 27 Our study demonstrates that some biomarkers might be indicative 
for both renal or hepatic injury, and future research should focus on the development 
of biomarker panels that can discriminate between different types of organ injury.
Validation and optimization of urinary biomarkers to predict and monitor DILI 
in clinical practice 
Biomarkers need to fulfill certain criteria in order to be useful in clinical practice. First, 
their specificity and sensitivity should be assessed. As discussed, many proteins 
identified in relation to DILI can be associated with other pathologies, such as kidney 
injury. This poor specificity requires a panel of biomarkers to discriminate between 
pathologies, as has been suggested also for urinary microRNA and metabolomics 
biomarkers.28, 29 Specificity can be determined by the assessment of biomarker 
patterns in patient samples with pathologies other than DILI, but also in patients with 
various types of liver pathologies caused by drug treatment. Sensitivity is defined as 
the number of true positives in a clinical trial. A high sensitivity of biomarkers for DILI 
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would assure that the medication of a patient is not unnecessarily stopped. Some 
protein biomarkers might endogenously be present in urine and can demonstrate 
changes in abundance in relation to DILI. For such biomarkers, normal reference 
values or toxicity threshold values need to be validated in order to evaluate their 
sensitivity. However, the SAFE-T consortium has recently demonstrated that even 
for the conventionally used biomarker for liver injury, plasma ALT, it is challenging to 
define reference values.30 Another criterium that a biomarker for DILI needs to meet 
is that it has to have predictive potential. The goal of having biomarkers for DILI is 
to monitor patients on a routine basis and to prevent an adverse event. To this end, 
biomarkers should be indicative of liver injury at an early stage, allowing cessation of 
drug treatment to prevent progression into clinically relevant liver injury. 
All these issues need to be addressed before a biomarker can be applied in clinical 
practice. Although biomarkers for DILI are identified in multiple models, including in vitro 
systems, animal models and selective patient samples, ultimately, their usefulness 
as clinical biomarker should be validated in samples from the human population. For 
DILI, it is difficult to determine the specificity, sensitivity and predictive values of a 
particular (set of) biomarker(s) because of the relatively low incidence.31 Moreover, 
because there are various pathologies of liver injury and multiple drugs that cause 
a specific DILI reaction, it is very difficult to collect a sufficient amount of samples 
for any specific type of DILI. Therefore, the majority of the biomarkers identified 
for DILI are in a preclinical phase and only few have been validated and used in a 
clinic setting.32 According to Matheis et al., the currently identified exploratory (pre)
clinical biomarkers lack predictivity and prognostic value.33 Even institutions such 
as the US Food and Drug Administration agency (FDA) have made little progress 
in validation of new potential biomarkers for DILI. In fact, the current FDA-TRACK 
(Transparency Results Accountability Credibility Knowledge Sharing) program is 
aimed at identifying new biomarkers for DILI using preclinical experiments, rather 
than validation of already identified proteins. Contrary, public-private partnerships 
such as the SAFE-T consortium have been established to get novel biomarkers 
for DILI in clinical practice with the combined efforts of academia, government and 
companies involved in drug development. The SAFE-T consortium is specifically 
aimed at delivering protein biomarkers for DILI, but also for drug-induced kidney 
and vascular injury.33 Their approach is to invest in collecting a large number of 
samples from DILI patients around the world by biobanking and measuring potential 
biomarkers that have been selected from literature in these human samples. Efforts 
have also been made to build a database that contains data from preclinical studies, 
clinical studies, but also validation data. An example is the assessment of high-
mobility group box-1 protein and cytokeratin 18 as prognostic serum biomarkers 
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during clinical APAP-induced DILI.34 Recently, also the utility of the suggested serum 
biomarkers, glutamate dehydrogenase (GLDH), purine nucleoside phosphorylase 
(PNP), malate dehydrogenase (MDH) and paraxonase 1 (PON1), as indicators of 
liver injury was assessed in a large study including healthy subjects, and patients 
with a variety of liver impairments and several cases of APAP intoxication.35 That 
study demonstrated that both GLDH and MDH might be used as biomarkers for 
DILI in humans.  Another type of biomarkers for DILI that seems promising are the 
microRNAs, of which miR-122 has shown to predict APAP-induced DILI in mice 
and humans.36 For miR-122 and other microRNAs to be implemented as clinically 
relevant biomarkers for DILI, more detailed knowledge on specificity, sensitivity and 
the dynamic range is needed.37  Also for non-protein biomarkers, similar problems 
are being encountered regarding validation, because of the relatively rare incidence 
and multifactorial nature of DILI. In addition to human sample collection, investing 
in translational in vitro methods to get as much information of the human relevance 
of newly identified biomarkers could aid in making a better selection of their clinical 
relevance and implementation into clinical practice. 
Besides validation, some additional (practical) issues have to be overcome before 
urinary protein biomarkers can be implemented in clinically. Urine sample collection 
should be standardized to avoid variations in protein profiles. It has been shown that 
mid-stream as compared to first-void urine is most suitable, especially in women, 
because this matrix is not or only to a minor extent contaminated with proteins 
secreted from the urethra.38  In order to keep protein degradation to a minimum, urine 
samples should be rapidly frozen with protease inhibitors added and freeze/thaw 
cycles should be kept to a minimum.39 On the other hand, for one of the biomarkers 
for APAP-induced hepatotoxicity, carbonic anhydrase 3, only protein fragments 
correlated with liver injury, whereas the whole protein could not be detected in urine 
(Chapter 2). To evaluate the applicability of specific protein fragments as biomarkers, 
the dynamics of these fragments should be assessed by investigating whether the 
protein degrades rapidly in (pre-)urine, is reabsorbed partly by the kidney tubules, 
or is restricted by the glomerulus from being filtered. In general, the urinary protein 
content is highly variable among individuals and can be influenced by factors such 
as diet, disease, use of medication, genetic, and gender differences.40 Therefore, 
any panel of biomarkers should be robust enough to be detectable from the highly 
variable urinary protein content. In addition, the concentration of urinary protein 
biomarkers should be normalized to protein abundance. Various factors have 
been suggested to normalize urinary biomarker protein concentration, including 
total urinary protein concentration, urine volume, urine concentration of creatinine, 
albumin, β2-microglobulin, and parameters related to MS, such as spectral counts, 
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ion currents and isotopic labeling.2, 8 However, hitherto, no consensus has been 
reached for protein normalization.
Taking all of the above into account, the ideal urinary biomarker for DILI should 
probably consist of a panel of proteins that is specific for DILI, but should still be able 
to distinguish between the various pathologies of liver injury. The urinary proteins 
should be stable to withstand deviations from the ideal sample collection protocol, 
including time until storage and changes in temperature, and should be robust 
enough to be unaffected by interindividual variation, such as dilution of urine, use 
of other medication, diet, gender and genetic differences. Most of all, the proteins 
should be detectable before the onset of hepatic injury to prevent DILI.
 
Mechanistic insight in DILI due to proteomics profiling
The proteins that we identified in urine could be useful as predictive biomarkers, 
but could also give insight into the mechanisms that are involved in the underlying 
pathologies.41 The urinary protein profile observed after DF treatment pointed 
towards liver regeneration and kidney injury, based on the known function of the 
proteins identified (Table 1). Involvement of these processes in DF-induced injury 
could be confirmed on the organ level, demonstrating the mechanistic insight the 
urinary proteome can give. Also plasma proteomics can reveal mechanisms that 
play a role in DILI. For APAP-induced liver injury, we showed the decreased plasma 
concentration of hepcidin. This led to the unraveling of an oxidative stress-mediated 
pathway leading to increased hepatic iron levels by reduced hepcidin concentrations, 
which can aggravate APAP-induced hepatic injury. Knowledge of such mechanisms 
can provide more insight in differences in susceptibility for adverse drug reactions 
such as DILI. For instance, subjects with genetically low levels of hepcidin might be 
more susceptible to iron loading and, therefore, to DILI mediated by oxidative stress. 
Protein profiling of urine from mice with APAP-induced liver injury led to another 
interesting finding that may offer new mechanistic insights. We identified multiple 
types of androgen binding proteins (ABPs; Chapter 2) in urine of mice treated with ≥ 
275 mg/kg APAP (Figure 2 and Table 2). The presence of these ABPs, which were 
identified as originating from the lacrimal and submandibular gland, was independent 
of the degree of liver injury. Although it is suggested that they are secreted mainly in 
tear fluid or saliva, it is not unlikely that they can also be secreted to the blood, similar 
to testis-specific ABPs that are secreted predominantly in the seminiferous tubules, 
but can be also found in blood.42 In addition, recent studies of Zhou et al. using 
Cyp2a5-null mice showed that ABPs can conjugate to APAP in the lateral nasal 
gland and transport the APAP-ABP adduct in blood, suggesting that ABPs act as a 
defense mechanism against the reactive metabolite of APAP, NAPQI.43 We, thus, 
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hypothesize that the lacrimal ABPs found in urine after APAP treatment may fulfill a 
similar detoxification function (Figure 3). Moreover, APAP is extensively metabolized 
in the liver and, therefore, the ABPs secreted in blood will encounter most of their 
target NAPQI at the site of the liver. It has been recently demonstrated that NAPQI 
can be measured in blood after APAP intoxication.44 Because the ABPs secreted in 
Figure 2. Specific bands detected with 1D gel electrophoresis in mice treated with 
≥257 mg/kg APAP
Urine of mice treated with ≥275 mg/kg APAP demonstrated the presence of 3 specific pro-
tein bands (A, B and C) on 1D gel electrophoresis, regardless of the degree of liver injury as 
indicated by plasma ALT concentration. Urine of control mice, mice treated with AMAP or a 
dose of ≤275 mg/kg did not show the presence of these protein bands.
Table 2. Identification of ABPs using VMALDI LTQ
Band Protein Identity Protein 
Mass 
(Da)
Peptide Sequence MH+
A Androgen binding protein 
delta
12581.4 R.SILDYISK.L 938.5193
B Androgen binding protein 
zeta
Pred. Sim to androgen 
binding protein eta
12526.5
9931.2
R.LWLYHELSAFN#GTPK.E
K.QYKDDPVILENTAK.I
1776.8956
1633.8432
C Androgen binding protein 
zeta
Androgen binding protein 
eta
12526.5
10281.3
R.LWLYHELSAFN#GTPK.E
K.EHAAAFIEK.I
K.ENKEHAAAFIEK.I
K.YKDDPETLENTEK.L
K.EDVHLFLFGTPEEYVN#YVEK.Y
1776.8956
1015.5207
1386.7012
1581.7279
2429.157
For each protein identified by vMALDI-LTQ the protein mass is given in Da and the peptide 
sequences by which the protein was identified are given with their corresponding molecular 
weight (MH+) in Da.
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blood still have the capacity to bind androgens,45 it is not unlikely that they transport 
these hormones to the liver. In fact, only 0.5-4% of the androgens in blood is not 
bound to proteins.46 Androgens can influence intracellular signaling in a genomic 
way via the Androgen Receptor (AR), but also rapidly via non-genomic actions 
involving ion channels, the Sex Hormone-Binding Globuline Receptor (SHBGR) 
or G-Protein Coupled Receptors (GPCRs) as depicted in Figure 3.47, 48 These 
rapid actions typically involve second messenger signal transduction cascades 
that ultimately modulate the transcriptional activity of the AR or other transcription 
factors.49 Androgens can modulate the expression of proteins that play an important 
role in mechanisms underlying APAP-induced liver injury, such as oxidative stress 
and glutathione homeostasis.50, 51 Interestingly, gender differences in susceptibility to 
APAP-induced liver injury have been reported in mice, showing that males are more 
susceptible than females.52 Of course, additional research is needed to investigate 
this hypothesis further. 
Results from this thesis and literature demonstrate that based on the proteins 
identified in urine after DILI, new hypotheses can be generated on mechanisms 
underlying the pathology and differences in susceptibility. A useful tool for unraveling 
new toxicological pathways based on the proteins identified in urine of animals or 
human subjects, is using toxicological pathway analysis software that assesses 
the potential association between panels of proteins. An example is the Ingenuity 
Pathway Analysis software (Ingenuity Systems, Redwood City, CA, USA), which was 
used by Collins et al. to discover the pathways involved in drug-induced hepatotoxicity 
in rat after LC/MS analysis of hepatic proteins.53 This way, more information can be 
obtained from sparse urine samples collected from subjects with DILI and even more 
scarcely available idiosyncratic DILI samples. 
Necessity of translational research to study idiosyncratic DILI
Although DILI has a high impact on patient health and can lead to restrictions in drug 
use or approval by regulatory authorities, mechanistic insights in DILI progresses 
slowly, because of limited sample availability. Alternatives for studying DILI are the 
use of in vitro and in vivo models. It has become apparent that when using alternative 
animal models to investigate DILI, species differences have to be taken into account. 
For instance, the alleged non-toxic isomer of APAP, 3-acetamidophenol (AMAP), has 
been used as a negative control to discriminate between the pharmacological and 
toxic effects of APAP. However, it was recently demonstrated that AMAP is non-toxic 
in mice, but is just as toxic as APAP in rats and humans.54 In general, the concordance 
in drug-induced toxicity between humans and animals is relatively low.55 For example, 
MTX is associated with multiple types of hepatic injury as adverse reaction, including 
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7 steatosis, fibrosis and cirrhosis.56, 57 Although most human cases of hepatic injury are caused by chronic MTX treatment, animal models have been developed to assess 
the early features of hepatic injury after a single dose.58, 59 In line with these studies, 
we performed an animal study in which we treated CH3/HeOUJIco mice with a single 
oral dose of 100 mg/kg bw MTX and collected a 24 h urine sample to identify urinary 
proteins related to the early processes involved in steatosis. However, using this 
treatment regimen, we were not able to find any change in liver function or histology 
Figure 3. Hypothesized roles of androgen and androgen-binding protein in APAP-me-
diated liver injury
Androgen-binding protein (ABP) is released from secreting organs, such as the lacrimal 
gland, into the blood stream in order to conjugate and excrete plasma NAPQI in the urine. In 
blood, ABP can bind androgens (A) and transport these to the liver. Androgens with ABP as 
cofactor can activate the sex hormone-binding globuline receptor (SHBGR) for rapid signal 
transduction. Androgens released from ABP can induce intracellular signaling also via other 
mechanisms, including passive membrane diffusion and subsequent binding to the andro-
gen receptor (AR), binding to the G-protein coupled receptor (GPCR) or ion channels. Ulti-
mately, this will lead to the transcription of genes with androgen responsive elements (ARE).
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indicative of steatosis (data not published).
Nevertheless, in order to speed up knowledge on DILI, animal in vivo models and 
animal or preferably human cell-based assays have to be developed to investigate 
the principles of DILI, which subsequently need to be validated for their translational 
potency, as we have done for APAP-induced liver injury. The advantages of in vitro 
models are that they can be realized in a high-throughput fashion for the screening 
of potential hepatotoxic drugs and to reduce the number of experimental animals. 
Human cell-based models can be of more translational value for human DILI than 
animal-based models. For example, DF treatment did not result in hepatic injury in 
mice in vivo, but incubation of mouse, rat and human PCLS with DF did result in 
the presence of toxicity markers, similar to APAP (Chapter 5). However, the obvious 
drawback of in vitro models is the lack of an entire organism and therefore, various 
systemic metabolic and regulatory processes may be overlooked. Moreover, human 
material is not always or indefinitely available and immortalized cell lines may lose 
relevant properties because of drastic dedifferentiation of the cultures. 60, 61 Currently, 
new in vitro models are being developed to increase human tissue resemblance by 
incorporating 3D cell culturing methods and the use of cell co-cultures.62-64
Despite species differences, animal models can be useful to assess the role 
of certain proteins or enzymes in the development of DILI, for instance by using 
knockout mice. For various enzymes, their role in APAP-induced liver injury has been 
investigated in knockout mice, including caveolin-1, superoxide dismutase 1 and 
NFκB p50.65-67 Furthermore, animals can be genetically modified in such a way that 
they express a humanized protein that is believed to play a role in human DILI.68 The 
assumption that has to be made for such an approach is that the humanized protein 
will interact with animal proteins in a way that resembles the human situation in DILI. 
Apart from mechanistic studies, animal models can be very useful in the search for 
biomarkers. In this thesis, we have shown the benefits of identifying biomarkers for 
liver injury in animals first and subsequently confirmed these in the scarce human 
samples (Chapter 2). Urine proved to be a suitable source for translational biomarker 
identification in APAP-induced liver injury; however, the approach might not work for 
all drugs that cause DILI, in particular for those drugs that induce an idiosyncratic 
reaction. Various animal models have been developed, but their design strongly 
depends on which hypothesis for idiosyncratic DILI was studied.69 We showed that 
DF did not lead to severe hepatic injury in mice (Chapter 4), whereas DILI has been 
reported to occur in humans. Even the combined administration of DF plus LPS did 
not evoke an adverse event in mouse liver. We were, however, able to demonstrate 
a protein profile in medium of PCLS after DF incubation, similar to APAP incubation 
(Chapter 5). This demonstrates that for drugs of which the hepatotoxic effect seen 
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in humans cannot be mimicked in animals, in vitro models may be more appropriate 
than in vivo models. Consequently, this indicates that for effective biomarker 
identification and evaluation for idiosyncratic DILI, a translational approach is 
necessary. For this, we propose to initially focus on identifying biomarkers that are 
predictive for the various pathologies underlying idiosyncratic DILI, including acute 
hepatocellular injury, cholestasis and fibrosis, induced by non-idiosyncratic drugs 
or chemicals, such as APAP for acute hepatocellular injury. Such biomarkers can 
be identified with in vitro assays and animal models and validated using human 
samples. Administering model drugs or compounds representative for the different 
pathologies of hepatic injury, will aid in relating a potential biomarker to hepatic 
injury. Consequentially, the identified relevant biomarkers for human hepatic injury 
should subsequently be validated for application in idiosyncratic DILI, again using a 
translational approach implementing in vitro models, animal models and, ultimately, 
the limited available human samples. With this approach there is a priori knowledge 
on the predictive potential of the proposed biomarkers for hepatic injury, which could 
facilitate assessing their usefulness in idiosyncratic DILI.
Future directions
Currently, the main hurdle to be taken to accompany the innovation in biomarkers 
and experimental models for DILI is to collect a sufficient amount of suitable samples 
of patients with DILI and idiosyncratic DILI. For this, biobanking has evolved as 
a way to collect a large number of human samples from various ethnicities to 
ensure a representative study population for DILI.70 Such initiatives are faced with 
a number of practical and ethical problems that have to be overcome to validate 
biomarkers with clinical relevance.71 One of the issues that needs to be addressed 
first is to standardize sample collection and storage procedures to minimize pre-
analytical variation. Eventually, when a large number of human samples has been 
collected successfully, it is essential to implement high-throughput screening for the 
presence of potential biomarkers, for instance by using protein arrays, to maintain an 
appropriate workflow and efficient use of the valuable samples. 
In order to make progress in mechanistic development of biomarkers for DILI, 
combined efforts of academia and companies are pivotal, because it enables 
the fundamental knowledge obtained in academia to be implemented faster in 
development of new biomarkers and techniques for screening in drug development. 
The number of initiatives that combine research in academics and companies as 
public-private partnerships is increasing, of which the D3-201 consortium of Top 
Institute Pharma is an example. The goal of this consortium was to identify potential 
biomarkers on the molecular, cellular and in vivo level and evaluate them in human 
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DILI samples to obtain novel, non-invasive biomarkers. This thesis demonstrates 
that this consortium has contributed to biomarker development for DILI in identifying 
novel urinary biomarkers for DILI, such as CaM, and indicating the potential of 
proteins previously identified as serum biomarkers to be used as urinary biomarkers 
for DILI, such as regucalcin. Next to biomarker identification and validation, DILI can 
be addressed by investigating the factors that determine interindividual susceptibility 
for DILI. Within the Phenotype Standardization Project (PSP) the International 
Serious Adverse Effect Consortium (iSAEC) studies the genomic basis of specific 
drug-related adverse reactions to ultimately identify individuals at risk for DILI a 
priori.72, 73 They recently identified variation in class I and II HLA genotypes to be 
predictive of susceptibility for amoxicillin-clavulanate-induced DILI.74 To enhance 
screening for DILI during drug development, computational methods can be used 
that combine in vitro and in vivo data to predict adverse reactions for a new drug. 
The DILIsym consortium, led by the Hamner Institute, focuses on developing such 
a mathematical model to predict DILI, in which in vitro data regarding absorption, 
distribution, metabolism and elimination of a drug can be used to carry out an in vitro 
to in vivo extrapolation for multiple species.75, 76 Computational models can also be 
used to investigate and compare toxicological pathways involved in DILI of various 
drugs as has been demonstrated by Bhattacharya et al.77 In addition, consortia have 
been founded to obtain validated and standardized procedures for urine proteomics, 
which will help in synchronizing urine sample collection and biomarker identification. 
To this end, the European Kidney and Urine Proteomics (EuroKUP) consortium 
has characterized male and female human urine samples for their proteome and 
peptidome, using various proteomics platforms to be used as reference standards.78 
The Human Kidney and Urine Proteome Project (HKUPP) has developed standard 
guidelines and protocols for proteome analysis for non-proteinuric urine.79 
In the past few years, progress has been made in the field of DILI regarding 
development of experimental models to investigate the underlying mechanisms and 
identification of potentially new biomarkers to predict DILI, as described in this thesis. 
The next step will be directed towards validation of these models and biomarkers to 
allow implementation in drug development and clinical practice. With all these efforts 
combined, future research will result in better diagnostic and prognostic biomarkers 
for DILI and increased insight into the mechanisms that are involved in this type of 
adverse drug reaction. 
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Introduction
Drug-induced liver injury (DILI) is the leading cause of acute liver injury and is 
within the top three reasons of drug withdrawal. DILI can present as any of the 
pathologies known in liver injury, including hepatocellular injury, cholestasis, fibrosis, 
cirrhosis and hepatitis. These adverse drug reactions can be very serious, leading 
to hospitalization, liver transplantation and even death. A small proportion of these 
adverse drug reactions is termed ‘idiosyncratic’, meaning that they are not related to 
the structure, dose or mode of action of the drug. For many drugs, the mechanisms 
underlying the (idiosyncratic) liver injury have not been elucidated. Various factors 
may play a role in the development of DILI, such as metabolic activation of the drug, 
induction of oxidative and nitrosative stress and activation of the immune system. 
The occurrence of idiosyncratic DILI appears to be influenced by interindividual 
susceptibility, which can be caused by polymorphisms in HLA genes, differences 
in metabolic enzyme activity and/or the presence of a virus or bacteria at the time 
of drug treatment. A major issue with (idiosyncratic) DILI is that the conventionally 
used biomarkers to monitor liver function are not adequate to predict such an 
adverse event. Therefore, more predictive and preferably non-invasive biomarkers 
are needed. With the availability of such biomarkers, patients could be routinely 
monitored when using drugs at risk and consequently reduce the incidence of DILI 
and prevent drug withdrawal.
Proteomics tools have been increasingly implemented for biomarker detection in 
various tissues and fluids, including liver, blood and urine. Especially urine is of 
interest as it partly mirrors the blood proteome composition, is easy to profile because 
of the relatively low amount of high abundance proteins, and urine can be collected 
in a non-invasive way. 
In this thesis, we have used urine proteomics as primary tool to identify proteins that 
are associated with different types of DILI and could potentially be implemented as 
predictive biomarkers. In addition, we used these proteomics techniques to obtain 
more insight in the mechanisms that are involved in the development of DILI.    
 
Biomarker identification and unraveling of mechanisms underlying 
acetaminophen-induced liver injury 
Acetaminophen (APAP) is an over-the-counter analgesic that is associated with 
acute, hepatocellular injury. It is metabolized in the liver by cytochrome P450 2E1 
into the reactive metabolite N-acetyl-p-benzoquinone imine (NAPQI), which is 
detoxified by glutathione conjugation when therapeutic levels of APAP are used. 
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In case of APAP overdose, the glutathione pool becomes depleted and NAPQI can 
bind to intracellular proteins, consequently damaging the hepatocytes and leading 
to the formation of oxidative stress. We used APAP as model compound to study 
acute, liver injury.
In chapter 2, we treated male FVB mice with increasing doses of APAP via i.p. 
injection and collected 24 h urine samples. Using matrix-assisted laser desorption/
ionization time-of-flight mass spectrometry (MALDI-TOF MS), we observed a 
differential urinary protein profile in mice treated with the highest doses of APAP 
compared to control mice. These protein profiles associated with the degree of 
liver injury caused by APAP, as assessed by liver histology and plasma ALT levels. 
Further analysis led to the identification of 12 proteins that were associated with 
APAP-induced liver injury, including superoxide dismutase 1(SOD1), regucalcin, 
carbonic anhydrase 3 (CA3), fatty acid binding protein 1 (FABP1) and calmodulin 
(CaM). Of these proteins, CA3, SOD1 and CaM also proved to be present in urine 
of a severe human APAP intoxicant. Moreover, urinary CaM concentrations were 
increased in human APAP intoxicants that did not show plasma ALT elevation, but 
correlated to the plasma APAP concentration. In addition, urinary CaM concentration 
was increased in patients with acute, hepatocellular injury caused by drugs other 
than APAP, indicating that urinary CaM might be a biomarker for acute DILI.
APAP-induced liver injury is mediated predominantly by metabolic activation and 
oxidative stress. Recent studies have suggested a potentiating role for iron in DILI, 
although its regulatory mechanism has not been completely understood. The study 
described in chapter 3 was designed to unravel the iron-regulating pathways in 
mice after APAP-induced hepatotoxicity. Mice with severe injury showed a significant 
increase in liver iron concentration and oxidative stress. Concurrently, the plasma 
concentration of hepcidin, the key regulator in iron metabolism, was significantly 
decreased as measured with surface-enhanced laser desorption/ionization (SELDI)-
TOF MS, as well as the hepatic hepcidin antimicrobial peptide (Hamp) mRNA 
expression levels. We showed that hepcidin transcription was inhibited by several 
hepcidin-regulating factors, including the bone morphogenetic protein / small mother 
against decapentaplegic (BMP/SMAD) pathway, CCAAT/enhancer-binding protein 
α (C/EBPα) and possibly also erythropoietin (EPO). Down-regulation of the BMP/
SMAD signaling pathway was most likely caused by hypoxia-inducible factor 1α 
(HIF-1α), which was increased in mice with severe APAP-induced liver injury. HIF-
1α stimulates cleaving of hemojuvelin, the cofactor of the BMP receptor, thereby 
blocking BMP-induced signaling. In addition, gene expression levels of C/ebpα were 
significantly reduced and Epo mRNA expression levels were significantly increased 
after APAP intoxication. These factors are regulated through HIF-1α during oxidative 
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stress and the results suggest that HIF-1α is a key modulator in reduced hepcidin 
transcription after APAP-induced hepatotoxicity. Eventually, these processes lead to 
hepatic iron loading associated with APAP cytotoxicity. 
Insight in diclofenac-induced organ toxicity 
Diclofenac (DF) is a widely prescribed non-steroidal anti-inflammatory drug for 
treatment of rheumatic disorders, the use of which is associated with liver injury. 
In chapter 4, we used urinary proteomic profiling to identify the pattern of adverse 
reactions induced by DF. Female CH3/HeOUJIco mice were treated with 75 mg/kg 
bw DF by oral gavage and 24 h urine was collected, in which differentially excreted 
proteins were identified by MALDI-TOF MS and electrospray ionization (ESI) LTQ, 
and further analyzed by Q-PCR, immunohistochemistry and Western blotting. 
These proteins included epidermal growth factor, transthyretin, kallikrein, clusterin, 
fatty acid binding protein 1 and urokinase, which are known to be related to liver 
regeneration and kidney injury. Both organs showed enhanced levels of oxidative 
stress as determined by the presence of thiobarbituric reactive substances in organ 
homogenates. Kidney injury was confirmed by histology and increased mRNA 
expression of Kidney in jury molecule 1 (Kim1) and Interleukin-6 (Il-6). No additional 
signs of hepatic injury were detected, but mRNA expression of Signal transducer 
and activator of transcription 3 (Stat3) and protein expression of proliferating cell 
nuclear antigen (PCNA) were increased, indicating liver regeneration. In conclusion, 
urinary proteome analysis revealed that DF treatment in mice induced kidney and 
liver injury. Within 24 h, however, the liver was able to recover by activating tissue 
regeneration processes. Hence, the proteins found in urine of DF-treated mice 
represent kidney damage rather than hepatic injury.
Translational biomarker assessment using precision-cut liver slices 
Animal models are often used to study DILI; however, it became evident that not all 
types and features of human DILI can be mimicked in an animal model. This holds 
true especially for idiosyncratic DILI as human susceptibility appears to play a major 
role. In addition, species differences in sensitivity for adverse effects can complicate 
the use of animal models. Translational research using both in vivo and in vitro 
methods should be implemented to overcome these difficulties. In chapter 5 the 
applicability of protein profiling of the incubation medium of precision-cut liver slices 
(PCLS) from human, mouse and rat exposed to DILI-inducing drugs for biomarker 
identification using MALDI-TOF MS. PCLS were incubated with acetaminophen 
(APAP), 3-acetamidophenol (AMAP), diclofenac (DF) and lipopolysaccharide (LPS) 
for 24-48h. PCLS medium from all species treated with APAP demonstrated  similar 
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changes in protein profiles as previously found in mouse urine after APAP-induced 
liver injury (Chapter 2), including the same key proteins: superoxide dismutase 1, 
carbonic anhydrase 3 and calmodulin. Further analysis showed that the concentration 
of hepcidin, a hepatic iron-regulating hormone, was reduced in PCLS medium after 
APAP treatment, resembling the decreased mouse plasma concentrations of hepcidin 
observed after APAP treatment (Chapter 3). Interestingly, comparable results were 
obtained after AMAP incubation in rat and human PCLS, but not in mouse PCLS. 
Incubation with DF, which is associated with idiosyncratic DILI (Chapter 4), but not 
with LPS, resulted in the same toxicity parameters as observed for APAP, albeit to a 
lesser extent.  In conclusion, the PCLS system is a promising, translational model for 
identification of species differences and potential proteomic biomarkers.
Potential of proteomics for biomarker detection in human urine samples for 
methotrexate–induced hepatic fibrosis
Hepatic fibrosis is an adverse drug reaction of methotrexate (MTX) seen after long-
term use in psoriasis patients. Currently, patients are monitored for MTX-induced 
hepatic fibrosis by performing liver biopsy, which is risky and burdensome for the 
patient, or by measuring plasma procollagen type III aminopeptide (PIIINP), which 
is not conclusive. The goal of the study described in chapter 6 was to identify novel 
predictive and preferably non-invasive biomarkers to monitor psoriasis patients for 
MTX-induced hepatic fibrosis. To this end, urine samples were collected from 60 
psoriasis patients treated with MTX and divided into two categories: low cumulative 
dose (<1500 mg MTX) and high cumulative dose (>1500 mg). Urinary proteins were 
profiled using MALDI-TOF MS and identified using ESI LTQ. In urine of psoriasis 
patients with high cumulative MTX dose, multiple proteins were identified that 
have been associated with hepatic fibrosis, such as N-cadherin, inter-alpha-trypsin 
inhibitor heavy chain H4, haptoglobin and serotransferrin. These proteins may be 
candidate urinary biomarkers to monitor MTX-induced hepatic fibrosis. 
Conclusion 
In this thesis, we used proteomic profiling with MALDI-TOF MS and additional 
techniques to find biomarkers for different types of DILI, and to gain insight into 
the underlying pathophysiological mechanisms. For this, we used a translational 
approach involving measurements in PCLS medium, and animal and human 
samples. Urine proved to be a rich source for proteomic profiling and biomarker 
detection, as the ongoing processes in the organism are reflected in this body fluid, 
which can be easily collected in a non-invasive manner in animals and humans. 
The potential urinary biomarkers that are identified using proteomics techniques 
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will have to be further validated in future research to establish their predictive 
potential, sensitivity and specificity for human DILI. For this, human urine samples 
collection by means of biobanking and the collaboration between academic 
hospitals and companies will be of great importance. 
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Inleiding
Een groot deel van de gevallen van acute leverschade ontstaat als bijwerking van 
geneesmiddelen. Daarnaast is leverschade als bijwerking een van de belangrijkste 
redenen om geneesmiddelen van de markt te halen. Geneesmiddel-geïnduceerde 
leverschade (drug-induced liver injury; DILI) kan tot uiting komen in verschillende 
vormen, zoals hepatocellulaire schade, cholestase, fibrose, cirrhose en hepatitis. DILI 
kan zeer ernstig zijn en leiden tot ziekhuisopname, levertransplantatie en zelfs sterfte. 
Een klein deel van deze bijwerkingen wordt ‘idiosyncratisch’ genoemd; dit betekent 
dat de bijwerking niet gerelateerd is aan de bekende werking van het geneesmiddel, 
de dosis waarin het geneesmiddel gegeven is of de chemische struktuur van het 
geneesmiddel. Voor veel geneesmiddelen zijn de mechanismen die ten grondslag 
liggen aan hun (idiosyncratische) bijwerking nog niet opgehelderd. Het is wel bekend 
dat verschillende factoren een rol kunnen spelen bij het ontstaan van een bijwerking, 
waaronder metabole activatie van het geneesmiddel, het onstaan van oxidatieve 
en nitrosatieve stress, en activatie van het immuunsysteem. Bovendien lijkt het 
optreden van een idiosyncratische bijwerking gerelateerd te zijn aan interindividuele 
gevoeligheid, welke bepaald wordt door polymorfismen in HLA-genen, verschillen in 
metabole enzymactiviteit en/of de aanwezigheid van bacteriën en virussen ten tijde 
van de geneesmiddelbehandeling. Een groot probleem met (idiosyncratische) DILI 
is dat de gebruikelijke biomarkers om leverfunctie te monitoren, niet in staat zijn een 
dergelijke bijwerking te voorspellen. Om die reden zijn er beter voorspellende en 
liefst niet-invasieve biomarkers voor DILI nodig. Zulke biomarkers kunnen gebruikt 
worden om patiënten te monitoren wanneer ze met een risiciovol geneesmiddel 
behandeld worden. Op die manier kan de incidentie van DILI worden verminderd 
en voorkomen worden dat geneesmiddelen van de markt moeten worden gehaald.
Grootschalige eiwitanalyse- en identificatietechnieken (proteomics) worden in 
toenemende mate aangewend om biomarkers in verschillende weefsels en 
lichaamsvloeistoffen te detecteren, waaronder leverweefsel, bloed en urine. Met 
name urine is een aantrekkelijke lichaamsvloeistof om biomarkers in te meten, 
omdat het gedeeltelijk de eiwitsamenstelling van het bloed weerspiegelt. Urine 
bevat bovendien relatief weinig overmatig aanwezige eiwitten vergeleken met bloed, 
waardoor het makkelijker is om alle eiwitten te profilen. Daarnaast kan urine op een 
niet-invasieve manier verzameld worden.
In dit proefschrift hebben we proteomics toegepast om eiwitten te identificeren die 
gerelateerd zijn aan verschillende typen DILI. Deze biomarkers zouden uiteindelijk 
kunnen fungeren als voorspellende biomarkers in urine. Dezelfde technieken zijn 
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ook gebruikt om meer inzicht te verkrijgen in de onderliggende processen die een 
rol spelen in het onstaan van DILI.
 
Identificatie van biomarkers gerelateerd aan DILI veroorzaakt door paracetamol 
(acetaminophen) en het ontrafelen van betrokken mechanismen
Paracetamol (USA: acetaminophen), chemische naam N-acetyl-p-aminophenol 
(APAP), is een vrij verkrijgbare pijnstillend geneesmiddel dat na overdosering acute, 
hepatocellulaire schade veroorzaakt. APAP wordt in de lever gemetaboliseerd door 
het enzym cytochroom P450 2E1 waarbij de reactieve intermediair N-acetyl-p-
benzoquinonimine (NAPQI) onstaat. NAPQI wordt bij therapeutische concentraties 
van APAP gedetoxificeerd door conjugatie met glutathion, maar bij een overdosis 
raakt de glutathionvoorraad op en bindt NAPQI aan intracellulaire macromoleculen, 
zoals eiwitten en DNA. Als gevolg hiervan worden zogenaamde zuurstofradicalen 
gevormd en ontstaat oxidatieve stress, waardoor de hepatocyten direct worden 
beschadigd. In deze studie hebben we APAP als modelstof genomen om acute 
leverschade te bestuderen.
In Hoofdstuk 2 hebben we mannelijke FVB-muizen behandeld met verschillende 
doseringen APAP via intraperitoneale (i.p.) injectie en vervolgens gedurende 24 
uur urine verzameld. Met behulp van ‘matrix assisted laser desorption/ionization 
time-of-flight mass spectrometry’ (MALDI-TOF MS) zijn de eiwitten in de urine 
geanalyseerd en zagen we een verschillend patroon bij muizen met leverschade 
als gevolg van APAP-inname vergeleken met controle muizen. De eiwitprofielen 
in de urine van muizen met leverschade waren gerelateerd aan de mate van 
leverschade veroorzaakt door APAP, die was bepaald door middel van histologie en 
plasmawaarden van het enzym alanine-aminotransferase (ALT). Met aanvullende 
analysetechnieken konden we in de eiwitprofielen de identiteit vaststellen van 12 
eiwitten, die gerelateerd waren aan de door APAP veroorzaakte leverschade. Dit 
waren ondermeer superoxidedismutase 1 (SOD1), regucalcine, carboanhydrase 3 
(CA3), vetzuurbindendeiwit 1 (fatty acid binding protein 1, FABP1) en calmoduline 
(CaM). Van deze eiwitten bleken SOD1, CA3 en CaM ook aanwezig te zijn in de urine 
van een 5-jarig patiëntje met een ernstige APAP-intoxicatie. De concentratie van 
CaM in urine bleek bovendien gecorreleerd te zijn met de plasmaconcentratie van 
APAP in patiënten met een APAP-intoxicatie die nog geen verhoogde ALT-waarden 
in plasma vertoonden. Ook in patiënten met acute leverschade, veroorzaakt door 
andere geneesmiddelen dan APAP, was de concentratie van CaM in urine verhoogd, 
wat aangeeft dat CaM mogelijk een geschikte biomarker voor DILI zou kunnen zijn.
Leverschade als gevolg van een APAP-intoxicatie wordt voornamelijk veroorzaakt 
door metabole activatie van het medicijn en oxidatieve stress. Recentelijk is ook 
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ijzer aangemerkt als mogelijke factor in het ontstaan van DILI, hoewel het precieze 
mechanisme nog onduidelijk is. De studie beschreven in Hoofdstuk 3 was ontworpen 
om de rol van ijzer en de bijbehorende regulatoire mechanismen te bepalen in 
leverschade als gevolg van APAP. Muizen met ernstige leverschade vertoonden een 
significante stijging in ijzerconcentratie en oxidatieve stress in de lever. Tegelijkertijd 
was er sprake van een verlaagde plasmaconcentratie van hepcidine, een belangrijke 
regulatoire factor in de ijzerhuishouding. Ook de expressie van het hepcidinegen 
(Hamp) was verminderd. We hebben in deze studie aangetoond dat de productie 
van hepcidin geremd werd door verscheidene hepcidine-regulerende factoren, 
waaronder de ‘bone morphogenetic protein / small mother against decapentaplegic’ 
(BMP/SMAD)-signaaltransductieroute, ‘CCAAT/enhancer-binding protein α’ (C/
EBPα) en mogelijk ook erythropoietine (EPO). Remming van de BMP/SMAD-route 
werd hoogstwaarschijnlijk veroorzaakt door ‘hypoxia-inducible factor 1α’ (HIF-1α), 
welke verhoogd was in muizen met ernstige leverschade. HIF-1α kan het signaal van 
de BMP/SMAD-route blokkeren door het knippen van hemojuveline, een cofactor 
van de BMP-receptor, te stimuleren. De genexpressie van C/ebpα was significant 
verminderd en de mRNA-expressie van Epo was significant verhoogd na toediening 
van APAP. Beide factoren worden gereguleerd door HIF-1α tijdens oxidatieve stress. 
Deze resultaten suggereren dat HIF-1α belangrijk is voor de transcriptie van het 
hepcidinegen tijdens leverschade veroorzaakt door APAP. Deze processen leiden 
uiteindelijk tot ijzerstapeling in de lever, wat bijdraagt aan leverceltoxiciteit.
Inzicht in orgaantoxiciteit veroorzaakt door diclofenac
Diclofenac (DF) is een ontstekingsremmende pijnstiller die behoort tot de categorie 
van ‘non-steroidal anti-inflammatory drugs’ (NSAIDs). DF wordt veel voorgeschreven 
bij de behandeling van reumatische aandoeningen, waarbij soms leverschade als 
bijwerking wordt gezien. In Hoofdstuk 4 hebben we met behulp van proteomics 
de veranderingen in eiwitprofielen in urine bepaald die mogelijk samengaan met 
de bijwerkingen veroorzaakt door DF. Vrouwelijke CH3/HeOUJIco-muizen werden 
behandeld met een orale dosis DF van 75 mg/kg en 24-uurs urine werd verzameld. 
De verschillen in eiwitpatronen in urine werden geanalyseerd met behulp van MALDI-
TOF-MS en electrospray-ionizatie (ESI) LTQ, en verder bestudeerd met Q-PCR, 
immunohistochemie en Westernblot-analyse. De eiwitten die specifiek aangetoond 
werden in urine van muizen behandeld met DF waren epidermale groeifactor (EGF), 
thransthyretine, kallikreïne, clusterine, FABP1 en urokinase, welke betrokken zijn bij 
leverregeneratie en nierschade. Zowel in lever- als nierweefsel werden verhoogde 
waarden voor thiobarbituurzuur-reactieve producten gevonden, die wijzen op de 
aanwezigheid van oxidatieve stress. Nierschade werd bevestigd met behulp van 
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histologie en de verhoogde mRNA-expressie van ‘Kidney injury molecule-1’ (Kim1) 
en Interleukine-6 (Il-6). Er werden geen tekenen van leverschade waargenomen, 
maar wel duidelijke aanwijzingen voor leverregeneratie door de verhoogde mRNA-
expressie van ‘Signal transducer and activator of transcription 3’ (Stat3) en de 
eiwitexpressie van ‘Proliferating Cell Nuclear Antigen’ (PCNA). Analyse van de 
eiwitten in de urine van muizen behandeld met DF heeft aangetoond dat er zowel 
sprake was van lever- als nierschade. Het is bekend dat de lever in staat is om zich 
binnen 24 uur te herstellen door middel van weefselregeneratie. Derhalve reflecteren 
de eiwitten in urine van met DF behandelde muizen in deze studie eerder nier- dan 
leverschade.
Analyse van translationele biomarkers in ‘precision-cut liver slices’
Voor het bestuderen van DILI wordt veelal gebruik gemaakt van diermodellen, maar 
het is gebleken dat niet alle karakteristieken van leverschade in de mens in een 
diermodel nagebootst kunnen worden. Dit is met name het geval voor idiosyncratische 
DILI, waarbij vooral interindividuele verschillen in gevoeligheid een rol spelen. Ook 
de verschillen in gevoeligheid voor DILI tussen diersoorten bemoeilijken het gebruik 
van diermodellen. Om deze beperkingen in de vertaling van resultaten van dier naar 
mens te overbruggen zullen verschillende in vitro- en in vivo-modellen gebruikt moeten 
worden. In Hoofdstuk 5 hebben we in samenwerking met de onderzoeksgroep 
van Prof. Groothuis van de RU Groningen onderzocht of het ‘precision-cut liver 
slices’ (PCLS)-systeem geschikt is als ex vivo-model om biomarkers voor DILI te 
identificeren. Hiervoor werden PCLS van muis, rat en mens gedurende 24-48 uur 
blootgesteld aan APAP, 3-acetamidophenol (AMAP), DF en lipopolysaccharide 
(LPS), een bestanddeel van bacteriën dat een ontstekingsreactie in de lever kan 
veroorzaken. De eiwitprofielen in het medium van de PCLS na incubatie werden 
met behulp van MALDI-TOF-MS geanalyseerd en vergeleken met de eiwitprofielen 
in urine van muizen met leverschade als gevolg van APAP (Hoofdstuk 2). Incubatie 
met APAP van PCLS van muis, rat en mens leidde tot vergelijkbare eiwitprofielen 
als die eerder waren gevonden in de urine van muizen. Hierbij werden dezelfde 
eiwitten geïdentificeerd als in muizenurine bij APAP-toxiciteit, waaronder SOD1, 
CA3 en CaM. Bovendien gaf AMAP in PCLS van rat en mens, en niet in muis, 
toxiciteit-gerelateerde eiwitprofielen. Aanvullend hebben we ook gekeken naar de 
concentratie van hepcidine in het PCLS-medium, waarvan we eerder in muis zagen 
dat de plasmaconcentratie daalt door APAP-toxiciteit (Hoofdstuk 3). Ook hier werd 
gevonden dat APAP-incubatie leidde tot een daling van de hepcidineconcentratie 
in het PCLS-medium van alle species en van AMAP-incubatie alleen bij PCLS van 
rat en mens. Naast APAP werden ook de effecten van DF onderzocht. In vivo is het 
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lastig om de idiosyncratische leverschade die veroorzaakt kan worden door DF na 
te bootsen (Hoofdstuk 4), maar in het PCLS-systeem zagen we bij alle species 
een daling in de hepcidineconcentratie en stijging in de hoeveelheid SOD1, CA3 
en CaM, hoewel de effecten minder uitgesproken waren als bij APAP. Incubatie met 
LPS leidde niet tot verandering van het eiwitprofiel, maar wel tot een significante 
stijging van de hepcidineconcentratie, wat overeenkomt met het effect van LPS 
op de plasma hepcidine concentratie in vivo.  Deze resultaten laten de relevantie 
zien van het PCLS-systeem als model voor het bestuderen van DILI, waarbij het 
translationele aspect door gebruik van meerdere species een belangrijke aanvulling 
is op de huidige in vitro- en in vivo-modellen. 
Proteomicsonderzoek naar biomarkers voor leverfibrose in humane urine als 
gevolg van methotrexaat
Leverfibrose is een bijwerking van chronisch methotrexaat (MTX)-gebruik, die vaak 
wordt gezien bij psoriasispatiënten. In de huidige praktijk wordt het optreden van 
leverfibrose in deze patiënten vastgesteld door middel van een leverbiopsie. Dit 
is echter risicovol en belastend voor de patiënt. Een andere minder belastende 
methode is het meten van het procollageen-type III-aminopeptide in plasma, maar de 
voorspellende waarde van deze test is beperkt. Het doel van de studie beschreven 
in Hoofdstuk 6 was om nieuwe, voorspellende, niet-invasieve biomarkers te 
vinden voor leverfibrose door MTX in de urine van psoriasispatiënten. Hiervoor 
werd urine verzameld van 60 psoriasispatiënten, die behandeld werden met een 
lage cumulatieve dosis (<1500 mg) MTX en een hoge cumulatieve dosis (>1500 
mg). Het eiwitprofiel in de urine werd bepaald met MALDI-TOF-MS en identificatie 
van afzonderlijke eiwitten met ESI LTQ. In urine van de groep patiënten met een 
hoge cumulatieve MTX-dosis werden meerdere eiwitten geïdentificeerd die zijn 
geassocieerd met leverfibrose, zoals N-cadherine, ‘inter-aplha-trypsin inhibitor 
heavy chain H4’, haptoglobine en serotransferrine. Deze eiwitten zijn potentiële 
nieuwe biomarkers om leverfibrose als gevolg van MTX-gebruik te volgen.
Conclusie
In dit proefschrift hebben we gebruik gemaakt van proteomicsmethoden, zoals 
eiwitprofilering met MALDI-TOF-MS en additionele technieken, om biomarkers 
te vinden voor verschillende typen DILI en om meer inzicht te krijgen in de 
pathofysiologische mechanismen die ten grondslag liggen aan deze bijwerkingen. 
Hiervoor hebben we een translationele opzet gekozen waarbij gebruik werd gemaakt 
van leverslices en urinemonsters van dier en mens en in vivo-diermodellen. Urine 
bleek een rijke bron te zijn voor eiwitprofilering en detectie van biomarkers, omdat 
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de processen die zich in het lichaam afspelen in deze lichaamsvloeistof worden 
weerspiegeld. Urine kan gemakkelijk en op niet-invasieve wijze verzameld worden 
in dier en mens. De potentiële urine biomarkers die met behulp proteomicsmethoden 
worden geïdentificeerd, zullen in de toekomst verder gevalideerd moeten worden om 
hun voorspellende waarde, sensitiviteit en specificiteit voor humane DILI te bepalen. 
Hierbij zullen het verzamelen van humane urine monsters middels biobanking 
en projecten waarin samengewerkt wordt door de academische ziekenhuizen en 
bedrijven een grote rol gaan spelen.  
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List of abbreviations
2D DIGE two-dimensional difference gel electrophoresis
ABP  androgen-binding protein
ACN  acetonitril
ALK  activin-like kinase
ALT  alanine aminotransferase
AMAP  3-acetamidophenol
ANOVA  analysis of variance
APAP  acetaminophen
AR  androgen receptor
ARE  androgen responsive element
AST  aspartate aminotransferase
BMI  body mass index
BMP  bone morphogenetic protein
BSA  bovine serum albumin
C8  chromatography 8
CA3  carbonic anhydrase 3
CaM  calmodulin
CCl4  carbon tetrachloride
C/EBPα CCAAT/enhancer-binding protein α
CHCA  α-cyano-4-hydroxy-cinnamic acid
CHOP  C/EBP-homologous protein
CYP  cytochrome P450
DA  Dalton
DF  diclofenac
DILI  drug-induced liver injury
DILIN  U. S. Drug-Induced Liver Injury Network
DMSO  dimethyl sulfoxide
EGF  epidermal growth factor
EGFR  epidermal growth factor receptor
ELISA  enzyme-linked immunosorbent assay
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EPO  erythropoietin
ER  endoplasmatic reticulum
ESI  electrospray ionization
EuroKUP European Kidney and Urine Proteomics
FDA  U. S. Food and Drug Administration
FVB  Friend leukemia virus B
GLDH  glutamate dehydrogenase
GPCR  G-protein coupled receptor
GSH  glutathione
GST  glutathione-S-transferase
H&E  hematoxylin and eosin
HAMP  hepcidin antimicrobial peptide
HIF-1α  hypoxia-inducible factor 1α
HJV  hemojuvelin
HKUPP  Human Kidney and Urine Proteome Project
HLA  human leukocyte antigens
HRP  horseradish peroxidase
HSP  heat shock protein
IL-6  interleukin-6
IMI  Innovative Medicines Initiative
IS  internal standard
ISEAC  International Serious Adverse Effect Consortium
ITIH4  inter-alpha-trypsin inhibitor heavy chain 4
KIM1  kidney injury molecule-1
LC  liquid chromatography
L-FABP  liver fatty acid binding protein
LPS  lipopolysaccharide
LTQ  linear trap quadrupole
MALDI  matrix-assisted laser desorption/ionization
MDH  malate dehydrogenase
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MMP-2  matrix metalloproteinase-2 
MRP  multidrug resistance-associated protein
MS  mass spectrometry
MSP  microScout plate
MTX  methotrexate 
NAFLD  non-alcoholic fatty liver disease
NAPQI  N-acetyl-p-benzoquinone imine
NASH  non-alcoholic steatosis hepatitis
NGAL  neutrophil gelatinase-associated lipocalin
NSAID  non-steroidal anti-inflammatory drug
PAI  plasminogen activator inhibitor
PAS  periodic acid Schiff
PASI  psoriasis area and severity index
PBS  phosphate buffered saline
PCLS  precision-cut liver slices
PCNA  proliferating cell nuclear antigen
PCR  polymerase chain reaction
PIIINP  procollagen type III aminopeptide
PMCA  plasma membrane Ca2+ ATPase transporter
PNP  purine nucleoside phosphorylase
PON1  paraxonase 1
PRED  predicted
PSP  Phenotype Standardization Project
RA  rheumatoid arthritis
RE  reticulo-endothelial
ROS  reactive oxygen species
RT  room temperature
SAFE-T Safer and Faster Evidence-based Translation
SDG  sorbitol dehydrogenase 
SDS  sodium dodecyl sulfate
SELDI  surface-enhanced laser desorption/ionization 
SHBGR sex hormone-binding globuline receptor
SMAD  small mother against decapentaplegic
SOD  superoxide dismutase
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STAT3  signal transducer and activator of transcription 3  
TAA  thioacetaamide
TAMH  tumor growth factor-α transgenic hepatocyte
TBAR  thiobarbituric acid reactive substances
TCDD  2, 3, 7, 8 – tetrachlorodibenzo-p-dioxin
TFA  trifluoroacetic acid
Th2:   T-helper type 2
TIMP-1  tissue-inhibitor metalloprotease-1
TNFα:  tumor necrosis factor α 
TOF  time-of-flight
TRACK  Transparency Results Accountability Credibility Knowledge Shar  
  ing
WCX  weak cation exchange
191
Curriculum vitae
8
Curriculum vitae
Rachel van Swelm werd geboren op 7 april 1985 te Arcen. In 2003 behaalde zij haar 
VWO-diploma aan het Valuas college in Venlo. Daarna startte zij met de opleiding 
Biomedische Wetenschappen aan de Radboud Universiteit Nijmegen. Tijdens deze 
opleiding heeft ze haar bachelorstage gedaan bij de afdeling Kindergeneeskunde van 
het UMC St Radboud onder begeleiding van Prof. Dr. L. van den Heuvel. Voor haar 
masteropleiding heeft ze twee hoofdvakken gekozen: toxicologie en pathobiologie. 
De onderzoeksstage van 6 maanden voor het hoofdvak pathobiologie heeft ze 
gedaan bij de afdeling Psychoneurofarmacologie van het UMC St Radboud onder 
begeleiding van Dr. J. Olivier. De tweede onderzoeksstage van 6 maanden voor het 
hoofdvak toxicologie heeft ze deels verricht bij NOTOX B.V. te ’s-Hertogenbosch 
onder begeleiding van Dr. M. Stitzinger, Dr. M. Van Tuyl en Dr. H. Emmen; en 
deels bij de afdeling Farmacologie en Toxicologie van het UMC St Radboud onder 
begeleiding van Dr. R. Masereeuw en Prof. Dr. F. Russel. In 2008 is zij afgestudeerd 
voor beide hoofdvakken en aansluitend begonnen met haar promotieonderzoek bij 
afdeling Farmacologie en Toxicologie van het UMC St Radboud, onder supervisie 
van Dr. R. Masereeuw en Prof. Dr. F. Russel. Dit promotieonderzoek maakte 
deel uit van het Top Institute Pharma-consortium D3-201 en heeft geresulteerd in 
meerdere publicaties en dit proefschrift. Tijdens het promotietraject heeft ze ook 
de postdoctorale opleiding tot toxicoloog afgerond, waarvoor zij verscheidene 
cursussen gevolgd heeft. Gedurende het promotieonderzoek heeft ze meerdere 
masterstudenten begeleid. Vanaf oktober 2012 is ze met veel plezier werkzaam als 
postdoconderzoeker op een project van de Nierstichting bij afdeling Farmacologie 
en Toxicologie van UMC St Radboud. 
192
Chapter 8
8
List of publications
Van Swelm RP, Hadi M, Laarakkers CM, Masereeuw R, Groothuis GM, Russel FG. 
Protein pofiling in incubation medium of mouse, rat and human precision-cut liver slices 
for biomarker detection regarding acute drug-induced liver injury. Provisionally accepted in 
Journal of Applied Toxicology.
Van Swelm RP, Laarakkers CM, Kooijmans-Otero M, de Jong EM, Masereeuw R, Russel 
FG. Biomarkers for methotrexate-induced liver injury: urinary protein profiling of psoriasis 
patients. Toxicology Letters, in press. 
Van Swelm RP, Laarakkers CM, Pertijs JC, Verweij V, Masereeuw R, Russel FG. Urinary 
proteomic profiling reveals diclofenac-induced renal injury and hepatic regeneration in mice. 
Toxicology and Applied Pharmacology, 2013 269(2):141-149. 
Hadi M, Dragovic S, van Swelm R, Herpers B, van de Water B, Russel FG, Commandeur 
JN, Groothuis GM. AMAP, the alleged non-toxic isomer of acetaminophen, is toxic in rat and 
human liver. Archives of Toxicology, 2013. 87(1):155-165.
Van Swelm RP, Laarakkers CM, van der Kuur EC, Morava-Kozicz E, Wevers RA, Augustijn 
KD, Touw DJ, Sandel MH, Masereeuw R, Russel FG. Identification of novel translational 
urinary biomarkers for acetaminophen-induced acute liver injury using proteomic profiling in 
mice. PLOS ONE, 2012, 7(11):e49524. 
Van Swelm RP, Laarakkers CM, Blous L, Peters JG, Blaney Davidson EN, van der Kraan 
PM, Swinkels DW, Masereeuw R, Russel FG. Acute acetaminophen intoxication leads 
to hepatic iron loading by decreased hepcidin synthesis. Toxicological Sciences, 2012, 
129(1):225-233.
Van den Boogaard M, van Swelm RP, Russel FG, Heemskerk S, van der Hoeven JG, 
Masereeuw R, Pickkers P. Urinary protein profiling in hyperactive delirium and non-delirium 
cardiac surgery ICU patients. Proteome Science, 2011, 9:13.
Tjalsma H, Laarakkers CM, van Swelm RP, Theurl M, Theur I, Kemna EH, van der Burgt 
YE, Venselaar H, Dutilh BE, Russel FG, Weiss G, Masereeuw R, Fleming RE, Swinkels 
DW. Mass spectrometry analysis of hepcidin peptides in experimental mouse models. PLOS 
ONE, 2011, 6(3):e16762.
193
List of publications
8
Olivier JD, van der Hart MG, van Swelm RP, Dederen PJ, Homberg JR, Cremers T, Deen 
PM, Cuppen E, Cools AR, Ellenbroek BA. A study in male and female 5-HT transporter 
knockout rats: an animal model for anxiety and depression disorders. Neuroscience, 2008, 
152(3):573-84.   
194
Chapter 8
8
195
Dankwoord
8
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Na 4 jaar (en een beetje meer) promotieonderzoek is dit proefschrift het resultaat 
van alle inspanningen. Natuurlijk had ik dit niet alleen kunnen bereiken en daarom 
wil ik graag iedereen bedanken die me tijdens deze periode op één of andere manier 
heeft geholpen.
Allereerst wil ik graag mijn promotor Prof. Dr. Frans Russel bedanken voor de 
begeleiding tijdens mijn promotietraject. Ik vond het prettig dat ik de vrijheid en steun 
kreeg om naar eigen inzicht invulling te geven aan het onderzoek, maar ook altijd 
bij je terecht kon met vragen. Ondanks een wat hobbelige start van het project, ben 
ik erg blij met dit resultaat, waarbij jouw inzicht en raad onmisbaar zijn geweest. 
Ik heb er erg veel van geleerd en het heeft me vooral ook gemotiveerd om in het 
academisch onderzoek te blijven. 
Vervolgens wil ik graag mijn copromotor dr. Roos Masereeuw bedanken. We 
hebben vaak overlegd over de aanpak van dit project en stap voor stap zijn we bij dit 
eindproduct gekomen. Ik heb veel geleerd van de voortdurende ontwikkelingen en 
ben je dankbaar voor de discussies die we hierover gevoerd hebben. Je stimuleert mij 
om me verder te profileren binnen het onderzoek en steeds weer nieuwe uitdagingen 
aan te gaan. Door jouw optimisme en steun doe ik dit ook met veel enthousiasme. 
Lieve Coby, de eerste keer dat ik jou ontmoette als analiste op het TIP-project was 
ik best geïntimideerd; wat een pittige tante! Niet veel later heb ik jou beter leren 
kennen als een heel hartelijk en op een goede manier kritisch persoon. Ik vond, 
en nog steeds vind, het heel prettig om met jou samen te werken. Je hebt me altijd 
weten te prikkelen om dieper over mijn onderzoek na te denken. Zonder jou was dit 
onderzoek niet op deze manier tot stand gekomen.
Naast Coby leerde ik ook de andere leden van de IJzergroep kennen: Dorine, 
Harold, Erwin, Rian, Siem, Guus, Annemarie en Joyce. Ondanks dat ik geen vast 
deel uitmaakte van jullie afdeling, voelde ik me er toch thuis, mede dankzij de 
gezellige barbecues en de open sfeer die ik voelde als ik op jullie afdeling rondliep. 
Waarschijnlijk heeft dit er aan bijgedragen dat ik nu weer onderzoek doe naar 
hepcidine en nog met enige regelmaat bij jullie te vinden ben.
 
This research was part of the D3-201 consortium of Top Institute Pharma. I’d 
like to thank all the participants of this project for their support and sharing the 
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knowledge that was gained in these four years.  Mackenzie and Geny, thanks for 
our fruitful collaboration on the proteomics profiling in PCLS medium. I think this 
really made our research translational. Kevin, bedankt voor alle moeite die je in de 
monsterverzameling van urine van DILI-patiënten hebt gestopt; ik weet dat het veel 
werk was. Lydia, samen hebben we een dierstudie uitgevoerd met paracetamol; het 
was fijn om eens samen met iemand anders de metabole kooien uit te wassen. Arjè, 
Monique, Martijn en Elmar, bedankt voor het samenwerken aan de kinase-assays. 
Miranda en Miranda van NOTOX, bedankt voor alle hulp bij de plasmabepalingen.
Gedurende de dierstudies was de hulp van de dierverzorgers en biotechnici van de 
SPF-afdeling van het CDL erg belangrijk. In het bijzonder wil ik Daphne en Debby 
bedanken voor alle hulp en het gezellig maken van de dierverblijven tijdens mijn 
studies met de rode lamp :-).
Het identificeren van de eiwitten was een cruciaal onderdeel van dit project en 
dat was zonder de hulp van Maurice, Hans en Jolein van de Proteomics Faciliteit 
Nijmegen niet gelukt; hartelijk dank daarvoor.
Voor de verzameling van urine van patiënten met een paracetamolintoxicatie hebben 
we samengewerkt met de Apotheek van het Radboud UMC. Rob  en Khalid, bedankt 
voor het mogelijk maken van deze monsterverzameling en het werk wat jullie hierin 
gestopt hebben.
De studie naar methotrexaat-gerelateerde leverschade werd uitgevoerd in 
samenwerking met de afdeling Dermatologie. Marisol, je hebt veel werk gehad aan 
het verzamelen van alle urinemonsters en het verzamelen van de patiëntgegevens. Ik 
ben erg dankbaar dat je zo veel monsters hebt weten te verzamelen voor dit project. 
Dr.  Elke de Jong, het was erg fijn om met jou te overleggen over de resultaten van 
deze studie; vooral jouw enthousiasme werkt aanstekelijk.
Beste studenten Patty, Mohammad, Linda en Sharon; jullie hebben allemaal 
bijgedragen aan het totstandkomen van mijn proefschrift en aan de ontwikkeling van 
mijzelf als onderzoeker, bedankt daarvoor.
Door de collega’s op de afdeling Farmacologie-Toxicologie heb ik het werken aan 
mijn onderzoek als erg prettig ervaren. Er was geen dag dat ik geen zin had om 
naar het werk te gaan. Daarvoor wil ik iedereen die op de afdeling werkt en in mijn 
promotieperiode gewerkt heeft hartelijk bedanken. Tegen een aantal mensen wil ik 
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graag nog iets meer zeggen.
Hanneke, jij was zelf net begonnen als promovendus op een TIP-project toen ik in 
jouw U-tje terecht kwam en daarmee was je ook een goed voorbeeld voor mij. We 
hebben (heel) veel gekletst en ik heb vaak bij jou mogen slapen als we een borrel 
hadden of gingen stappen.  Ik heb ontzettend genoten van onze tijd samen op het lab 
en ik wil je graag bedanken voor alle gesprekken, discussies en gezelligheid. 
Jitske, jij bent mijn ‘partner in crime’ als het op versieren van de werkplekken aan 
komt. Verder ben jij, net zoals ik, to-the-point, waarschijnlijk kunnen we daarom zo 
goed met elkaar overweg. Ik vind het heel fijn om met jou samen te werken, maar 
de volgende keer dat ik jarig ben hoeft mijn foto niet per se aan de slagboom van de 
parkeergarage!
Karl, toen je op het lab kwam heb ik je een plekje aangeboden aan mijn labtafel en ik 
heb er (bijna) geen spijt van gehad. Ik heb ontzettend met je gelachen, maar ook veel 
goede gesprekken gehad. En ik ken maar weinig mensen die ieder karakter van de 
serie ‘Allo allo’ na kunnen doen. Jammer dat het je niet lukt om Limburgs te praten... 
Oja, ik weet dat jij het niet alleen was, maar je was er altijd bij betrokken; dus bedankt 
voor de kaart, het versieren van mijn auto, het verstoppen van mijn computer en mijn 
scherm, het afplakken van mijn muis, het omdraaien van de muisknoppen, enz, enz. 
Anita, we hebben samen verschillende cursussen en congressen meegemaakt en 
lekker door San Francisco geslenterd; dat vond ik erg gezellig. Weten we nu eigenlijk 
hoe lang de Golden Gate Bridge echt is? ;-) Heel veel succes met het afronden van 
jouw proefschrift en met je verdere carrière.
Janny, ik wil jou graag bedanken voor alle gezellige, maar ook serieuze gesprekken 
en voor alle hulp. Fijn dat ik nu jouw U-genoot mag zijn! Ik zou je ook wel willen 
bedanken voor de bestellingen, maar je zei dat ik dat niet mocht doen, dus doe ik 
dat maar niet ;-)
Vivienne, jij bent mijn vraagbaken en toeverlaat als het gaat om de dierproeven. Ik 
vind het prettig om met jou samen te werken, niet alleen vanwege jouw expertise, 
maar zeker ook vanwege de gezelligheid. 
Jeanne, bedankt voor de momenten waarop we samen enthousiast achter de 
microscoop zaten om een kleuring te bekijken. Je was altijd bereid om te helpen en 
ik vind het leuk dat je zo betrokken bent.
Jeroen, bedankt dat je hebt geprobeerd me te leren skieën, althans... je was er om 
mijn eerste pogingen op de piste te filmen. Wonderbaarlijk dat niemand iets gebroken 
heeft tijdens mijn afdalingen of tijdens de rit naar de skihal toe (‘zag je dat...?!?’). 
Rick G. (Greup), op een of andere manier heb jij altijd wel tips om me te helpen, of 
het nu gaat om onderwijs of alles wat bij het publiceren van een artikel komt kijken, 
en daar ben ik je heel dankbaar voor. Bovendien kan ik je humor erg waarderen.
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Elnaz, thank you very much for letting me stay at your place, I really enjoyed it. Tom, 
bedankt voor jou tips over hoe het ‘heurt’. Misschien zal ik het ooit leren en helpt mij 
dat nog in de toekomst. Julien, I’ll never forget your impression of Karl for his video, 
it was legendary! But I also appreciated the humoristic person that you are yourself. 
Sanna, bedankt voor jouw feministische input :-). Hierdoor had ik af en toe een break 
van alle grapjes op het lab. Martijn, bedankt voor de Limburgse invloeden op het lab 
en succes met het verder plaveien van je gouden-keien-pad. Verder wil ik ook graag 
Maarten, Marieke, Niels, Jan, Lindsey, Rick M, Sabrina, Pedro, Kim, Reginald, Azza, 
Bas, Frank en Alwin bedanken voor de gezelligheid op het lab.
Vriendinnen van de studie: Jozette, Kim, Lotte en Emmy; wat gaat de tijd snel hè! 
Een paar jaar geleden studeerden we één voor één af en nu beginnen de promoties 
alweer te komen. Bedankt voor alle gezellige activiteiten samen en met aanhang. 
Hoogtepunten waren natuurlijk de jaarlijkse dagjes uit, weekendjes weg en de 
Oktoberfesten in Arcen!
Lineke, ik kan me nog zo goed herinneren dat we in de brugklas zaten, en nu zijn we 
alweer ‘volwassen’. Ook al zien we elkaar niet zo vaak als we zouden willen, ik ben 
erg dankbaar voor onze vriendschap!
Susan, wat hebben we toch gelachen in de periode dat we iedere zondag in de vis- 
en frietkraam stonden. Bedankt voor die ‘goeie oude tijd’. Ik ben er niet rouwig om 
dat we beiden een carriere-switch gemaakt hebben. Gelukkig zien we elkaar nog 
geregeld, maar dan zonder die frituurlucht!
Natuurlijk wil ik ook alle vriend(inn)en in Arcen bedanken: Steffie en Vincent, Rianne 
en Robbie, Emie, Linda en Dirk, Elisabeth, Tanja, Lydia, Inge, Jacqueline en Jamie, 
Saya en Paul, Manuela en Luc, Marian en Angelo, Tim en Dominique en alle anderen 
van wiens gezelschap ik heb mogen genieten. Jullie zorgen er voor dat ik ‘gewoon’ 
Rachel kan zijn en even niet hoef na te denken over mijn onderzoek. Helaas zien 
we elkaar allemaal niet meer zo veel als vroeger en zijn er zelfs mensen uit Arcen 
verhuisd (!); maar ik ben blij voor alle gezellige momenten die we samen hebben 
gehad en hopelijk nog zullen hebben. Dames, bedankt voor alle avondjes stappen, 
de surpiseavonden, en het inmiddels jaarlijkse weekendje weg; ik heb met volle 
teugen genoten van die momenten!
Riecky en Theey, bedankt voor alle goede zorgen en oprechte interesse.
Opa en oma Cornelissen en opa van Swelm, bedankt voor alle goede tijden die we 
mogen meemaken.
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Esther en Marijn, ik vind het erg leuk dat we nu zo dicht bij elkaar wonen. Esther, 
bedankt voor alle steun, gezellige filmavondjes  en hartelijke zus-tot-zus gesprekken 
over eigenlijk alles wat maar op ons pad kwam. 
Youri, we hebben samen aardig wat ritjes op en neer naar Nijmegen gemaakt. Fijn 
dat ik met jou alle aspecten van wetenschappelijk onderzoek kan bespreken. Ik ben 
blij dat ik je nog elke week zie, ook al woon je nu een eindje verder weg. 
Lieve pap en mam, jullie hebben me al vroeg geleerd om dingen zelf te regelen en 
verantwoordelijkheid te nemen. Dat was toen niet altijd leuk of gemakkelijk, maar 
ik ben jullie er ontzettend dankbaar voor, want die vaardigheden komen me nu ten 
goede.  Ontzettend bedankt voor alle liefde en steun (en de humor van pap) waarmee 
ik heb mogen opgroeien tot wie ik nu ben; ik zou niet beter hebben kunnen wensen.
Diesel en Jason, bedankt voor alle liefde en uitgebreide knuffelsessies. 
Lieve Thijs, in de tijd dat we samen zijn, zijn we volwassen geworden, hebben een 
huis verbouwd en hebben we onze carrières opgestart. We hebben al veel samen 
meegemaakt en zijn nog steeds gelukkig, dus volgens mij kunnen we nu alles aan! 
Bedankt voor alle steun en begrip die je voor mij hebt. Jij zorgt ervoor dat ik mijn 
doelen kan bereiken, maar je let er ook goed op dat ik tijd voor mezelf en ons samen 
neem. Ik hoop dat we nog lang kunnen genieten van elkaar en alle plannen voor de 
toekomst kunnen uitvoeren.
200
Chapter 8
8
201
Appendice
8
Appendice
Thesis series of the Institute for Genetic and Metabolic Disease
Radboud University Medical Centre
1. Guillard, M. (2012). Biochemical and clinical investigations in the diagnosis of   
 congenital disorders of glycosylation.Radboud University Nijmegen, Nijmegen, The  
 Netherlands.
3 Jonckheere, A. (2013). Mitochondrial Medicine: assay development and application  
 with special emphasis on human complex V.Radboud University Nijmegen,   
 Nijmegen, The Netherlands
4. Wessels, J. (2013). Mitochondrial proteomics: method development and   
 application. Radboud University Nijmegen, Nijmegen, The Netherlands
5.  Vries de, H. (2012). Risk assessment of biological treatment in inflammatory bowel  
 disease & analysis of genetic susceptibility factors. Radboud University Nijmegen,  
 Nijmegen, The Netherlands
6.  Brom, M. (2013). Development of a tracer to image pancreatic beta cells. Radboud  
 University Nijmegen, Nijmegen, The Netherlands
7. Schuurs-Hoeijmakers, J.H.M. (2012). Gene identification in intellectual disability.   
 Radboud University Nijmegen, Nijmegen, The Netherlands
8.  Esch van, A. (2012). Genetic and clinical aspects of chronic pancreatitis. Radboud  
 University Nijmegen, The Netherlands
9. Calvaruso, M. (2013). Mitochondrial complex I assembly in man and mouse.   
 Radboud University Nijmegen, The Netherlands
10.  Wortmann, S. (2013). The 3−methylglutaconic acidurias – revisited. Radboud   
 University Nijmegen, The Netherlands
11.  Janssen, M. (2013). The molecular mechanism behind Polycystic Liver Disease.   
 And the allele that went missing... Radboud University Nijmegen, The Netherlands
12. Nouws, J. (2013). Human mitochondrial complex I biogenesis: connections   
 between mitochondrial translation, fatty acid oxidation and complex I assembly.   
 Radboud University Nijmegen, The Netherlands
13.  Swelm van R. P. L. (2013). Urinary protein profiling of drug-induced liver injury. 
 Search for biomarkers and mechanisms. Radboud University Nijmegen, The   
 Netherlands
14. Chrispijn, M. (2013). Phenotype and Treatment of Polycystic Liver Disease: Where  
 Hepatology meets Radiology. Radboud University Nijmegen, The Netherlands

